| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1001 |
EPH60 Predictive Value of Gensini Score in Severe Coronary Lesions in Algerian Patients Undergoing Coronary Angiography
|
Boukheloua, M.
|
|
|
26 |
12S |
p. S213-S214
|
artikel
|
| 1002 |
EPH107 Predictors and Consequences of Pediatric Nurses' Burnout: An Integrative Review
|
Khatatbeh, H.
|
|
|
26 |
12S |
p. S222-S223
|
artikel
|
| 1003 |
EPH109 Predictors of Individual General Life Satisfaction in the German General Social Survey (ALLBUS) Cohorts from 2010 to 2021
|
Pfaff, H.U.
|
|
|
26 |
12S |
p. S223
|
artikel
|
| 1004 |
EPH5 Prevalence and Predictive Factors of Severe Coronary Lesions in Algerian Patients Undergoing Coronary Angiography
|
Boukheloua, M.
|
|
|
26 |
12S |
p. S203
|
artikel
|
| 1005 |
EPH149 Prevalence, Burden of Disease, and Treatment Patterns of Vitiligo in Patients Across European Countries
|
Delattre, C.
|
|
|
26 |
12S |
p. S231
|
artikel
|
| 1006 |
EPH140 Prevalence Estimation of Thymidine Kinase 2 Deficiency: An Ultra-Rare Autosomal Recessive Mitochondrial Disease
|
Ma, Y.
|
|
|
26 |
12S |
p. S229
|
artikel
|
| 1007 |
EPH112 Prevalence, Incidence, and Patient Characteristics of Valvular Heart Disease Using the National Database of Health Insurance Claims in Japan
|
Igarashi, A.
|
|
|
26 |
12S |
p. S223
|
artikel
|
| 1008 |
EPH134 Prevalence of and Associated Factors for Therapy Delay Due to COVID-19 Pandemic Among Breast Cancer Patients in Europe
|
Gremke, N.
|
|
|
26 |
12S |
p. S228
|
artikel
|
| 1009 |
EPH196 Prevalence of GI Comorbidities by Age Group Among Patients With Rett Syndrome: An Analysis of Coded EHR and Pharmacy Data and Clinical Notes
|
May, D.
|
|
|
26 |
12S |
p. S238-S239
|
artikel
|
| 1010 |
EPH3 Prevalence of Polypharmacy in the Statutorily Insured German Population
|
Wilke, K.
|
|
|
26 |
12S |
p. S203
|
artikel
|
| 1011 |
EPH151 Prevalence of Risk Factors for Serious Adverse Events Among Rheumatoid Arthritis Patients Prescribed Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors: A Merative Marketscan Cross-Sectional Study
|
Janak, J.C.
|
|
|
26 |
12S |
p. S231-S232
|
artikel
|
| 1012 |
EPH11 Prevalence, Risk Factors, and Characterization of Individuals with Long COVID Using Electronic Health Records in Over 1.5 Million COVID Cases in England
|
Wang, H.I.
|
|
|
26 |
12S |
p. S204
|
artikel
|
| 1013 |
EPH115 Primary Prevention Strategies for Stroke: A Multilevel Approach
|
Andreyan Georgiev, M.
|
|
|
26 |
12S |
p. S224
|
artikel
|
| 1014 |
EPH93 Progression From Cutaneous to Systemic Lupus Erythematosus: A Systematic Literature Review
|
Singh, B.
|
|
|
26 |
12S |
p. S220
|
artikel
|
| 1015 |
EPH96 Projected Prevalence of Acute, Chronic, and End-Stage Kidney Disease in the UK From 2023 to 2033
|
Agathangelou, G.
|
|
|
26 |
12S |
p. S220
|
artikel
|
| 1016 |
EPH206 Public Health Impact of Nirsevimab Against Lower Respiratory Infections Associated with Respiratory Syncytial Virus Among Chinese Infants
|
Lai, X.
|
|
|
26 |
12S |
p. S241
|
artikel
|
| 1017 |
EPH99 Public Health Impact of Replacing Monovalent and Quadrivalent Meningococcal Vaccines By Pentavalent Vaccine in the United States
|
Żerda, I.
|
|
|
26 |
12S |
p. S221
|
artikel
|
| 1018 |
EPH100 Public Health Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in Mexico
|
Orengo, J.
|
|
|
26 |
12S |
p. S221
|
artikel
|
| 1019 |
EPH108 Quality of Life of Menopausal Women
|
Tóthné Simon, K.
|
|
|
26 |
12S |
p. S223
|
artikel
|
| 1020 |
EPH260 Rare Diseases and Kidney Stones: Are Stones in Amino Acid Transport Disorders Special?
|
Wahler, S.
|
|
|
26 |
12S |
p. S251
|
artikel
|
| 1021 |
EPH98 Real-World Effectiveness and Safety of Tixagevimab-Cilgavimab: A Target Trial Emulation Study
|
Yan, V.
|
|
|
26 |
12S |
p. S221
|
artikel
|
| 1022 |
EPH87 Real-World Evidence Study on Hemophilia B Treatment with Factor IX and Corresponding Treatment Costs in Finland
|
Meisgen, S.
|
|
|
26 |
12S |
p. S219
|
artikel
|
| 1023 |
EPH82 Real-World Outcomes in Patients with Resected Non-Small Cell Lung Cancer (NSCLC) Receiving (NEO)Adjuvant Treatment in Germany: An I-O Optimise Analysis
|
Baltus, H.
|
|
|
26 |
12S |
p. S217-S218
|
artikel
|
| 1024 |
EPH13 RSV Hospitalizations’ Burden in New-Born Patients and Potential Impact of Maternal Vaccination: A French Analysis
|
Fahfouhi, Y.
|
|
|
26 |
12S |
p. S204-S205
|
artikel
|
| 1025 |
EPH127 School Environment and Mental Health State in Brazilian Adolescents – Evaluating Public Policy Opportunities
|
Menegotto, G.
|
|
|
26 |
12S |
p. S227
|
artikel
|
| 1026 |
EPH234 Shedding Light into the Dark of Unknown Cost-of-Illness and Burden-of-Disease Associated with RSV across Age Groups in Austria
|
Walter, E.
|
|
|
26 |
12S |
p. S246
|
artikel
|
| 1027 |
EPH188 Social Determinants of Health and Treatment Receipt Among Privately and Publicly Insured Adults Diagnosed With Cancer in the United States
|
Hsu, C.Y.
|
|
|
26 |
12S |
p. S237
|
artikel
|
| 1028 |
EPH251 Subtype Distribution of Amyloidosis in the United States: Insights from an Electronic Health Records Database Analysis
|
Laires, P.A.
|
|
|
26 |
12S |
p. S249
|
artikel
|
| 1029 |
EPH236 Suicidal Behavior in Patients with Chronic Pain: A Systematic Review and Meta-Analysis
|
Kwon, C.Y.
|
|
|
26 |
12S |
p. S246
|
artikel
|
| 1030 |
EPH52 Survey of Situation and Severity of Public Problems Affecting Health in an Industrial District in Thailand
|
Rutjanathamrong, P.
|
|
|
26 |
12S |
p. S212
|
artikel
|
| 1031 |
EPH80 Survival and Best Recorded Response (BRR) in Patients With Advanced Merkel Cell Carcinoma (MCC): Analysis of a Prospective German MCC Registry Study (MCC TRIM) of the German Dermatologic Cooperative Oncology Group
|
Mahmoudpour, S.H.
|
|
|
26 |
12S |
p. S217
|
artikel
|
| 1032 |
EPH247 Survival and Risk of Death Analysis of Patients with Myelofibrosis Treated with Ruxolitinib
|
Stoeva, V.
|
|
|
26 |
12S |
p. S248
|
artikel
|
| 1033 |
EPH230 Systematic Literature Review on the Clinical and Economic Burdens of Antimicrobial Resistance in the Japanese Population
|
Yuasa, A.
|
|
|
26 |
12S |
p. S245
|
artikel
|
| 1034 |
EPH31 Systematic Literature Review on the Global Epidemiology of Angelman Syndrome
|
Arregui Rementeria, M.
|
|
|
26 |
12S |
p. S208
|
artikel
|
| 1035 |
EPH48 Targeted Influenza Vaccination in at Risk Populations – How Avoided Cases Translate into Clinical and Economic Benefits for Czech Republic, Hungary, and Romania
|
Fraisier, B.
|
|
|
26 |
12S |
p. S211
|
artikel
|
| 1036 |
EPH222 Temporal Analysis of Diabetes, Hypertension, and Asthma Prevalence: A Comparative Study in European Countries (FRANCE, SPAIN, BELGIUM, ROMANIA, AND ITALY) Using a Real-World Ambulatory Medical Database (2018-2022)
|
Seck, D.
|
|
|
26 |
12S |
p. S243-S244
|
artikel
|
| 1037 |
EPH224 Temporal Trends of Percutaneous Transluminal Coronary Angioplasty Procedure and Mortality Rates in the Brazilian Public Healthcare: A Real World Data Analysis From 2014 to 2022
|
Marcolino, M.
|
|
|
26 |
12S |
p. S244
|
artikel
|
| 1038 |
EPH44 Temporary Soft Tissue Coverage in Burn Patients - Which Materials Are Used - and By Whom? Analysis of German Billing Data
|
Wahler, S.
|
|
|
26 |
12S |
p. S210
|
artikel
|
| 1039 |
EPH71 Tendencies in Hospital Burn Care for Children in Germany
|
Wahler, S.
|
|
|
26 |
12S |
p. S215
|
artikel
|
| 1040 |
EPH212 The Acceptability of Human Papillomavirus Vaccination in the United Kingdom: A Review of the Literature on Barriers and Facilitators to Vaccination
|
Karakusevic, A.
|
|
|
26 |
12S |
p. S242
|
artikel
|
| 1041 |
EPH207 The Adverse Event Profiles of Modafinil in Approved Indications and Off-Label Use for Major Depressive Disorder: A Systematic Review and Meta-Analysis
|
Jung, J.
|
|
|
26 |
12S |
p. S241
|
artikel
|
| 1042 |
EPH167 The Conceptualization of Cardiometabolic Disease Policy Model in the UK
|
Putri, S.
|
|
|
26 |
12S |
p. S234
|
artikel
|
| 1043 |
EPH147 The Costs of Unaddressed Hearing Loss in Chilean Children with Bilateral Microtia and External Auditory Canal Atresia and Cost Effectiveness of Different Treatment Interventions
|
Kiesewetter, K.
|
|
|
26 |
12S |
p. S231
|
artikel
|
| 1044 |
EPH92 The Development of an Interactive Visual Tool to Communicate the Burden of Atopic Dermatitis in Finland
|
Peltonen, I.
|
|
|
26 |
12S |
p. S220
|
artikel
|
| 1045 |
EPH232 The Disease Burden and Healthcare Resource Utilization of Gram-Negative Multi-Drug Resistant Bacteria
|
Young, J.
|
|
|
26 |
12S |
p. S245-S246
|
artikel
|
| 1046 |
EPH219 The Effect of Gestational Weight Gain on Pregnancy Outcome
|
Kozmann, K.
|
|
|
26 |
12S |
p. S243
|
artikel
|
| 1047 |
EPH183 The Effects of COVID-19 on Mental Health
|
Kim, A.
|
|
|
26 |
12S |
p. S237
|
artikel
|
| 1048 |
EPH145 The Epidemiology of Asthma in Children Between 2004 and 2021 Using Livingstone: An Online, Automated Analytical Platform
|
Bitchell, L.
|
|
|
26 |
12S |
p. S230
|
artikel
|
| 1049 |
EPH231 The Impact of COVID-19 on National Disease Dynamics: Population-Based Interrupted Time Series Study in South Korea
|
Choi, K.
|
|
|
26 |
12S |
p. S245
|
artikel
|
| 1050 |
EPH177 The Impact of COVID-19 on National Mortality: Population-Based Interrupted Time Series Study in South Korea
|
Suh, H.S.
|
|
|
26 |
12S |
p. S236
|
artikel
|
| 1051 |
EPH17 The Impact of COVID-19 Preventive Restrictions on the Development of Diseases of Despair: A Multi-Group Time Series Analysis
|
Wolde, F.
|
|
|
26 |
12S |
p. S205
|
artikel
|
| 1052 |
EPH141 The Impact of Short Bowel Syndrome in Adult Patients in Portugal
|
Sameiro Lemos, M.
|
|
|
26 |
12S |
p. S229
|
artikel
|
| 1053 |
EPH56 The Impact of the COVID-19 Pandemic on Cardiovascular Disease Prevention and Corresponding Geographical Inequalities in England: Interrupted Time Series Analysis
|
Castanon, A.
|
|
|
26 |
12S |
p. S213
|
artikel
|
| 1054 |
EPH91 The Incidence of Uveitis in the United Kingdom 2004-2021
|
Buxton, A.
|
|
|
26 |
12S |
p. S219
|
artikel
|
| 1055 |
EPH90 The Increasing Incidence of Respiratory Syncytial Virus (RSV) in Ireland
|
Patterson, K.
|
|
|
26 |
12S |
p. S219
|
artikel
|
| 1056 |
EPH57 The Market Dynamics of GP IIb/IIIa Inhibitors in Germany: A Closer Look at Eptifibatide and Aggrastat
|
Wahler, S.
|
|
|
26 |
12S |
p. S213
|
artikel
|
| 1057 |
EPH117 The Phollow Cohort: Real-World Therapeutic Adherence to Blood Glucose-Lowering Drugs (EXCLUDING INSULINS) in Portugal
|
Romão, M.
|
|
|
26 |
12S |
p. S224-S225
|
artikel
|
| 1058 |
EPH264 The Potential Public Health Impact of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine Among Adults Aged 60 and Older in Italy: Preliminary Results of a Markov Model Analysis
|
Puggina, A.
|
|
|
26 |
12S |
p. S251
|
artikel
|
| 1059 |
EPH262 The Preparedness and Contribution of Community Pharmacists During Public Health Crises
|
Nazaryan, L.
|
|
|
26 |
12S |
p. S251
|
artikel
|
| 1060 |
EPH55 The Prevalence and Comorbidities of Prurigo Nodularis – A Danish Register-Based Study From 1995 to 2021
|
Ibler, K.S.
|
|
|
26 |
12S |
p. S212
|
artikel
|
| 1061 |
EPH203 The Prevalence of Alopecia Areata in Germany: Results of an Insurance Claims Database Analysis
|
Augustin, M.
|
|
|
26 |
12S |
p. S240
|
artikel
|
| 1062 |
EPH211 The Public Health Impact of mRNA-1273 Fall Booster Vaccination in the Netherlands
|
Wondimu, A.
|
|
|
26 |
12S |
p. S242
|
artikel
|
| 1063 |
EPH184 The Relevance of Insomnia in Relation to Other High-Impact Pathologies. a Systematic Literature Review
|
Egea, C.
|
|
|
26 |
12S |
p. S237
|
artikel
|
| 1064 |
EPH58 The Risk of First and Recurrent Mace Associated with Elevated Lp(A) in a Primary Prevention Population
|
Benbow, H.
|
|
|
26 |
12S |
p. S213
|
artikel
|
| 1065 |
EPH235 The Road to an HIV Cure: Approaches and Strategies in Current Clinical Trials
|
Goulding, R.
|
|
|
26 |
12S |
p. S246
|
artikel
|
| 1066 |
EPH193 The Role of Adjuvant Atezolizumab in Reducing Recurrence-Related Treatment Costs in Resected Early-Stage PD-L1 High Non-Small Cell Lung Cancer across Europe
|
Arnold, M.
|
|
|
26 |
12S |
p. S238
|
artikel
|
| 1067 |
EPH225 The Shifting Patterns of Childhood Obesity: Insights from Population-Based Data
|
Alhamed, A.
|
|
|
26 |
12S |
p. S244
|
artikel
|
| 1068 |
EPH49 The Short-Run and Long-Run Behavioral Effects of Vaccination Enforcement in Turkey
|
Baser, O.
|
|
|
26 |
12S |
p. S211
|
artikel
|
| 1069 |
EPH15 Transmission Dynamics and Vaccination Strategies for Chikungunya Virus (CHIKV): An Outbreak Simulation Study in Rome, Italy
|
Tiozzo, G.
|
|
|
26 |
12S |
p. S205
|
artikel
|
| 1070 |
EPH258 Treatment Pattern of Pemphigus Vulgaris in UK : A Retrospective Cohort Study Using Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES)
|
Blein, C.
|
|
|
26 |
12S |
p. S250-S251
|
artikel
|
| 1071 |
EPH136 Treatment Patterns and Epidemiological Characteristics in Adult Patients With III-IVB HNSCC From a Reference Center in Mexico
|
Manzo-Merino, J.
|
|
|
26 |
12S |
p. S228
|
artikel
|
| 1072 |
EPH174 Trends in Hospitalization of Patients with Wilson's Disease in Germany
|
Wahler, S.
|
|
|
26 |
12S |
p. S235
|
artikel
|
| 1073 |
EPH76 Triptan Switches for Danish Migraine Patients Treated With at Least Three Distinct Triptans Before Discontinuation—A Register Based Study
|
Ashina, M.
|
|
|
26 |
12S |
p. S216
|
artikel
|
| 1074 |
EPH265 Updated Estimations of the HPV Vaccination Deficit Among Girls in Greece: Early Signs of Recovery?
|
Gountas, I.
|
|
|
26 |
12S |
p. S251-S252
|
artikel
|
| 1075 |
EPH273 Using Real-World Data Sources in England to Quantify the Burden of Non-Alcoholic Steatohepatitis
|
Davidson, J.
|
|
|
26 |
12S |
p. S253
|
artikel
|
| 1076 |
EPH46 Validation of Dynamic Transmission Model for Varicella Immunization Program in Germany
|
Żerda, I.
|
|
|
26 |
12S |
p. S210-S211
|
artikel
|
| 1077 |
EPH124 Validity of Outpatient ICD-10 Codes to Identify Respiratory Syncytial Virus (RSV) – Estimating Sensitivity and Specificity of Health Administrative Claims Data
|
Steinmann, M.
|
|
|
26 |
12S |
p. S226
|
artikel
|
| 1078 |
EPH248 Varying Latency Impact on Incidence of Second Primary Malignancy Among Patients with B-Cell Malignancy
|
Knight, T.
|
|
|
26 |
12S |
p. S248
|
artikel
|
| 1079 |
EPH68 What Are the Main Symptoms of Long COVID? Real World Medical Data Cross-Referenced with Social Network Content
|
Paris, C.
|
|
|
26 |
12S |
p. S214-S215
|
artikel
|
| 1080 |
EPH54 What Do the Students Think About Food Safety Knowledge at the University of Pécs?
|
Keczeli, V.
|
|
|
26 |
12S |
p. S212
|
artikel
|
| 1081 |
EPH135 Years of Life Lost and Productivity Costs Due to Premature Cancer-Related Mortality in Egypt
|
Poellinger, B.
|
|
|
26 |
12S |
p. S228
|
artikel
|
| 1082 |
HPR145 Access of Rare Disease Treatments in the Nordics
|
Gabbouj, S.
|
|
|
26 |
12S |
p. S279
|
artikel
|
| 1083 |
HPR166 Access to Innovative Treatment Through Performance-Based Contracts in France: Recommendations From Multidisciplinary Experts’ Workshops
|
Coquerelle, S.
|
|
|
26 |
12S |
p. S282-S283
|
artikel
|
| 1084 |
HPR139 Access to Targeted Therapies for Solid Tumors in Turkey
|
Karaomerlioglu, I.
|
|
|
26 |
12S |
p. S278
|
artikel
|
| 1085 |
HPR87 A Comparative Analysis of Market Access Processes Between Ukraine and Germany
|
Walzer, S.
|
|
|
26 |
12S |
p. S269
|
artikel
|
| 1086 |
HPR122 A Conceptual Modeling Framework for Manufacturers to Navigate the Inflation Reduction Act and to Negotiate a “Fair Maximum Price”
|
Libanore, A.
|
|
|
26 |
12S |
p. S275
|
artikel
|
| 1087 |
HPR10 Added Benefit and Revenues of Oncology Drugs Approved By the European Medicines Agency between 1995 and 2020
|
Brinkhuis, F.
|
|
|
26 |
12S |
p. S256
|
artikel
|
| 1088 |
HPR128 Addressing Bias in Health Applications: A Path Towards Health Equity
|
Cossio, M.
|
|
|
26 |
12S |
p. S276
|
artikel
|
| 1089 |
HPR71 All Back to Square One: What Follows from the New Algorithm for Drug Pricing in Germany?
|
Gensorowsky, D.
|
|
|
26 |
12S |
p. S266
|
artikel
|
| 1090 |
HPR130 Analysis of Extemporaneous Compounding of Medicines During COVID-19 and Wartime in Ukraine
|
Zaliska, O.
|
|
|
26 |
12S |
p. S276-S277
|
artikel
|
| 1091 |
HPR133 Analysis of Information Content on the Web Services About Antihypertensive Medicines in Ukraine
|
Zaliska, O.
|
|
|
26 |
12S |
p. S277
|
artikel
|
| 1092 |
HPR79 Analysis of Newly FDA Approved Medicines and the Licensing Status By Titck in Turkiye
|
Citil, E.
|
|
|
26 |
12S |
p. S267
|
artikel
|
| 1093 |
HPR34 Analysis of Public Health Insurance Expenditures in Turkiye By SGK between 2020-2021-2022
|
Erdoğan, A.
|
|
|
26 |
12S |
p. S259
|
artikel
|
| 1094 |
HPR74 Analysis of the Guangdong-Hong Kong-Macau Greater Bay Area Urgent-Use Medicine Scheme—An Opportunity for Early Access in Mainland China
|
Leong, K.W.
|
|
|
26 |
12S |
p. S266
|
artikel
|
| 1095 |
HPR160 An Ecological Study of 4 Drug Categories Consumption Inequities in Spain
|
Carmo, M.
|
|
|
26 |
12S |
p. S281
|
artikel
|
| 1096 |
HPR14 Applications for Tafamidis (Vyndaqel®) Under a Managed Access Protcol in Ireland
|
Lucey, S.
|
|
|
26 |
12S |
p. S257
|
artikel
|
| 1097 |
HPR38 Arbitral Awards on Reimbursement Prices Since 2019 in Germany: What We Can Learn?
|
Kiesel, L.M.
|
|
|
26 |
12S |
p. S260
|
artikel
|
| 1098 |
HPR221 A Reconstruction and Validation of the Rationale Underlying the Ec Proposal to Make Regulatory Data Protection (RDP) Conditional upon Supply in EU Member States
|
Cueva Oemer, S.
|
|
|
26 |
12S |
p. S291
|
artikel
|
| 1099 |
HPR43 Are There Any Common Denominators for Early Access Programs in Europe?
|
Ecker, T.
|
|
|
26 |
12S |
p. S261
|
artikel
|
| 1100 |
HPR42 A Review of Approved Managed Entry Agreements in Sweden
|
Pandey, K.
|
|
|
26 |
12S |
p. S261
|
artikel
|
| 1101 |
HPR104 A Review of Biosimilar Utilization across EU4 and UK Since the Introduction of the First Biosimilar
|
Schmidt, K.
|
|
|
26 |
12S |
p. S272
|
artikel
|
| 1102 |
HPR12 Assessing COA Label Claims Based on Single-Arm Trials in Rare Diseases: A Review of US FDA Labels
|
Thakker, D.
|
|
|
26 |
12S |
p. S256-S257
|
artikel
|
| 1103 |
HPR119 Assessing Health Policies in Turkiye: Expert Insights on Current Challenges and Policy Recommendations from Written Motions
|
Kahveci, S.
|
|
|
26 |
12S |
p. S275
|
artikel
|
| 1104 |
HPR66 Assessing the Impact and Strategic Implications of the HTA Regulation 2021/20282 on National Processes: A Scoping Review and Stakeholders Perspectives Through Semi-Structured Interviews
|
Desmet, T.
|
|
|
26 |
12S |
p. S265
|
artikel
|
| 1105 |
HPR168 Assessment of Equity in Healthcare Financing for Uganda
|
Kamara, Y.
|
|
|
26 |
12S |
p. S283
|
artikel
|
| 1106 |
HPR220 Assessment of the Relevance and Credibility of Indirect Treatment Comparisons (ITCs) to Help Inform Health Technology Assessment (HTA) and Reimbursement Decision-Making: Results of a 5-Country Payer Survey
|
Katsoulis, I.
|
|
|
26 |
12S |
p. S291
|
artikel
|
| 1107 |
HPR111 ATMPs in Europe: Do We Have an Access Gap?
|
Ecker, T.
|
|
|
26 |
12S |
p. S273
|
artikel
|
| 1108 |
HPR2 Baseline Characteristics of Patients Applying for Reimbursment of Liraglutide (Saxenda®) for Weight Management Under a Managed Access Protocol in Ireland
|
Gorry, C.
|
|
|
26 |
12S |
p. S255
|
artikel
|
| 1109 |
HPR51 Better Safe Than Sorry? Identification of Drug Combinations for Targeted Price Regulation in German Claims Data
|
Witte, J.
|
|
|
26 |
12S |
p. S262
|
artikel
|
| 1110 |
HPR107 Bilateral Price Comparison of 50 Particularly Cost-Intensive Drugs – What Is the Impact of Different Reimbursement Rules?
|
Walter, E.
|
|
|
26 |
12S |
p. S273
|
artikel
|
| 1111 |
HPR148 Bio-Hybrid Medicinal Products: Widening Access or Product Differentiation?
|
Schneider, P.
|
|
|
26 |
12S |
p. S279
|
artikel
|
| 1112 |
HPR1 Bulgaria National Stroke Program: Prevention Strategies
|
Dacheva, A.
|
|
|
26 |
12S |
p. S255
|
artikel
|
| 1113 |
HPR3 Burden of HIV/AIDS Assessment and Forecast for 2030 in Turkiye
|
Erkut, Y.
|
|
|
26 |
12S |
p. S255
|
artikel
|
| 1114 |
HPR92 Burnt Out or Something More? Investigating Drivers of and Spatial Variation in NHS Staff Turnover Intention
|
Tikhonovsky, N.
|
|
|
26 |
12S |
p. S269-S270
|
artikel
|
| 1115 |
HPR198 By Any Genes Necessary: Review of Pipeline Developments and Access Hurdles Likely to be Faced By Gene Therapies
|
Orchard, M.
|
|
|
26 |
12S |
p. S288
|
artikel
|
| 1116 |
HPR129 Catastrophic Health Expenditure: A Comparative Analysis of in Elderly Household and Non-Elderly Household in Korea
|
Choi, M.
|
|
|
26 |
12S |
p. S276
|
artikel
|
| 1117 |
HPR157 Challenges and Potential Solutions in Implementing a Bundle Payment Program for Osteoarthritis
|
Vutova, Y.
|
|
|
26 |
12S |
p. S281
|
artikel
|
| 1118 |
HPR81 Challenges in the Identification of Unmet Needs in Rare Diseases: Towards the Development of a Framework
|
Vanneste, A.
|
|
|
26 |
12S |
p. S268
|
artikel
|
| 1119 |
HPR158 Challenges, Opportunities and Policy Ways Forward to Systematically Embed the Use of Patient Experience Data in Healthcare Decision-Making: Insights From Multi-Stakeholder Interviews
|
Vanneste, A.
|
|
|
26 |
12S |
p. S281
|
artikel
|
| 1120 |
HPR49 Clinical Rationales Support Access to Novel Combination Therapies in Oncology: Are We Trying to Play a New Game with the Old Rules?
|
Berger, A.
|
|
|
26 |
12S |
p. S262
|
artikel
|
| 1121 |
HPR77 Community-Based Health Insurance and Migrant Organizations: Senegalese Associations’ Response to Legal Vulnerability and Transnational Medical Needs
|
Diop Wayal, M.
|
|
|
26 |
12S |
p. S267
|
artikel
|
| 1122 |
HPR69 Comparison of Price Trends for Medicines Pre- and Post-Early Access in Key Markets (France, UK, Australia)
|
Watt, A.
|
|
|
26 |
12S |
p. S265-S266
|
artikel
|
| 1123 |
HPR181 Comprehensive and Standardized Value Assessment of Innovative Cancer Treatments: A Multi-Criteria Decision Analysis (MCDA) Tool for Switzerland
|
Kuhlmey, F.
|
|
|
26 |
12S |
p. S285
|
artikel
|
| 1124 |
HPR68 Comprehensive Genomic Profiling Approaches in Europe and the US: A Review of Guidelines and Recommendations for Solid Tumors
|
von Wilamowitz-Moellendorff, C.
|
|
|
26 |
12S |
p. S265
|
artikel
|
| 1125 |
HPR127 Corporate Social Responsibility in Health Technology Industry, in Greece
|
Liopa, M.
|
|
|
26 |
12S |
p. S276
|
artikel
|
| 1126 |
HPR209 Criteria for Decision-Making on Drug Financing in Spain: How Do We Measure Them and What Relevance Does Each One Have?
|
Rejon-Parrilla, J.C.
|
|
|
26 |
12S |
p. S290
|
artikel
|
| 1127 |
HPR136 Designing an Effective Bundle Payment Program for Osteoarthritis
|
Vutova, Y.
|
|
|
26 |
12S |
p. S278
|
artikel
|
| 1128 |
HPR40 DiGA in Germany: Achievable Prices After Price Negotiation or a Decision of the Arbitration Board
|
Meyer-Harms, R.
|
|
|
26 |
12S |
p. S260
|
artikel
|
| 1129 |
HPR219 "Direct Access" Experiment in France: Potential Impact on the Pricing of Innovative Medicines
|
Kloc, K.
|
|
|
26 |
12S |
p. S291
|
artikel
|
| 1130 |
HPR192 Does Including Biosimilars Earlier in the Treatment Pathways Lead to Cost Savings in Rheumatology?
|
Tak, S.
|
|
|
26 |
12S |
p. S287
|
artikel
|
| 1131 |
HPR8 Drug Approvals for Advanced Breast Cancer in Brazil: Historical Perspective and Comparative Cost-Effectiveness Analysis
|
Goncalves, V.
|
|
|
26 |
12S |
p. S256
|
artikel
|
| 1132 |
HPR174 Effects of Having a Usual Source of Care with Physician on Medical Expenses in Korea
|
Choi, M.
|
|
|
26 |
12S |
p. S284
|
artikel
|
| 1133 |
HPR159 Emerging Trends Shaping the Healthcare Ecosystem in the Middle East and North Africa Region
|
Daccache, C.
|
|
|
26 |
12S |
p. S281
|
artikel
|
| 1134 |
HPR175 Estimating the Impact of the Elective Recovery Plan on Reducing Elective Waiting Lists in England
|
King, R.
|
|
|
26 |
12S |
p. S284
|
artikel
|
| 1135 |
HPR134 Ethical Considerations in Pay-for-Performance Programs for Diabetes
|
Vutova, Y.
|
|
|
26 |
12S |
p. S277
|
artikel
|
| 1136 |
HPR183 Evaluating the Saving Potential of Lenalidomide Before and After Transition to the Reference Price System in Finland
|
Sarnola, K.
|
|
|
26 |
12S |
p. S286
|
artikel
|
| 1137 |
HPR180 Evaluating the Success of the National Bundle Payment Program for Osteoarthritis
|
Vutova, Y.
|
|
|
26 |
12S |
p. S285
|
artikel
|
| 1138 |
HPR200 Evolution in Public Procurement for Medical Devices in Italy
|
Liberati, M.S.
|
|
|
26 |
12S |
p. S288
|
artikel
|
| 1139 |
HPR152 Evolution of the Use of Medicines in Special Situations and Management Measures for Their Rational Use
|
Paco, N.
|
|
|
26 |
12S |
p. S280
|
artikel
|
| 1140 |
HPR29 Evolution of the Utilization of the Aifa 5% Fund for Orphan Drugs and Rare Diseases
|
Tartarelli, F.
|
|
|
26 |
12S |
p. S259
|
artikel
|
| 1141 |
HPR59 Evolving Global Regulatory Landscape for Approval of Biosimilars: A Structured Literature Review on Current Challenges and Future Considerations
|
Car, E.S.
|
|
|
26 |
12S |
p. S263-S264
|
artikel
|
| 1142 |
HPR80 Examination of the Changes in the Turkish Pharmaceutical Market between 2007 and 2021
|
Erkut, Y.
|
|
|
26 |
12S |
p. S267
|
artikel
|
| 1143 |
HPR98 Examining Reimbursement and Pricing Decisions of Oncohematological Medicines in Spain
|
Aceituno Mata, S.
|
|
|
26 |
12S |
p. S271
|
artikel
|
| 1144 |
HPR176 Exploring Diverse Health Financing Models in Europe
|
Wijn, W.
|
|
|
26 |
12S |
p. S284-S285
|
artikel
|
| 1145 |
HPR17 Exploring Heterogeneity in Biosimilars Dynamics in Italy: Results From Three Chronic Therapeutic Areas
|
Tettamanti, A.
|
|
|
26 |
12S |
p. S257
|
artikel
|
| 1146 |
HPR102 Factors Influencing Orphan Drug Net Prices in the EU4 and US – Insights from Payers
|
Ergin, Y.
|
|
|
26 |
12S |
p. S272
|
artikel
|
| 1147 |
HPR165 Financial-Based Managed Entry Agreements for Drugs in Romania: From Simple to Complex
|
Radu, P.
|
|
|
26 |
12S |
p. S282
|
artikel
|
| 1148 |
HPR76 Financial Feasibility Study of Incremental Modified Drugs Development by Domestic Pharmaceutical Industry
|
Sakulbumrungsil, R.
|
|
|
26 |
12S |
p. S267
|
artikel
|
| 1149 |
HPR146 Fit for Purpose Policy Recommendations Related to Funding, Pricing, and Procurement of Point-of-Care Tests Used in Patients With Respiratory Tract Infections
|
Vogler, S.
|
|
|
26 |
12S |
p. S279
|
artikel
|
| 1150 |
HPR33 Follow the Money: Reporting Public Contributions and Incentives on Research and Development Programs for Agenzia Italiana Del Farmaco (AIFA; ITALIAN MEDICINES AGENCY)
|
Pourrahmat, M.M.
|
|
|
26 |
12S |
p. S259
|
artikel
|
| 1151 |
HPR110 From Paper to Patients: Revealing the Impact of the United Kingdoms' (UK) Health Technology Assessment (HTA) Policies on Advanced Therapy Medicinal Products (ATMPS)
|
Dhingra, B.
|
|
|
26 |
12S |
p. S273
|
artikel
|
| 1152 |
HPR78 From Submission to Reimbursement: Navigating the COVID-19 Ripple Effect on Therapy Access in Canada
|
Purkayastha, P.
|
|
|
26 |
12S |
p. S267
|
artikel
|
| 1153 |
HPR149 Generic Pricing Policy Frees Up $1 Billion: Statin Pricing and Expenditure from 2010-2022 in Australia.
|
Lee, L.
|
|
|
26 |
12S |
p. S280
|
artikel
|
| 1154 |
HPR25 Germany: Leading the Way for Digital Health Technology Assessment in Europe
|
Patel, M.
|
|
|
26 |
12S |
p. S258
|
artikel
|
| 1155 |
HPR90 Global Disparities in P4P Programs for Diabetes Care: A Comprehensive Analysis
|
Vutova, Y.
|
|
|
26 |
12S |
p. S269
|
artikel
|
| 1156 |
HPR97 Healthcare Systems Resilience and the COVID-19 Emergency: How Care Can Be Improved Within the Current Budget and Resources Constraint by Increasing the Efficiency of Healthcare Delivery
|
Ahir, H.
|
|
|
26 |
12S |
p. S271
|
artikel
|
| 1157 |
HPR208 Health Related Quality of Life Inequalities in Greece
|
Yfantopoulos, I.
|
|
|
26 |
12S |
p. S289-S290
|
artikel
|
| 1158 |
HPR28 Health Technology Assessment of New Drugs in Spain: Understanding the Evaluators’ Evidence Needs
|
Carmo, M.
|
|
|
26 |
12S |
p. S258
|
artikel
|
| 1159 |
HPR138 How Are Patient Experience Data Reported in Regulatory Evaluation of Medicinal Products? A Document Analysis of European Public Assessment Reports
|
Verbeke, C.
|
|
|
26 |
12S |
p. S278
|
artikel
|
| 1160 |
HPR18 How Will Recent Pricing Regulations Impact the Global Pricing Landscape?
|
Rémy, C.
|
|
|
26 |
12S |
p. S257-S258
|
artikel
|
| 1161 |
HPR161 HTA and Economic Evaluations for a Genomic Strategy in Italy
|
Di Brino, E.
|
|
|
26 |
12S |
p. S281-S282
|
artikel
|
| 1162 |
HPR84 Impact of AIFA Monitoring Registries Closure on Drugs’ Turnover Trends in Italy
|
Candelora, L.
|
|
|
26 |
12S |
p. S268
|
artikel
|
| 1163 |
HPR93 Impact of Generic Competition on Prices, Public Spending and Utilization of Antiepileptic Medicines in Bulgaria
|
Mitkova, Z.
|
|
|
26 |
12S |
p. S270
|
artikel
|
| 1164 |
HPR62 Impact of GKV Financial Stabilization Act on Drug Pricing in Germany – Early Experiences of the Reform
|
Lach, K.
|
|
|
26 |
12S |
p. S264
|
artikel
|
| 1165 |
HPR186 Implementation of Risk-Sharing Agreement in Patients with Lung Cancer Treated with Immunotherapy Based on RWD in the Czech Republic
|
Bártová, A.
|
|
|
26 |
12S |
p. S286
|
artikel
|
| 1166 |
HPR5 Implementing a Value-Based Payment Model for Patients with Osteoarthritis
|
Vutova, Y.
|
|
|
26 |
12S |
p. S255
|
artikel
|
| 1167 |
HPR191 Incentives for Using Biosimilars in France and Europe: Analysis, Assessment and Perspectives
|
Tuvi, C.
|
|
|
26 |
12S |
p. S287
|
artikel
|
| 1168 |
HPR112 International Market Access Strategies for Artificial Intelligence-Based Medical Devices: Can We Standardized the Process to Faster Patient Access?
|
Farah, L.
|
|
|
26 |
12S |
p. S274
|
artikel
|
| 1169 |
HPR120 Investigating the Nature and Scope of Innovative Payment and Pricing Schemes for Health Technologies
|
Ardito, V.
|
|
|
26 |
12S |
p. S275
|
artikel
|
| 1170 |
HPR32 Is NRDL Supporting Access or Hindering Access in China? A Time-Trend Analysis From 2017-2022
|
Leong, K.W.
|
|
|
26 |
12S |
p. S259
|
artikel
|
| 1171 |
HPR116 Is Payment Innovation Keeping Up With Therapy Innovation? A New Taxonomy of Innovative Payment Solutions to Aid Effective Implementation
|
McElwee, F.
|
|
|
26 |
12S |
p. S274
|
artikel
|
| 1172 |
HPR187 Is the Older Adult Subgroup of the Rare Disease Population Marginalized on Purpose? an Analysis of Equity Issues Encountered By the (OLDER) Rare Disease Population
|
Uwitonze, J.
|
|
|
26 |
12S |
p. S286-S287
|
artikel
|
| 1173 |
HPR31 Is the UK’S Ilap Process Delivering Its Intended Benefits? a Review of Access to Orbis Designated Oncology Products within the UK
|
Gaultney, J.
|
|
|
26 |
12S |
p. S259
|
artikel
|
| 1174 |
HPR64 Lack of Incentives, Lack of Sanctions, Lack of Compliance: Early Notification of Impending Drug Shortages in Eight European Countries
|
Ravela, R.
|
|
|
26 |
12S |
p. S264-S265
|
artikel
|
| 1175 |
HPR201 Lessons from the COVID-19 Vaccines Taskforce
|
Bell, E.
|
|
|
26 |
12S |
p. S288-S289
|
artikel
|
| 1176 |
HPR41 Linking the Price of a Drug to Its Real-Life Performance: A Solution for Financing Innovative Therapies in France?
|
Azzazene, S.
|
|
|
26 |
12S |
p. S261
|
artikel
|
| 1177 |
HPR196 Loss of Exclusivity (LOE): Impact Analysis across Europe-5 and Select Nordic Countries
|
Mali, P.K.
|
|
|
26 |
12S |
p. S288
|
artikel
|
| 1178 |
HPR108 Managed Entry Agreements and Appropriateness Tools Over the Last Three Years in Italy
|
Fagnocchi, G.
|
|
|
26 |
12S |
p. S273
|
artikel
|
| 1179 |
HPR195 Market Access Implications of Early Access to Medicines Scheme in the UK
|
Jaiswal, H.
|
|
|
26 |
12S |
p. S287-S288
|
artikel
|
| 1180 |
HPR153 Market Access Strategies for Advanced Therapy Drugs: A Comparative Analysis of the European and American Markets, Authorizations and Withdrawals
|
Claver Sicilia, C.
|
|
|
26 |
12S |
p. S280
|
artikel
|
| 1181 |
HPR101 Maximizing the Quality of Comparative Evidence in Externally Controlled Studies—The Need for a Unified Framework
|
Cockerham, A.
|
|
|
26 |
12S |
p. S271
|
artikel
|
| 1182 |
HPR35 Modelling the Effects of Smoking on Healthy Life Expectancy (HLE) in England
|
Pijper, A.
|
|
|
26 |
12S |
p. S260
|
artikel
|
| 1183 |
HPR207 Moving to Outcomes-Based Agreements in Algeria: Sharing Experiences Between Saudi Arabia and Algeria
|
Elsisi, G.
|
|
|
26 |
12S |
p. S289
|
artikel
|
| 1184 |
HPR216 Multi-Stakeholder Perspectives on Interpretation, Challenges, and Ways Forward for the Unmet Medical Need Concept – Semi-Structured Interviews
|
Claessens, Z.
|
|
|
26 |
12S |
p. S290
|
artikel
|
| 1185 |
HPR167 Neutralizing Efficacy of Expired Snake Antivenoms: A Systematic Review of Preclinical Studies and Real-World Experience
|
Soopairin, S.
|
|
|
26 |
12S |
p. S283
|
artikel
|
| 1186 |
HPR194 New Framework for Early Access to Drugs in France: Feedback After a One-Year Use in University Public Hospitals of Paris
|
Denoual, C.
|
|
|
26 |
12S |
p. S287
|
artikel
|
| 1187 |
HPR151 New Proposed European Commission Pharmaceutical Regulation – Potential Changes and Impact on Biosimilars
|
Yap, B.
|
|
|
26 |
12S |
p. S280
|
artikel
|
| 1188 |
HPR106 New Proposed European Commission Pharmaceutical Regulation – Potential Changes and Impact on Manufacturers With a Focus on Eastern & Southern European Member States
|
Yap, B.
|
|
|
26 |
12S |
p. S272
|
artikel
|
| 1189 |
HPR182 Oncology Combination Market Access Conundrum in Europe
|
Mycka, J.
|
|
|
26 |
12S |
p. S285
|
artikel
|
| 1190 |
HPR11 Oncolytic Therapies in China: Laying the Groundwork for a Successful Launch
|
Jiang, L.
|
|
|
26 |
12S |
p. S256
|
artikel
|
| 1191 |
HPR85 Opinions on Sustainable Healthcare Financing Options for Funding New Medical Technologies in ASEAN-6
|
Gill, J.L.
|
|
|
26 |
12S |
p. S268-S269
|
artikel
|
| 1192 |
HPR124 Opportunities for Improving Healthcare for Migrant Populations, as Identified by Healthcare Teams in Various Regions of Chile
|
Cabieses, B.
|
|
|
26 |
12S |
p. S276
|
artikel
|
| 1193 |
HPR188 Orphan Drugs – How Will the New Proposed European Union (EU) Commission Pharmaceutical Regulation Impact Therapies for Rare Diseases?
|
Yap, B.
|
|
|
26 |
12S |
p. S287
|
artikel
|
| 1194 |
HPR100 Orphan Drugs in Algeria and Six Other Countries: A Cross Comparison Study
|
Chaouch, R.
|
|
|
26 |
12S |
p. S271
|
artikel
|
| 1195 |
HPR177 Overview of Reimbursement Criteria for Bariatric Surgery in 23 Countries
|
Mustapha Sharaf, A.
|
|
|
26 |
12S |
p. S285
|
artikel
|
| 1196 |
HPR115 Patient Access Network: Multi-Stakeholder Shared Policy Strategies for Medical Device Access
|
Di Brino, E.
|
|
|
26 |
12S |
p. S274
|
artikel
|
| 1197 |
HPR89 Payer Rejections and Prescription Abandonment Among Patients Newly Prescribed Oral Anticoagulants for Venous Thromboembolism
|
Hines, D.M.
|
|
|
26 |
12S |
p. S269
|
artikel
|
| 1198 |
HPR46 Payers’ Perceptions of Current Policy Approaches to Address Antimicrobial Resistance in Europe
|
Satish, K.
|
|
|
26 |
12S |
p. S262
|
artikel
|
| 1199 |
HPR162 Pharmaceutical Rebates – An Anglo-French Comparison
|
Wang, G.
|
|
|
26 |
12S |
p. S282
|
artikel
|
| 1200 |
HPR96 Pieces: Productivity Losses Due to Premature Mortality From Cancer in Greece
|
Yfantopoulos, N.
|
|
|
26 |
12S |
p. S270
|
artikel
|
| 1201 |
HPR63 Plasma Last Liter Economics and Its Impact on the Costs of Major Human Polyvalent Immunoglobulins in Europe
|
Galduf, J.
|
|
|
26 |
12S |
p. S264
|
artikel
|
| 1202 |
HPR54 Policy Approaches to the Regulation and Reimbursement of Pediatric Medicines: Comparing Canadian, European, and UK Health Systems
|
Cressman, C.
|
|
|
26 |
12S |
p. S263
|
artikel
|
| 1203 |
HPR103 Potential Impacts of the EMA-HMA Join Statement Supporting Biosimilar Interchangeability in Biosimilar Access in the EU
|
Ribeiro, A.
|
|
|
26 |
12S |
p. S272
|
artikel
|
| 1204 |
HPR205 Predicting Drug Price Erosion in Germany Associated With Indication Expansion, to Understand the Potential Launch Price Benchmark for a New Product
|
Weir Lavelle, P.
|
|
|
26 |
12S |
p. S289
|
artikel
|
| 1205 |
HPR23 Preparing Healthcare Systems for Broader Cell & Gene Therapy (CGT) Access: What Needs to Change for Pharma, Healthcare Systems, and Patients so All Benefit From CGTs?
|
Green, N.
|
|
|
26 |
12S |
p. S258
|
artikel
|
| 1206 |
HPR65 Pricing and Reimbursement Mechanisms for Advanced Therapeutic Medicinal Products in 20 Countries
|
Rejon-Parrilla, J.C.
|
|
|
26 |
12S |
p. S265
|
artikel
|
| 1207 |
HPR47 Pricing Lottery or Reasonable Algorithm? Insights From the DiGA Arbitration Board
|
Gensorowsky, D.
|
|
|
26 |
12S |
p. S262
|
artikel
|
| 1208 |
HPR105 Profitability in the Global Pharmaceutical Industry: A Contested Space
|
Shaw, B.
|
|
|
26 |
12S |
p. S272
|
artikel
|
| 1209 |
HPR95 Public-Private Partnership Model in Oncology: Business Opportunities for Next Generation Contract Research Organizations in the Context of CancerX
|
Khambholja, K.
|
|
|
26 |
12S |
p. S270
|
artikel
|
| 1210 |
HPR140 Quantifying the Impact of Novel Anti-Cancer Therapies on Health Inequalities in Survival Based on Kaplan-Meier Curves
|
Zebrowska, K.
|
|
|
26 |
12S |
p. S278
|
artikel
|
| 1211 |
HPR56 Rare Disease Policies and Orphan Drug Designation Processes in European and Asia-Pacific (APAC) Countries
|
Gerhardt, L.
|
|
|
26 |
12S |
p. S263
|
artikel
|
| 1212 |
HPR218 Recent Advances in Voluntary European Cross-Border Collaborations in Joint HTA and Drug Pricing/Procurement
|
Skowron, R.
|
|
|
26 |
12S |
p. S291
|
artikel
|
| 1213 |
HPR86 Reducing Inequity: Does the New EU Pharmaceutical Legislation Address Challenges to Pharmaceutical Access in Central and Eastern Europe?
|
Stringfellow, N.
|
|
|
26 |
12S |
p. S269
|
artikel
|
| 1214 |
HPR99 Regional Access Timelines in Italy: Factors Affecting Speed and Equity
|
Mastroianni, G.
|
|
|
26 |
12S |
p. S271
|
artikel
|
| 1215 |
HPR44 Regional Inequalities in Access to Specialized Healthcare in the Brazilian Unified Health System
|
Braga, A.
|
|
|
26 |
12S |
p. S261
|
artikel
|
| 1216 |
HPR72 Regulation and Reality of the Market Access Process for Digital Health Applications (DiGA) in Germany
|
Koerber, F.
|
|
|
26 |
12S |
p. S266
|
artikel
|
| 1217 |
HPR55 Reimbursement of High Priced One-Shot Treatments in Korea: KYMRIAH and ZOLGENSMA Case Study
|
Shin, E.
|
|
|
26 |
12S |
p. S263
|
artikel
|
| 1218 |
HPR204 Reimbursement Status of Centrally Authorized Drugs in Spain per Therapeutic Area and Orphan Designation
|
Carmo, M.
|
|
|
26 |
12S |
p. S289
|
artikel
|
| 1219 |
HPR15 Review and Evaluation of Health Equity Considerations in Health Technology Assessments in Cystic Fibrosis
|
Lee, L.Y.
|
|
|
26 |
12S |
p. S257
|
artikel
|
| 1220 |
HPR123 Risk Sharing Agreements in the Asia-Pacific Region: A Systematic Literature Review on New Pricing Modalities to Improve Value Access
|
Verma, A.
|
|
|
26 |
12S |
p. S275-S276
|
artikel
|
| 1221 |
HPR184 Social Determinants of Health (SDoH) and Other Predictors in Treatment Initiation with CDK4/6 Inhibitors in Medicare Patients with HR+/HER2– Metastatic Breast Cancer (MBC)
|
Goyal, R.K.
|
|
|
26 |
12S |
p. S286
|
artikel
|
| 1222 |
HPR37 Squaring the Circle? Leveraging Early Access / Compassionate Use Pathways to Provide Market-Specific Real-World Evidence Before Launch
|
Tzaras, D.
|
|
|
26 |
12S |
p. S260
|
artikel
|
| 1223 |
HPR217 Stakeholders' Perspectives on the Unmet Medical Need Concept: A EU Pharmaceutical Strategy Survey Analysis
|
Claessens, Z.
|
|
|
26 |
12S |
p. S290-S291
|
artikel
|
| 1224 |
HPR143 Standardizing Cross-Border Access to Advanced Therapies
|
Werbrouck, A.
|
|
|
26 |
12S |
p. S278-S279
|
artikel
|
| 1225 |
HPR173 Supply-Side Stakeholders’ Opinions and Perspectives on the Development of Medical Tourism in the Region of Thessaly, Greece
|
Giannake, G.
|
|
|
26 |
12S |
p. S284
|
artikel
|
| 1226 |
HPR144 Support of RWE in the Price and Reimbursement Decision-Making Process for Rare Diseases in Spain
|
De La Paz Cañizares, I.
|
|
|
26 |
12S |
p. S279
|
artikel
|
| 1227 |
HPR118 The Assessment of Alternative or Abbreviated Market Access Pathways for Pharmaceutical Reimbursement in 13 European Markets
|
Schepis Martinez, J.
|
|
|
26 |
12S |
p. S274-S275
|
artikel
|
| 1228 |
HPR82 The Comparative Analysis of Accelerated Coverage Pathways for Innovation (ACPI) for Digital Technologies: In the Landscape of Germany, France, and the United Kingdom
|
Ramkeesoon, A.
|
|
|
26 |
12S |
p. S268
|
artikel
|
| 1229 |
HPR202 The Digital Transformation: How Could Artificial Intelligence (AI) Re-Shape Drug Launch?
|
Robert, A.
|
|
|
26 |
12S |
p. S289
|
artikel
|
| 1230 |
HPR169 The Impact of Exercise on Health Expenditure in Children
|
Balkhi, B.
|
|
|
26 |
12S |
p. S283
|
artikel
|
| 1231 |
HPR185 The Influence of Value Frameworks on Payer and Oncologist Decision-Making in the United States (US)
|
Runyan, A.
|
|
|
26 |
12S |
p. S286
|
artikel
|
| 1232 |
HPR135 The Need for Novel Mechanisms to Tackle the Global Antimicrobial Resistance (AMR) Threat: Are Innovative Payment Models Enough?
|
Pan, J.
|
|
|
26 |
12S |
p. S277-S278
|
artikel
|
| 1233 |
HPR83 The Price Is Right or Is It? Navigating the Inflation Reduction Act (IRA) With Payer Perspectives on Evidence Needs, Fair Market Pricing, and Patient Access Implications
|
Patel, C.
|
|
|
26 |
12S |
p. S268
|
artikel
|
| 1234 |
HPR132 The Role of Economic Evaluation in HTA in Spain
|
Aceituno Mata, S.
|
|
|
26 |
12S |
p. S277
|
artikel
|
| 1235 |
HPR212 The Use of Managed Entry Agreements (MEAs) for Accessing Innovative Health Technologies
|
Kodjamanova, P.
|
|
|
26 |
12S |
p. S290
|
artikel
|
| 1236 |
HPR53 Timely Reimbursement: The Impact of Early Access Programmes in Non-Squamous Non-Small Cell Lung Cancer
|
Webb, S.
|
|
|
26 |
12S |
p. S263
|
artikel
|
| 1237 |
HPR170 Time to Reimbursement in Ireland; Utilizing Regression Analysis to Assess Factors Contributing to Overall Timelines
|
McLoughlin, D.
|
|
|
26 |
12S |
p. S283
|
artikel
|
| 1238 |
HPR199 To Operationalize the VBHC in the Medical Device Area – An Italian Experience
|
Borghetti, F.
|
|
|
26 |
12S |
p. S288
|
artikel
|
| 1239 |
HPR4 Transferable Exclusivity Vouchers: A Silver Bullet?
|
Herman, K.
|
|
|
26 |
12S |
p. S255
|
artikel
|
| 1240 |
HPR94 Treating Early Often Comes Too Late: Ensuring Patient Access to Early Cancer Detection and Treatment in Europe
|
Capdevila, C.
|
|
|
26 |
12S |
p. S270
|
artikel
|
| 1241 |
HPR45 Trends in Semaglutide Prescribing and Dispensing – a Nationwide Register-Based Study
|
Kari, H.
|
|
|
26 |
12S |
p. S261-S262
|
artikel
|
| 1242 |
HPR211 Turkiye Healthcare Inflation Review between 2017 to 2022
|
Erdoğan, A.
|
|
|
26 |
12S |
p. S290
|
artikel
|
| 1243 |
HPR73 Underfunding of Public Health System and Unmet Dental Needs Among the European Elderly Population
|
Yfantopoulos, I.
|
|
|
26 |
12S |
p. S266
|
artikel
|
| 1244 |
HPR163 Underinvestment in Pharmaceutical Care and Unmet Pharmaceutical Needs Among Older European Adults
|
Yfantopoulos, I.
|
|
|
26 |
12S |
p. S282
|
artikel
|
| 1245 |
HPR117 Underinvestment in Poland and Its Impact on Health Outcomes
|
Yfantopoulos, I.
|
|
|
26 |
12S |
p. S274
|
artikel
|
| 1246 |
HPR13 Unmet Needs in Rare Diseases: Insights on Definitions and Methodological Challenges From a Grey Literature Review
|
Broekmans, J.
|
|
|
26 |
12S |
p. S257
|
artikel
|
| 1247 |
HPR24 Utilisation and Expenditure on Blood Glucose Test Strips in Ireland—The Impact of Health Technology Management in Reducing and Containing Expenditure
|
Doran, S.
|
|
|
26 |
12S |
p. S258
|
artikel
|
| 1248 |
HPR67 Utilisation of Intermittent and Real-Time Continuous Blood Glucose Monitoring in the Irish Healthcare System
|
Gorry, C.
|
|
|
26 |
12S |
p. S265
|
artikel
|
| 1249 |
HPR9 Value Criteria for Outcomes Based Managed Entry Agreement of CAR-T in Relapsed or Refractory Multiple Myeloma (RRMM) through MCDA
|
Poveda, J.L.
|
|
|
26 |
12S |
p. S256
|
artikel
|
| 1250 |
HPR36 Volume Vs Value: Understanding the Pricing Dynamics of Multi-Indication Therapies in Weighted-Average List Price Markets
|
Gerhardt, M.
|
|
|
26 |
12S |
p. S260
|
artikel
|
| 1251 |
HPR60 Voluntary Scheme for Branded Medicines Pricing and Access vs Statutory Scheme: A Case of Six vs Half a Dozen?
|
Robert, A.
|
|
|
26 |
12S |
p. S264
|
artikel
|
| 1252 |
HPR109 What Drives Socially Acceptable Costs in Outcomes Based Agreements? a Survey Studying Gene Therapies
|
Van Der Lelie, L.
|
|
|
26 |
12S |
p. S273
|
artikel
|
| 1253 |
HPR164 What Is a Fair Price? A Review of Definitions for Fair Prices of Health Technologies
|
Salcher-Konrad, M.
|
|
|
26 |
12S |
p. S282
|
artikel
|
| 1254 |
HPR131 What Is a Year of Life Worth? Empirical Findings from Worldwide Economic Studies on the Value of a Statistical Life
|
Schlander, M.
|
|
|
26 |
12S |
p. S277
|
artikel
|
| 1255 |
HPR75 What Percent of the Growth in Annual French Social Health Insurance Budget Is Attributed to New Health Products? An Estimation Based on a Retrospective Review of Budget Impact Analyses
|
Faugères, L.
|
|
|
26 |
12S |
p. S266-S267
|
artikel
|
| 1256 |
HPR154 When Could a Managed Entry Agreement Create a Win-Win-Win Situation - Exploring the Window of Opportunity
|
Callenbach, M.
|
|
|
26 |
12S |
p. S280-S281
|
artikel
|
| 1257 |
HPR52 Working Market for Patients Living With Advanced Breast Cancer in Portugal: Call for Action
|
Borges, M.
|
|
|
26 |
12S |
p. S262-S263
|
artikel
|
| 1258 |
HPR171 WTP Threshold: A Review of International Approaches and Inspiration for Cultivation of Current Situation in the Czech Republic
|
Klimes, J.
|
|
|
26 |
12S |
p. S284
|
artikel
|
| 1259 |
HSD113 Access to Medicines, Care, and Services for Multiple Sclerosis Patients in Central and Eastern European Countries: A Comparative Analysis
|
Seitaridou, Y.
|
|
|
26 |
12S |
p. S315
|
artikel
|
| 1260 |
HSD9 Access to Precision Medicine in Mexico: Differences of Therapy Patterns for ALK+ and EGFR+ Non-Small Cell Lung Cancer (NSCLC) Patients
|
Sanchez, L.
|
|
|
26 |
12S |
p. S295
|
artikel
|
| 1261 |
HSD27 A 2013-2019 Comparative Study of Patient Safety Culture at 16 Hospitals in Shimane, Japan
|
Endo, S.
|
|
|
26 |
12S |
p. S299
|
artikel
|
| 1262 |
HSD116 Actual Use in Real World Setting of Anti-BCMA CAR T Cells in Relapsed/Refractory Multiple Myeloma in EU5 Countries and in the US
|
Maï, C.
|
|
|
26 |
12S |
p. S316
|
artikel
|
| 1263 |
HSD57 Adherence Teleassistance-Based Program Impact in a Real-Life Diabetes Colombian Patient Cohort
|
Mejia-Torres, S.
|
|
|
26 |
12S |
p. S304
|
artikel
|
| 1264 |
HSD99 Analysis of Evidence Information About Herbal Medicinal Products and Its Use for Postgraduate Pharmacy Trainings in Ukraine
|
Zaliska, O.
|
|
|
26 |
12S |
p. S313
|
artikel
|
| 1265 |
HSD132 Analysis of Factors Affecting Medication Adherence in Patients with Hypertension in South Korea
|
Cha, Y.
|
|
|
26 |
12S |
p. S319
|
artikel
|
| 1266 |
HSD106 Analysis of Health Economic Evidence in Clinical Practice Guidelines Published in China Between 2017 and 2022: An Investigative Study
|
Guo, W.
|
|
|
26 |
12S |
p. S314
|
artikel
|
| 1267 |
HSD94 Assessing Payer Perspectives on Novel Therapies for the Treatment of Gorlin Syndrome
|
Lopez Pont, M.A.
|
|
|
26 |
12S |
p. S312
|
artikel
|
| 1268 |
HSD76 Assessing the Carbon Intensity Profile of an Immunization Program Against RSV in Infants in the United Kingdom to Show the Reduction in Emissions Versus Standard of Care
|
Hudson, R.
|
|
|
26 |
12S |
p. S308
|
artikel
|
| 1269 |
HSD79 Assessment of Patient Satisfaction with Public Pharmacies Dispensing High-Cost Drugs in Greece
|
Georgi, C.
|
|
|
26 |
12S |
p. S308-S309
|
artikel
|
| 1270 |
HSD122 A Systematic Review on Equal Access to Treatment for Hearing Loss in Chile: Do All People Have the Same Opportunities to Receive Appropriate Treatment?
|
Scandurra, F.
|
|
|
26 |
12S |
p. S317
|
artikel
|
| 1271 |
HSD45 Atopic Dermatitis’ Treatment Patterns in Latin America: A Systematic Literature Review
|
Criado, P.R.
|
|
|
26 |
12S |
p. S302
|
artikel
|
| 1272 |
HSD81 Automated Report Generation with Chat GPT API for Cardiology: Performance Evaluation and Impact on Physician Burnout
|
Cossio, M.
|
|
|
26 |
12S |
p. S309
|
artikel
|
| 1273 |
HSD90 Beyond the Hospital Walls: Hospital at Home Programs for Cancer Patients Worldwide and the Road to Implementation in Greece
|
Braoudaki, E.
|
|
|
26 |
12S |
p. S311
|
artikel
|
| 1274 |
HSD64 Breast Cancer in the COVID-19 Pandemic Era: An Old Tool with Modern Innovations
|
Gioia, S.
|
|
|
26 |
12S |
p. S306
|
artikel
|
| 1275 |
HSD104 Comparative Analysis of Legislations and Market Access of Cannabis Medicines in Poland and Ukraine
|
Brezden, O.
|
|
|
26 |
12S |
p. S314
|
artikel
|
| 1276 |
HSD74 Cost Savings as a Result of Biosimilar Medications Adoption in One of the Tertiary Governmental Hospitals in Riyadh, Saudi Arabia.
|
Alshehri, N.
|
|
|
26 |
12S |
p. S308
|
artikel
|
| 1277 |
HSD107 Descriptive Analysis of Changes to Cardiovascular Healthcare Resource Use Recorded in Malaysian Real World Data from the Syntium Database before, during and after the COVID-19 Pandemic
|
Beecroft, S.
|
|
|
26 |
12S |
p. S314
|
artikel
|
| 1278 |
HSD101 Development of an Adjusted Outpatient Surgery Index (AOSI) Using Machine Learning Methods
|
Costa, P.
|
|
|
26 |
12S |
p. S313
|
artikel
|
| 1279 |
HSD130 Development of a Risk-Adjusted in-Hospital Complication Rate (RAICR) Using Machine Learning Methods
|
Costa, P.
|
|
|
26 |
12S |
p. S319
|
artikel
|
| 1280 |
HSD24 Digital Medical Services Delivered by Internet Hospitals via WeChat in China: A Qualitative Analytical Research
|
Lai, Y.F.
|
|
|
26 |
12S |
p. S298
|
artikel
|
| 1281 |
HSD129 Does Digital Healthcare Improve the Utilization of Public Hospitals in the Emirate of Dubai?
|
Dai-Woodys, L.L.
|
|
|
26 |
12S |
p. S319
|
artikel
|
| 1282 |
HSD86 Economic Attributes of Caregiver Burden Among Schizophrenia Patients: A Targeted Literature Review
|
Han, X.
|
|
|
26 |
12S |
p. S310
|
artikel
|
| 1283 |
HSD70 Economic Benefit of Empowering Community Pharmacists in the Diagnosis and Treatment of Acute Sore Throat in England
|
Aluko, P.
|
|
|
26 |
12S |
p. S307
|
artikel
|
| 1284 |
HSD53 Effect of COVID-19 Pandemic on the Delivery Time and the Point of Re-Order of Pharmaceuticals at the Logistics Services in a Governmental Hospital in Riyadh Saudi Arabia
|
Alshehri, N.
|
|
|
26 |
12S |
p. S303-S304
|
artikel
|
| 1285 |
HSD68 Emotions of Physicians Elicited by Their Patients’ Rare Disease Diagnoses: A Cross-Sectional Study in Europe and the United States
|
Omri, A.
|
|
|
26 |
12S |
p. S306
|
artikel
|
| 1286 |
HSD80 Employees Satisfaction Working at Arta General Hospital of Greece
|
Konstantinou, E.
|
|
|
26 |
12S |
p. S309
|
artikel
|
| 1287 |
HSD52 Employess Satisfaction Level from Working Conditions at the Public Psychiatric Hospital of Athens, Greece
|
Kosta, P.
|
|
|
26 |
12S |
p. S303
|
artikel
|
| 1288 |
HSD1 England's Population Health Agreement for Inclisiran – Evidence of Very Limited Prescribing Uptake
|
Wang, G.
|
|
|
26 |
12S |
p. S294
|
artikel
|
| 1289 |
HSD8 Enhancing Prostate Cancer Care by Optimizing Patient Engagement with Digital Tools
|
Tallentire, C.W.
|
|
|
26 |
12S |
p. S295
|
artikel
|
| 1290 |
HSD123 Environmental Impact of Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in the Netherlands
|
Quist, S.
|
|
|
26 |
12S |
p. S317-S318
|
artikel
|
| 1291 |
HSD73 Establishing a Learning Healthcare System for Metastatic Prostate Cancer in the Dutch Healthcare System: Preconditions and Potential Benefits of Real-World Data Utilization
|
Belleman, T.
|
|
|
26 |
12S |
p. S307-S308
|
artikel
|
| 1292 |
HSD108 Evaluating Electronic Therapeutic Protocols (ETPS) for Diabetes and Heart Failure in Greece: Results from a Quantitative Survey Amongst Practicing Physicians
|
Souliotis, K.
|
|
|
26 |
12S |
p. S314-S315
|
artikel
|
| 1293 |
HSD19 Evaluation of Vascular Access Modality for Hemodialysis Patients: Analysis of Real-World Data in Italy
|
Monteverde Spencer, G.T.
|
|
|
26 |
12S |
p. S297-S298
|
artikel
|
| 1294 |
HSD97 Exploring European Expert Opinion to Ensure Provision & Access of Optimal Ophthalmology Care & Outcomes in a Post-COVID World
|
Gale, R.
|
|
|
26 |
12S |
p. S312
|
artikel
|
| 1295 |
HSD59 Exploring Factors for Regional Differences in Inappropriate Psychotropic Drug Prescribing: Ecological Study Using a Claims Database in Japan
|
Fujisawa, M.
|
|
|
26 |
12S |
p. S304-S305
|
artikel
|
| 1296 |
HSD92 Factors Having an Impact on the Prescription of Cancer Treatments in Hospital at Home Program in Bronchopulmonary Cancer: A French Claims Database Analysis (2016-2021)
|
Pozzar, M.
|
|
|
26 |
12S |
p. S311
|
artikel
|
| 1297 |
HSD40 Fecal Incontinence of Patients After Stoma Reversal: A German Claims Data Analysis Reveals Concerns
|
Surendranathan, N.
|
|
|
26 |
12S |
p. S301
|
artikel
|
| 1298 |
HSD84 Financial Hardship from Neglected Tropical Diseases: A Systematic Literature Review and Meta-Analysis
|
Patikorn, C.
|
|
|
26 |
12S |
p. S309
|
artikel
|
| 1299 |
HSD38 From Unpersonalized to Personalized Breast Follow-up in Clinical Practice in the Netherlands: Will Artificial Intelligence Make a Difference?
|
Voets, M.
|
|
|
26 |
12S |
p. S300-S301
|
artikel
|
| 1300 |
HSD37 Gender Disparities in Treatment and Costs of Rectal Cancer at the End of Life Phase—An Analysis of German Claims Data
|
Greth, K.
|
|
|
26 |
12S |
p. S300
|
artikel
|
| 1301 |
HSD115 Genetic Testing in Chinese Breast Cancer Patients: A Survey on Knowledge, Receipt, and Willingness to Pay
|
Wei, X.
|
|
|
26 |
12S |
p. S316
|
artikel
|
| 1302 |
HSD41 Healthcare Models for Rare Diseases: A Systematic Literature Review for the Development of a Comprehensive Model in a Latin American Country
|
Ossa, M.E.
|
|
|
26 |
12S |
p. S301
|
artikel
|
| 1303 |
HSD117 Healthcare Resources Utilization (HCRU) and Exploration of the Patient Journey through Claims Database: An Application on Advanced Renal Cell Carcinoma (ARCC) Patients in France
|
Durand-Zaleski, I.
|
|
|
26 |
12S |
p. S316
|
artikel
|
| 1304 |
HSD44 Healthcare Resource Utilization of Severe Eosinophilic Asthma Patients Treated With Benralizumab in Real-Life: Results From the Portuguese BETREAT Study
|
Chaves-Loureiro, C.
|
|
|
26 |
12S |
p. S302
|
artikel
|
| 1305 |
HSD23 Health Technology Management - The Future of the Post-Reimbursement Phase?
|
Smith, A.
|
|
|
26 |
12S |
p. S298
|
artikel
|
| 1306 |
HSD12 Hepatocellular Carcinoma Patient Pathway in Portugal – From Diagnosis to Treatment – Results From Opal Study
|
Moital, I.
|
|
|
26 |
12S |
p. S296
|
artikel
|
| 1307 |
HSD91 High Costs, Low Quality of Life, Reduced Survival, and Room for Improving Treatment: An Analysis of Burden and Unmet Needs in Glioma
|
Pöhlmann, J.
|
|
|
26 |
12S |
p. S311
|
artikel
|
| 1308 |
HSD33 Horizontal Inequities in the Healthcare Expenditures for Communicable Disease: An Evidence from the National Sample Survey Data
|
Sriram, S.
|
|
|
26 |
12S |
p. S299-S300
|
artikel
|
| 1309 |
HSD11 Hospital Capacity Tool to Assess the Potential Impact of Using a Fixed Dose Combination of Pertuzumab/Trastuzumab for Subcutaneous Injection Versus Intravenous Pertuzumab/Trastuzumab in HER2+ Breast Cancer
|
Cunha, A.
|
|
|
26 |
12S |
p. S296
|
artikel
|
| 1310 |
HSD67 How Can a Digital Twin Help Achieve Technical Efficiency? an Application to the French Medical Genomics Pilot Sequencing Platform Auragen
|
Le Lay, J.
|
|
|
26 |
12S |
p. S306
|
artikel
|
| 1311 |
HSD31 Impact and Management of Comorbidities in People With Obesity: A Multinational Survey
|
Khare, S.
|
|
|
26 |
12S |
p. S299
|
artikel
|
| 1312 |
HSD49 Impact of Endoscope Choice on Nurse Time in GI Surgical Procedures: A Prospective Study in a Danish University Hospital
|
Nielsen, K.
|
|
|
26 |
12S |
p. S303
|
artikel
|
| 1313 |
HSD36 Impact of Non-Medical Factors on Patterns of Treatment in Patients With Cancer: A Systematic Literature Review
|
Thakur, D.
|
|
|
26 |
12S |
p. S300
|
artikel
|
| 1314 |
HSD82 Impact of the COVID-19 Pandemic in the Netherlands on Primary Healthcare Use and Clinical Outcomes in People with Type 2 Diabetes
|
van den Berg, J.
|
|
|
26 |
12S |
p. S309
|
artikel
|
| 1315 |
HSD127 Impact of the COVID-19 Pandemic on Frequency of Surgeries in Germany Based on Hospital Data
|
Schnaidt, S.
|
|
|
26 |
12S |
p. S318
|
artikel
|
| 1316 |
HSD72 Improving Patient Care for Chronic Kidney Disease-Related Anemia in Italy: A Survey to Evaluate the Nephrological Card As a Tool for Optimizing Treatment Pathway
|
Leone, F.P.C.
|
|
|
26 |
12S |
p. S307
|
artikel
|
| 1317 |
HSD50 Infantile Vaccination Coverage in Brazil From 2016-2022 – Effects of Pandemic Period in Non-COVID-19 Vaccination
|
Julian, G.S.
|
|
|
26 |
12S |
p. S303
|
artikel
|
| 1318 |
HSD4 Institutional and Geographical Variation in Discharge Destination Among Admission Avoidance Municipal Inpatient Acute Care Units in Norway
|
Yang, F.
|
|
|
26 |
12S |
p. S294
|
artikel
|
| 1319 |
HSD15 Investigating the Impact of Early Versus Late Diagnosis in Fabry Disease on Healthcare Resource Utilization and Associated Costs in Greece
|
Naoum, P.
|
|
|
26 |
12S |
p. S297
|
artikel
|
| 1320 |
HSD18 Itch Intensity and Therapeutic Management of Pruritus in the Real-World Setting
|
Rasouliyan, L.
|
|
|
26 |
12S |
p. S297
|
artikel
|
| 1321 |
HSD17 Key Features and Preferences for New High-Volume Low-Complexity Outpatient Care: Using Discrete Choice Experiments in Ophthalmology to Improve Diagnostic Service Delivery in England
|
Ndwandwe, S.
|
|
|
26 |
12S |
p. S297
|
artikel
|
| 1322 |
HSD5 Knowledge, Attitude, and Practice of Pharmacy Professionals Against Dispensing Antibiotics Without Prescription in Ethiopia
|
Haile, K.
|
|
|
26 |
12S |
p. S294-S295
|
artikel
|
| 1323 |
HSD103 Lifestyle Modifications and Medicines as the Foundation of Clinical Practice Guidelines
|
Roach, M.
|
|
|
26 |
12S |
p. S313-S314
|
artikel
|
| 1324 |
HSD32 Long COVID: Clinical Characteristics and Management in the Real-World Setting
|
Althoff, A.
|
|
|
26 |
12S |
p. S299
|
artikel
|
| 1325 |
HSD7 Longitudinal Analysis of Diagnostic Procedures for Sleep Disorders in the German In-Patient Sector
|
Braun, M.
|
|
|
26 |
12S |
p. S295
|
artikel
|
| 1326 |
HSD131 Long-Term Impact of a Comprehensive Care Coordination Program on Medicaid Expenditures Among Children and Young Adults with Chronic Diseases
|
Caskey, R.N.
|
|
|
26 |
12S |
p. S319
|
artikel
|
| 1327 |
HSD71 Management of Care for Patients With Actinic Keratosis in France: Reakt Study
|
Lévy, P.
|
|
|
26 |
12S |
p. S307
|
artikel
|
| 1328 |
HSD69 Maternal and Foeto-Neonatal Characteristics of Childbirths in Ethiopia: A Multilevel Mixed-Effect Analysis
|
Wami, G.
|
|
|
26 |
12S |
p. S307
|
artikel
|
| 1329 |
HSD46 Multidisciplinary Discussion for Interstitial Lung Disease Associated With Autoimmune Rheumatic Diseases: A Cross Sectional Survey to Evaluate the Experiences of Multidisciplinary Teams in Italy
|
Leone, F.P.C.
|
|
|
26 |
12S |
p. S302-S303
|
artikel
|
| 1330 |
HSD63 New Pathway in Anti-HER2 Treatments’ Administration in Breast Cancer in France: Which Impacts of the Involvement of an Advanced Practice Nurse in Hospital at Home Program?
|
Pozzar, M.
|
|
|
26 |
12S |
p. S305-S306
|
artikel
|
| 1331 |
HSD125 Non-Dispensed Prescriptions from the Public and Private Health Care Sectors: A Comparative Register Study
|
Nurminen, F.
|
|
|
26 |
12S |
p. S318
|
artikel
|
| 1332 |
HSD100 Opportunities and Barriers to Hub-and-Spoke Delivery Models for Advanced Therapy Medicinal Products in Europe: A Scoping Review
|
Ramos, A.
|
|
|
26 |
12S |
p. S313
|
artikel
|
| 1333 |
HSD75 Optimizing Preoperative Assessment Through a Digital Healthcare Platform for Triage and Stratification in Joint Replacement Surgery: A Real-World Evaluation
|
Gleave, F.
|
|
|
26 |
12S |
p. S308
|
artikel
|
| 1334 |
HSD98 Patient Characteristics and Treatment Patterns in Patients with Advanced Psoriasis in Specialty Care Settings in Finland
|
Koulu, L.
|
|
|
26 |
12S |
p. S312
|
artikel
|
| 1335 |
HSD119 Patient Pathways, Genetic Testing, and Diagnosis of X-Linked Retinitis Pigmentosa in Europe: Insights from the Cross-Sectional Explore Xlrp-1.2 Physician Survey
|
Denee, T.
|
|
|
26 |
12S |
p. S317
|
artikel
|
| 1336 |
HSD118 Patient Safety in Oncology: Quantifying the Hospital-Associated Risks with a Discrete-Events Simulation
|
Canobbio, M.
|
|
|
26 |
12S |
p. S316-S317
|
artikel
|
| 1337 |
HSD25 Patients’ Satisfaction from Primary Healthcare Services in 1ST Local Health Unit (LHU) of N. Philadelphia-N. Chalkidona Municipality Greece
|
Kalagia, P.
|
|
|
26 |
12S |
p. S298-S299
|
artikel
|
| 1338 |
HSD85 Patterns and Correlates of Physical Activity Among Nigerian Community-Dwelling Older Adults
|
Mbada, C.
|
|
|
26 |
12S |
p. S310
|
artikel
|
| 1339 |
HSD105 Pharmacists' Intervention in Access to Therapeutical Innovation in Portuguese Hospitals
|
Coelho, H.
|
|
|
26 |
12S |
p. S314
|
artikel
|
| 1340 |
HSD87 Physician Reported Reasons for Cidp Treatment Choice across 5 European Countries: Results from a Real-World Survey
|
Borsi, A.
|
|
|
26 |
12S |
p. S310
|
artikel
|
| 1341 |
HSD128 Preferences of Healthcare Providers in Switzerland for Attributes of Pediatric Hexavalent Vaccines
|
Samant, S.
|
|
|
26 |
12S |
p. S318-S319
|
artikel
|
| 1342 |
HSD102 Preferences of Nurses for Attributes of Pediatric Hexavalent Vaccines in the United Kingdom
|
Boeri, M.
|
|
|
26 |
12S |
p. S313
|
artikel
|
| 1343 |
HSD30 Real-World Prescribing of GLP-1s Among Patients With Overweight or Obesity in the United States
|
Rodriguez, P.
|
|
|
26 |
12S |
p. S299
|
artikel
|
| 1344 |
HSD58 Real-World Prescribing of Long-Acting Injectable Cabotegravir for Treatment of HIV in the United States
|
Rodriguez, P.
|
|
|
26 |
12S |
p. S304
|
artikel
|
| 1345 |
HSD111 Real-World Treatment Patterns of Ankylosing Spondylitis
|
Rasouliyan, L.
|
|
|
26 |
12S |
p. S315
|
artikel
|
| 1346 |
HSD112 Real-World Trends in APOE Genetic Testing Associated with Lecanemab
|
Cartwright, B.
|
|
|
26 |
12S |
p. S315
|
artikel
|
| 1347 |
HSD34 Real-World Usage of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with Axial Spondyloarthritis in Germany
|
Anjohrin, S.
|
|
|
26 |
12S |
p. S300
|
artikel
|
| 1348 |
HSD60 Real-World Usage of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with Psoriatic Arthritis in Germany
|
Song, J.
|
|
|
26 |
12S |
p. S305
|
artikel
|
| 1349 |
HSD21 Regional Differences in the Use of Ige Testing in Primary Care: The Case of Sweden
|
Pousette, A.
|
|
|
26 |
12S |
p. S298
|
artikel
|
| 1350 |
HSD55 Sex Differences in Guideline Adherence for Coronary Angiography in Patients with Suspected Chronic Coronary Artery Disease in Germany: Insights from the ENLIGHT-KHK Trial
|
Kentenich, H.
|
|
|
26 |
12S |
p. S304
|
artikel
|
| 1351 |
HSD121 Study of Effective Treatment of Genital Herpes in Women in Ukraine
|
Zaliska, O.
|
|
|
26 |
12S |
p. S317
|
artikel
|
| 1352 |
HSD43 Survey Research Using PRO Data in Clinical Practice: Lessons Learnt from the Nordic Countries
|
Buckley, C.
|
|
|
26 |
12S |
p. S302
|
artikel
|
| 1353 |
HSD120 Tafamidis in the Treatment of Transthyretin Amyloid Cardiomyopathy in Poland: Epidemiological Data and Demographic Data from an Expanded Access Program
|
Sobczyńska-Kilias, A.
|
|
|
26 |
12S |
p. S317
|
artikel
|
| 1354 |
HSD6 The CONNACT Program for Knee Osteoarthritis Can Potentially Lower 2-Year Costs of Outpatient Treatment
|
Lim, C.J.
|
|
|
26 |
12S |
p. S295
|
artikel
|
| 1355 |
HSD61 The Diagnostic Journey of Patients with Mild Cognitive Impairment and Alzheimer’s Disease Dementia, and the Importance of Biomarker Testing for Timely Diagnosis: A Real-World Survey in Europe
|
Vasileva, S.Z.
|
|
|
26 |
12S |
p. S305
|
artikel
|
| 1356 |
HSD62 The Emotional and Information Seeking Experience of Locally Advanced Cervical Cancer: Qualitative Research Findings from Brazil
|
Szamreta, E.A.
|
|
|
26 |
12S |
p. S305
|
artikel
|
| 1357 |
HSD10 The Hospital Care Pathway of Patients Treated By Axi-Cel and Tisa-Cel between 2018 and 2021 in France: A National Study Based on the Comprehensive Inpatient Stays Database
|
Thieblemont, C.
|
|
|
26 |
12S |
p. S295-S296
|
artikel
|
| 1358 |
HSD42 The Humanistic Impact of X-Linked Retinitis Pigmentosa (XLRP): Results from the Explore Xlrp-2 Retrospective Chart Review and Cross-Sectional Survey of Patients and Caregivers in 10 Countries
|
Denee, T.
|
|
|
26 |
12S |
p. S301-S302
|
artikel
|
| 1359 |
HSD13 The Impact of Co-Locating GP-Led Minor Injury Clinic on Pediatric Emergency Department
|
Pak, A.
|
|
|
26 |
12S |
p. S296
|
artikel
|
| 1360 |
HSD77 The Impact of the COVID-19 Pandemic on Patient Flow and Key Performance Indicators (KPIS) of Hippocration General Hospital of Athens
|
Chatzinikolaou, N.
|
|
|
26 |
12S |
p. S308
|
artikel
|
| 1361 |
HSD89 The Operational Effectiveness of Using an M L-Driven Patient Medical Record: A Simulated Comparative Study Using Real-World Data
|
Barnosky, V.
|
|
|
26 |
12S |
p. S310-S311
|
artikel
|
| 1362 |
HSD88 The Propensity to Receive Haematopoietic Stem Cell Transplantation in Diffuse Large B-Cell Lymphoma Patients Based on Sex, Ethnicity, and Deprivation: Results From National Cancer Registry Linked Real-World Datasets in England
|
João Carvalho, S.
|
|
|
26 |
12S |
p. S310
|
artikel
|
| 1363 |
HSD93 Towards Diagnosing Rare Diseases: Referral Behavior of Physicians in Europe
|
Omri, A.
|
|
|
26 |
12S |
p. S311-S312
|
artikel
|
| 1364 |
HSD3 Treatment and Associated Outcomes of Type-2 Diabetes Mellitus Patients With a Cardiovascular Comorbidity and Comparison With Guideline Recommendations: A German Claims Data Analysis
|
Gabler, M.
|
|
|
26 |
12S |
p. S294
|
artikel
|
| 1365 |
HSD35 Treatment and Dosage Patterns of Oral Corticosteroids Among Patients With Myasthenia Gravis: A Tale of Two Countries
|
Cai, Q.
|
|
|
26 |
12S |
p. S300
|
artikel
|
| 1366 |
HSD39 Treatment Pathway and Unmet Needs of Mantle Cell Lymphoma Patients: An Exploratory Study from Portugal
|
Dimitrovova, K.
|
|
|
26 |
12S |
p. S301
|
artikel
|
| 1367 |
HSD66 Treatment Pathway and Unmet Needs of Waldenström Macroglobulinemia: An Exploratory Study from Portugal
|
Dimitrovova, K.
|
|
|
26 |
12S |
p. S306
|
artikel
|
| 1368 |
HSD114 Treatment Patterns and Adverse Events (AEs) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in France, Italy, and the United Kingdom (UK)
|
Ysebaert, L.
|
|
|
26 |
12S |
p. S315-S316
|
artikel
|
| 1369 |
HSD124 Treatment Patterns in Pediatric Patients with Atopic Dermatitis
|
Kuo, T.
|
|
|
26 |
12S |
p. S318
|
artikel
|
| 1370 |
HSD96 Trends in the Therapeutic Management of Bullous Pemphigoid in the Real-World Setting
|
Althoff, A.
|
|
|
26 |
12S |
p. S312
|
artikel
|
| 1371 |
HSD95 Unmet Needs and Value Proposition for Genital Warts Novel Treatments: Payer Perception
|
Lopez Pont, M.A.
|
|
|
26 |
12S |
p. S312
|
artikel
|
| 1372 |
HSD2 Using Automated Data Extraction Methods to Understand the Evolution of Insulin Prescribing in the UK between 2021 and 2022
|
Qureshi, A.
|
|
|
26 |
12S |
p. S294
|
artikel
|
| 1373 |
HSD56 Utilization of Vascular Assessment Before Lower Extremity Amputation Among Patients With Diabetic Foot Ulcerations in the US
|
Zheng, H.
|
|
|
26 |
12S |
p. S304
|
artikel
|
| 1374 |
HSD22 Vaccine Preparation Time, Cost, and Preference Comparison Between Pre-Filled Syringe Formulations and Vaccines That Require Reconstitution: A Targeted Literature Review
|
Mehta, D.
|
|
|
26 |
12S |
p. S298
|
artikel
|
| 1375 |
HSD47 Value for Money of Multidisciplinary Programs for Integrated Care in Dialysis: Being Actively Involved and No Merely Listed Matters
|
Martínez-Vaquera, S.
|
|
|
26 |
12S |
p. S303
|
artikel
|
| 1376 |
HSD109 What Are the Main Challenges in Management Care of Stoma Patients in France: Guidelines from Shield Multidisciplinary Experts for Optimization
|
Romao, C.
|
|
|
26 |
12S |
p. S315
|
artikel
|
| 1377 |
HSD14 X-Linked Retinitis Pigmentosa Impacts Patients’ Independence, Work Status, and Quality of Life: Insights from the Cross-Sectional Explore Xlrp-1.2 Physician Survey
|
Denee, T.
|
|
|
26 |
12S |
p. S296
|
artikel
|
| 1378 |
HTA186 Accelerating Access to Medical Technologies: An Overview of the NICE Early Value Assessment Pilot Project in the UK
|
So, D.
|
|
|
26 |
12S |
p. S355
|
artikel
|
| 1379 |
HTA110 Acceptability of Surrogate Endpoints by Health Technology Assessment Bodies: Results from a Systematic Review of Transparency Committee Assessments in France
|
Massetti, M.
|
|
|
26 |
12S |
p. S339-S340
|
artikel
|
| 1380 |
HTA327 Acceptance of Real-World Evidence As Comparative Efficacy in Lieu of Trial Evidence: A Review of Past NICE Appraisals in Oncology
|
Morgan, J.
|
|
|
26 |
12S |
p. S383
|
artikel
|
| 1381 |
HTA22 Access to Orphan Pediatric and Adolescent Medicinal Products in Greece Over 4 Years (2018-2021)
|
Margetis, A.
|
|
|
26 |
12S |
p. S324
|
artikel
|
| 1382 |
HTA360 A Comparative Assessment of Systematic Literature Review Requirements for Health Technology Assessment, Globally
|
Wright, C.
|
|
|
26 |
12S |
p. S389-S390
|
artikel
|
| 1383 |
HTA117 A Comparison of Health Technology Appraisal (HTA) Timelines and Requirements for Orphan Technologies in 10 European Countries
|
Mumford, A.
|
|
|
26 |
12S |
p. S341
|
artikel
|
| 1384 |
HTA189 A Critical Appraisal of Economic Evaluations in RSV
|
Hudson, R.
|
|
|
26 |
12S |
p. S355
|
artikel
|
| 1385 |
HTA187 Advancing a Collaborative Value Assessment Framework for Next-Generation Sequencing/Comprehensive Genomic Profiling in Europe: Building on and Enhancing an Existing Framework – A Multi-Stakeholder Web-Delphi Approach
|
Kanavos, P.
|
|
|
26 |
12S |
p. S355
|
artikel
|
| 1386 |
HTA258 A Hospital-Based Health Technology Assessment of Near-Infrared Fluorescence Using Indocyanine Green for Sentinel Lymph Node Mapping for Breast Cancer and Gynecologic Cancer
|
Lettieri, E.
|
|
|
26 |
12S |
p. S370
|
artikel
|
| 1387 |
HTA345 Amplifying the Patient Voice: Characterising the Impact of Patient and Clinician Engagement (PACE) Meetings on SMC Decision Making
|
Horsburgh, S.
|
|
|
26 |
12S |
p. S386
|
artikel
|
| 1388 |
HTA232 A Multi-Criteria Decision Analysis Framework for the Value Assessment of First-Line Treatment of Adult Patients with Advanced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer
|
Martins, P.
|
|
|
26 |
12S |
p. S364
|
artikel
|
| 1389 |
HTA253 Analysis of HTA Assessments, Usage, and Reimbursement of Newly Introduced Outpatient Drugs in the Netherlands Between 2017 and 2021 – A Secondary Data Analysis
|
van Wijk, M.
|
|
|
26 |
12S |
p. S369
|
artikel
|
| 1390 |
HTA29 Analysis of the Change of the Added Benefit and Respective Reasons in Renewed Regular Benefit Assessments of Orphan Drugs Due to Exceeding the Sales Threshold in Germany
|
Brückel, S.
|
|
|
26 |
12S |
p. S325
|
artikel
|
| 1391 |
HTA353 Analysis of the Impact of Early Access Decisions on Pricing and Reimbursement Decisions in France
|
Abdelghani, I.
|
|
|
26 |
12S |
p. S388
|
artikel
|
| 1392 |
HTA136 Analysis of the Reimbursement and Pricing of Hybrid Medicines in France
|
Gaugy, P.
|
|
|
26 |
12S |
p. S345
|
artikel
|
| 1393 |
HTA216 Analyzing Delays in Economic Appraisal in France : A Comparative Study of 2021 and 2022
|
Grangeon, A.
|
|
|
26 |
12S |
p. S361
|
artikel
|
| 1394 |
HTA323 Analyzing Historic Health Technology Assessments (HTAs): Surrogate Endpoints (SEs) in the Interstitial Pneumonia With Autoimmune Features (IPF)/Interstitial Lung Disease (ILD) Therapeutic Domain
|
Mathers, L.
|
|
|
26 |
12S |
p. S383
|
artikel
|
| 1395 |
HTA180 Analyzing Transparency Committee Discussions: A Database Approach to Understanding Decision-Making Factors
|
Blachier, M.
|
|
|
26 |
12S |
p. S354
|
artikel
|
| 1396 |
HTA5 An Evaluation of the NICE Early Value Assessment: What Is the Opportunity for Digital Therapeutics?
|
Macaulay, R.
|
|
|
26 |
12S |
p. S320-S321
|
artikel
|
| 1397 |
HTA240 An Evaluation of the Reimbursement Status of CAR-T Cell Therapies in the EU-4 and UK
|
Rodrigues, T.
|
|
|
26 |
12S |
p. S366
|
artikel
|
| 1398 |
HTA89 An Increased Use of External Data to Inform Survival Extrapolations in NICE Technology Appraisals
|
Reitsma, F.
|
|
|
26 |
12S |
p. S336
|
artikel
|
| 1399 |
HTA167 Another Hurdle in Anticancer New Drug Listing in Korea—Setting the Reimbursement Scope
|
Kim, S.
|
|
|
26 |
12S |
p. S351
|
artikel
|
| 1400 |
HTA47 An Overview of the Challenges in the HTA of Interventions Involving Healthcare Reorganisation
|
Teljeur, C.
|
|
|
26 |
12S |
p. S329
|
artikel
|
| 1401 |
HTA222 Antimicrobial Resistance: Evolving Changes in Health Technology Assessment and Reimbursement of New Treatment Options
|
Sostar, J.
|
|
|
26 |
12S |
p. S362
|
artikel
|
| 1402 |
HTA328 An Updated Analysis of the Early Access Reform and Trends Observed in the Evaluation by the HAS
|
Gontier, P.
|
|
|
26 |
12S |
p. S384
|
artikel
|
| 1403 |
HTA296 Applying Continual Stakeholder Engagement to Develop Multi-Criteria Decision Analysis (MCDA) for Health Technology Assessment in Major Depressive Disorder (MDD)
|
Chapman, R.
|
|
|
26 |
12S |
p. S377-S378
|
artikel
|
| 1404 |
HTA246 A QALY Is Not a QALY When It Comes to Health Technology Appraisals of Pediatric Rare Diseases
|
Guest, S.
|
|
|
26 |
12S |
p. S367
|
artikel
|
| 1405 |
HTA107 Are All Unmet Needs Valued the Same? A Review of Disease Prioritization and Related Resource Allocation in Europe
|
Shaw, C.
|
|
|
26 |
12S |
p. S339
|
artikel
|
| 1406 |
HTA303 Are BSC and Patient-Individual Therapy as Appropriate Comparators Detrimental for AMNOG Benefit Assessment and Price Rebates in Germany?
|
Gunesch, A.P.
|
|
|
26 |
12S |
p. S379
|
artikel
|
| 1407 |
HTA33 Are Digital Health Therapeutics Reshaping the HTA Framework for Health Technologies?
|
Tutulea, E.
|
|
|
26 |
12S |
p. S326
|
artikel
|
| 1408 |
HTA24 Are the Hurdles Too High for Access to Gene Therapies in the UK?
|
Sideris, E.
|
|
|
26 |
12S |
p. S324
|
artikel
|
| 1409 |
HTA302 A Retrospective Analysis of the Impact of Treatment Effect on HTA Outcomes for Oncology Treatments Assessed in France and Germany
|
Hashim, S.
|
|
|
26 |
12S |
p. S378-S379
|
artikel
|
| 1410 |
HTA204 A Retrospective of the HAS Economic Appraisals Over the Last Ten Years
|
Gerrer, R.
|
|
|
26 |
12S |
p. S359
|
artikel
|
| 1411 |
HTA21 A Retrospective Review of Recent NICE Technology Appraisals From 2021 to 2023 to Investigate the Consideration and Acceptability of Cure Modelling Assumptions
|
Alexopoulos, S.T.
|
|
|
26 |
12S |
p. S324
|
artikel
|
| 1412 |
HTA299 A Review of NICE Technology Appraisals of Oncology Treatments in the Past 2 Years – Model Approaches, End of Life Status, and Recommendation Decisions
|
Jin, G.
|
|
|
26 |
12S |
p. S378
|
artikel
|
| 1413 |
HTA314 A Review of Pediatric Medicines Assessed by NICE Between 2018 and 2023
|
Karinou, E.
|
|
|
26 |
12S |
p. S381
|
artikel
|
| 1414 |
HTA209 A Review of the Differences Between the New EMA-EUnetHTA Joint Scientific Consultation Versus the Previous Ema-HTA Parallel Scientific Consultation
|
D'Ausilio, A.
|
|
|
26 |
12S |
p. S360
|
artikel
|
| 1415 |
HTA109 A Review of the Use of Indirect Treatment Comparisons to Support Health Technology Assessments in Ireland
|
Piper, R.
|
|
|
26 |
12S |
p. S339
|
artikel
|
| 1416 |
HTA269 Are We Leaving No One behind? Health Technology Assessment as a Pathway to Social Justice
|
Akunne, C.
|
|
|
26 |
12S |
p. S372
|
artikel
|
| 1417 |
HTA355 A Roadmap Towards Implementing HTA in Oman
|
AlRashdi, I.
|
|
|
26 |
12S |
p. S388-S389
|
artikel
|
| 1418 |
HTA283 A Scoping Review of Health Technology Assessment Agency (HTA) and Health Economic (HE) Modelling Guidelines for Identification of Health Economic Model Inputs
|
Lister, J.
|
|
|
26 |
12S |
p. S375
|
artikel
|
| 1419 |
HTA37 Assessing the Definition and Outcomes of Innovative Drugs by Health Technology Assessment Bodies in England, France, and Italy (Q1 2023)
|
Roberts, G.
|
|
|
26 |
12S |
p. S327
|
artikel
|
| 1420 |
HTA170 Assessing the Impact of the NICE Methods Review on Rare Diseases
|
Holdgate, O.
|
|
|
26 |
12S |
p. S351-S352
|
artikel
|
| 1421 |
HTA50 Assessing the Risk of Bias in Clinical Trials for Health Technology Assessments: Should Existing Tools Reflect the ICH E9(R1) Addendum on Estimands and Sensitivity Analyses?
|
Poythress, J.
|
|
|
26 |
12S |
p. S329
|
artikel
|
| 1422 |
HTA334 Assessment of Vaccines in Europe, the HPV Example: Can the EU Joint Clinical HTA Regulation Result in More Consistent Vaccine Evaluations and Improve Access Across EU Countries?
|
Kakanou, F.
|
|
|
26 |
12S |
p. S385
|
artikel
|
| 1423 |
HTA125 Assessment Outcome by HTA Agency Archetype: Five-Year Review for 20 European Countries
|
Izmirlieva, M.A.
|
|
|
26 |
12S |
p. S342
|
artikel
|
| 1424 |
HTA236 A Systematic Review of Clinical Efficacy and Safety Data in Penta-Refractory Multiple Myeloma: Findings Indicate the Challenges for HTA Submission
|
Worsley, C.
|
|
|
26 |
12S |
p. S365
|
artikel
|
| 1425 |
HTA333 A Systematic Review of Robotic-Assisted Surgery in Esophageal Cancer: Comparison with Open Esophagectomy
|
Jeong, C.H.
|
|
|
26 |
12S |
p. S385
|
artikel
|
| 1426 |
HTA62 A Systematic Review of the New NICE Highly Specialised Technologies Criteria: How Do NICE Judge Criteria 3 and 4 to be Met?
|
Berkley, A.
|
|
|
26 |
12S |
p. S330-S331
|
artikel
|
| 1427 |
HTA351 A Targeted Review Exploring How English and German Health Technology Assessment Agencies Differ in Their Appraisal of Digital Health Apps
|
Jadeja, A.
|
|
|
26 |
12S |
p. S388
|
artikel
|
| 1428 |
HTA92 A Targeted Review of Methods for Effect Modifier (EM) and Prognostic Factor Identification in Population Adjusted Indirect Comparisons (PAICs) in NICE Oncology Submissions
|
Cooper, M.
|
|
|
26 |
12S |
p. S336
|
artikel
|
| 1429 |
HTA39 A Valuable Perspective on Medical Devices – Assesing the Organizational Impact of Health Technologies in Decision-Making
|
Springborg, A.
|
|
|
26 |
12S |
p. S327
|
artikel
|
| 1430 |
HTA264 Baseline Natural History Models in Network Meta-Analysis: Guidance Versus Implementation in National Health and Care Excellence (NICE) Appraisals
|
Gittfried, A.
|
|
|
26 |
12S |
p. S371
|
artikel
|
| 1431 |
HTA30 Behavioural Structured Expert Elicitation: A Case Study to Inform Hospitalisation Due to Respiratory Syncytial Virus in the UK
|
Schurer, M.
|
|
|
26 |
12S |
p. S326
|
artikel
|
| 1432 |
HTA362 Being Specific About Analysis Prespecification: Challenges and Opportunities in the Context of EU HTA
|
Ivkovic, M.
|
|
|
26 |
12S |
p. S390
|
artikel
|
| 1433 |
HTA193 Benefits Not Captured in the Quality-Adjusted Life Year Calculation: What Role Do They Play in the National Institute for Health and Care Excellence's Updated Decision-Making Process?
|
Atkinson, E.
|
|
|
26 |
12S |
p. S356
|
artikel
|
| 1434 |
HTA356 Bridging the Gap between National and EUNETHTA21 HTA Methods. Are Marketing Authorisation Holders Ready for Joint Clinical Assessments?
|
Campbell, J.
|
|
|
26 |
12S |
p. S389
|
artikel
|
| 1435 |
HTA71 Bridging the Gap: Exploring the PICO Vs Estimand Frameworks in EU Health Technology Assessment (HTA)
|
Sieverding, M.
|
|
|
26 |
12S |
p. S332
|
artikel
|
| 1436 |
HTA48 Bridging the Gap: How to Align HTA and Health Care Decision Making in Switzerland
|
Van Haasteren, G.
|
|
|
26 |
12S |
p. S329
|
artikel
|
| 1437 |
HTA44 Broadening the HTA of Medical AI: A Review of Policy Reports to Inform Decision Makers
|
Boverhof, B.J.
|
|
|
26 |
12S |
p. S328
|
artikel
|
| 1438 |
HTA13 Broadening the Scope: Analysis of Oncology Reimbursement Decisions Following the Cancer Drugs List Introduction in Singapore
|
Tzaras, D.
|
|
|
26 |
12S |
p. S322
|
artikel
|
| 1439 |
HTA79 CADTH Reimbursement Recommendations for Mental Illness Health Products: 10-Year Trends in Relation to Non-Mental Illness Health Products and Recommendations From Other HTA Bodies
|
Singh, S.
|
|
|
26 |
12S |
p. S333
|
artikel
|
| 1440 |
HTA162 Canadian HTA and Early-Phase Evidence in Oncology: Current Trends and the Path Ahead
|
Fairhead, C.
|
|
|
26 |
12S |
p. S350
|
artikel
|
| 1441 |
HTA364 Can Artificial Intelligence and Machine Learning Be Used to Demonstrate the Value of a Technology for HTA Decision-Making?
|
Szawara, P.
|
|
|
26 |
12S |
p. S390
|
artikel
|
| 1442 |
HTA228 Can Just Three PICOs be Feasible for Oncology Assessments with the Joint EU HTA Framework, Whilst Considering All 27 Member States Specificities?
|
Chirico, G.
|
|
|
26 |
12S |
p. S363
|
artikel
|
| 1443 |
HTA226 Can Prior Indirect Treatment Comparisons (ITCs) Inform Health Technology Assessment (HTA) Strategy: A Case Study in Relapsed-Refractory Diffuse Large B Cell Lymphoma (RR-DLBCL)
|
Forsythe, A.
|
|
|
26 |
12S |
p. S363
|
artikel
|
| 1444 |
HTA161 Can We Elicit a Willingness to Pay Threshold for Oncology Treatments in Denmark?
|
Marocco, C.
|
|
|
26 |
12S |
p. S350
|
artikel
|
| 1445 |
HTA207 Can We Speak to GPT to Inform Health Technology Assessments?
|
Srivastava, T.
|
|
|
26 |
12S |
p. S359
|
artikel
|
| 1446 |
HTA124 Can You Have a Common Approach to the Statistical Analysis Plan When Conducting Real-World Evidence Studies to Meet Multi-HTA Requirements?
|
Paparrodopoulos, S.
|
|
|
26 |
12S |
p. S342
|
artikel
|
| 1447 |
HTA96 Carer Burden: Is HTA Helping or Harming the Gender Health Gap?
|
Ellicott, A.
|
|
|
26 |
12S |
p. S337
|
artikel
|
| 1448 |
HTA293 Challenges and Opportunities in Implementing the EUnetHTA21 Methodological Guidelines in the Context of EU HTA Regulation: Perspectives From Different Stakeholders on Different Markets (France, Italy, and Poland)
|
De Rosa, V.
|
|
|
26 |
12S |
p. S377
|
artikel
|
| 1449 |
HTA286 Challenges and Solutions to Estimating Environmental Impact in Health Technology Assessment
|
Hubbert, L.
|
|
|
26 |
12S |
p. S375
|
artikel
|
| 1450 |
HTA94 Challenges Facing the Health Technology Assessment (HTA) Submissions of Second Line Treatments for Advanced Oncology
|
Bhadti, S.
|
|
|
26 |
12S |
p. S337
|
artikel
|
| 1451 |
HTA18 Challenges of Identifying Health Utility Data for Patients With Penta-Refractory Multiple Myeloma to Inform HTA Reimbursement Discussion for Newer Treatment Options
|
Hibbs, R.
|
|
|
26 |
12S |
p. S323
|
artikel
|
| 1452 |
HTA210 Characteristics and Outcomes of Health Technology Assessment Submissions for Advanced Therapy Medicinal Products in Europe: Perspective From Non-EU5 Countries
|
Cardoso, A.
|
|
|
26 |
12S |
p. S360
|
artikel
|
| 1453 |
HTA338 Characterization of the Evidence Supporting the Relative Effectiveness Evaluations in Health Technologies Assessment: A Review
|
Ribeiro, C.
|
|
|
26 |
12S |
p. S385
|
artikel
|
| 1454 |
HTA223 Comparative Evaluation of the HTA Evidence Requirements and Outcomes for Digital Health Technologies in Germany and UK
|
Gaultney, J.
|
|
|
26 |
12S |
p. S362
|
artikel
|
| 1455 |
HTA230 Comparative Evaluation of the Performance of Two Value Attribution Frameworks When Applied to Combination Regimens in Oncology
|
Gaultney, J.
|
|
|
26 |
12S |
p. S364
|
artikel
|
| 1456 |
HTA235 Comparative Narrative Review of Oncology Value Assessment Frameworks: Enfortumab Vedotin (EV) for Treatment of Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
|
Ortiz Nunez, A.
|
|
|
26 |
12S |
p. S365
|
artikel
|
| 1457 |
HTA317 Comparing Ultra-Rare Disease Pathways Within the United Kingdom: Can Different Processes Lead to Market Access Variations?
|
Chalmers, K.
|
|
|
26 |
12S |
p. S381
|
artikel
|
| 1458 |
HTA276 Comparison of Health Technology Assessment Systems: A Review of Their Impact on Expenditure and Outcomes
|
Balkhi, B.
|
|
|
26 |
12S |
p. S373
|
artikel
|
| 1459 |
HTA17 Comparison of Methods for Modelling the Cost-Effectiveness of Atezolizumab as an Adjuvant Treatment in Stage II-IIIA Non-Small Cell Lung Cancer
|
Jovanoski, N.
|
|
|
26 |
12S |
p. S323
|
artikel
|
| 1460 |
HTA365 Comparison of the Use of Real-World Evidence for Clinical Effectiveness in HTA Pre- and Post- Introduction of the NICE Framework
|
Mackley, R.
|
|
|
26 |
12S |
p. S390-S391
|
artikel
|
| 1461 |
HTA198 Comparisons of Economic Evaluation Guidelines Between Japan and Six Countries (England, France, Germany, Sweden, Canada and Australia)
|
Nomoto, M.
|
|
|
26 |
12S |
p. S357
|
artikel
|
| 1462 |
HTA357 Cost-Comparisons, an Easier Route to NICE Recommendations?
|
Armand, J.
|
|
|
26 |
12S |
p. S389
|
artikel
|
| 1463 |
HTA2 Cost-Effectiveness of a Clinical Care Pathway for the Screening of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
|
Xiao, J.
|
|
|
26 |
12S |
p. S320
|
artikel
|
| 1464 |
HTA166 Cost-Effectiveness of Combination Pertuzumab+Trastuzumab Vs Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer (HER2+ eBC) in the Czech Republic
|
Motylova, S.
|
|
|
26 |
12S |
p. S351
|
artikel
|
| 1465 |
HTA116 Cost-Effectiveness of Nirmatrelvir/Ritonavir for the Treatment of Outpatient Sars-Cov-2 in Adult Patients at Risk for Developing Severe Disease in Greece
|
Kalogeropoulou, M.
|
|
|
26 |
12S |
p. S340-S341
|
artikel
|
| 1466 |
HTA131 Cost-Effectiveness Threshold in Denmark's New Health Technology Assessment Process: What Do We Know so Far?
|
Shire, I.
|
|
|
26 |
12S |
p. S344
|
artikel
|
| 1467 |
HTA57 Costing for Health Economics Evaluation: The Case of the Brazilian Universal Health System
|
Beume, T.M.
|
|
|
26 |
12S |
p. S330
|
artikel
|
| 1468 |
HTA262 Cost-Utility Analysis of Influenza Vaccination with a High Dose Quadrivalent Vaccine for the Brazilian Elderly Population in the Private Healthcare Sector
|
Watanabe, S.F.
|
|
|
26 |
12S |
p. S371
|
artikel
|
| 1469 |
HTA354 Cross Analysis of HAS Conclusions Amongst Products with an Economic Opinion Posted in 2022
|
Sambuc, C.
|
|
|
26 |
12S |
p. S388
|
artikel
|
| 1470 |
HTA104 Data on Patient-Reported Outcomes Is Not a Prerequisite for Achieving an Additional Benefit in German Early Benefit Assessment of New Medicinal Products Approved for Dermatological Diseases
|
Gabriel, M.R.
|
|
|
26 |
12S |
p. S338
|
artikel
|
| 1471 |
HTA318 Delays in NICE Highly Special Technology (HST) Appraisal for Medicines That Treat Ultra-Orphan Conditions
|
Ringger, D.
|
|
|
26 |
12S |
p. S382
|
artikel
|
| 1472 |
HTA34 Demonstrating Similar or Greater Health Benefits Based on Indirect Evidence: A Review of NICE Evaluations That Include a Cost-Comparison Approach
|
Haycock, M.
|
|
|
26 |
12S |
p. S326-S327
|
artikel
|
| 1473 |
HTA137 Determining Relevant Thresholds for Reimbursement of Healthcare Interventions: Should We Prohibit the Use of the QALY at Last?
|
Johnson, K.
|
|
|
26 |
12S |
p. S345
|
artikel
|
| 1474 |
HTA160 Development of a Web Application for Self-Assessment and Monitoring of Colorectal Surgery Outcome Indicators in the ESCA Study
|
Andalo', A.
|
|
|
26 |
12S |
p. S349-S350
|
artikel
|
| 1475 |
HTA265 Development of the Reliant Checklist to Support the HTA Deliberation
|
Monleón, C.
|
|
|
26 |
12S |
p. S371
|
artikel
|
| 1476 |
HTA153 Did OS Immaturity Preclude from Receiving a Positive Recommendation: Review of Recent Oncology NICE/TA?
|
Petitjean, A.
|
|
|
26 |
12S |
p. S348
|
artikel
|
| 1477 |
HTA130 Different Approaches to the Health Economic Evaluations for the Health Technology Assessment Submissions
|
Smela, B.
|
|
|
26 |
12S |
p. S343-S344
|
artikel
|
| 1478 |
HTA199 Digital Health Application (DiGA) vs Other Digital Health Technologies (DHT) as Part of Disease Management Programs (DMP)—Assessment Requirements in Germany Diverge Between HTA Authorities
|
Maier, M.
|
|
|
26 |
12S |
p. S357-S358
|
artikel
|
| 1479 |
HTA191 Discussion of Health Inequalities in the NICE Single Technology Appraisal Process: A Review of Recent Submissions in NHS England Core20PLUS5 Focus Clinical Areas
|
Treharne, C.
|
|
|
26 |
12S |
p. S356
|
artikel
|
| 1480 |
HTA194 Do Health Technology Assessment (HTA) Bodies Recommend the Conduct and Submission of Artificial Intelligence-Based Literature Reviews (AILRS)?
|
Mangat, G.
|
|
|
26 |
12S |
p. S356
|
artikel
|
| 1481 |
HTA11 Drivers of Positive Health Technology Assessment Outcomes for Oncology Drugs in Three Global Markets
|
Norwood-Knutsson, C.
|
|
|
26 |
12S |
p. S322
|
artikel
|
| 1482 |
HTA143 Drug Market Access Delays in France: What Role May Cost-Effectiveness Evaluations Play in Varying These Timescales?
|
Cartolano, P.
|
|
|
26 |
12S |
p. S346
|
artikel
|
| 1483 |
HTA284 Early Access in France: Descriptive Analysis of Eap Decisions Two Years after the Reform
|
Le Mao, J.
|
|
|
26 |
12S |
p. S375
|
artikel
|
| 1484 |
HTA146 Early Access in France: Reasons for Refusals and Impact on Market Access
|
Theuillon, T.
|
|
|
26 |
12S |
p. S347
|
artikel
|
| 1485 |
HTA65 Economic Evaluation of Medical Devices By the French National Authority (2014-2022): Where Do We Stand?
|
Midy, F.
|
|
|
26 |
12S |
p. S331
|
artikel
|
| 1486 |
HTA83 Economic Evaluations in Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Challenges for Health Technology Assessment (HTA) Submissions
|
Forbes, C.
|
|
|
26 |
12S |
p. S334
|
artikel
|
| 1487 |
HTA341 Egyptian Guidelines for Pharmacoeconomic Evaluations: Toward Standardization of Drug Reimbursement Applications
|
Roushdy, M.
|
|
|
26 |
12S |
p. S386
|
artikel
|
| 1488 |
HTA281 Environmental Considerations in HTA: Can HTA Bodies Contribute to Environmental Sustainability?
|
Mansinho, J.N.
|
|
|
26 |
12S |
p. S374
|
artikel
|
| 1489 |
HTA179 Environmental Impact and Health Technology Assessment: State of Art and Future Perspectives
|
Antonazzo, I.C.
|
|
|
26 |
12S |
p. S353
|
artikel
|
| 1490 |
HTA290 Environmental Sustainability in HTA: Are HTA Bodies Applying Environmental Criteria in Their Decision-Making?
|
Szawara, P.
|
|
|
26 |
12S |
p. S376
|
artikel
|
| 1491 |
HTA118 Estimands in Health Technology Assessments: Methodological Considerations and Recommendations
|
Morga, A.
|
|
|
26 |
12S |
p. S341
|
artikel
|
| 1492 |
HTA330 EU HTA: How Will Joint Clinical Assessment (JCA) Address the Specifics of Gene Therapies?
|
Mueller, E.
|
|
|
26 |
12S |
p. S384
|
artikel
|
| 1493 |
HTA205 EU Joint Clinical Assessments on Health Technologies Is Approaching—Are We Prepared?
|
Morrison, S.
|
|
|
26 |
12S |
p. S359
|
artikel
|
| 1494 |
HTA272 EUnetHTA's HTA Core Model®: A Critical Assessment and Future Outlook
|
Bannister, C.
|
|
|
26 |
12S |
p. S372-S373
|
artikel
|
| 1495 |
HTA332 Evaluating Transcatheter Valve Replacement in Tricuspid Regurgitation: Complexities and Limitations of Existing Models
|
Moreau, R.
|
|
|
26 |
12S |
p. S384-S385
|
artikel
|
| 1496 |
HTA244 Evaluation of the Acceptance of Real-World Evidence (RWE) in Eunethta Joint Clinical Assessments (JCA) to Support Evidence for Reimbursement Decisions
|
Natividad, M.
|
|
|
26 |
12S |
p. S367
|
artikel
|
| 1497 |
HTA75 Evaluation of the Clinical and Economic Effectiveness of Continuous Glucose Monitoring in Adults With Type 1 Diabetes Mellitus in the Healthcare System of the Republic of Kazakhstan
|
Baissalbayeva, A.
|
|
|
26 |
12S |
p. S333
|
artikel
|
| 1498 |
HTA310 Evolution of French Economic Opinions Published By the Economic Evaluation and Public Health (CEESP) in Oncology
|
Doghri, O.
|
|
|
26 |
12S |
p. S380
|
artikel
|
| 1499 |
HTA142 Evolution of French Economic Opinions Published by the Economic Evaluation and Public Health Committee (CEESP)
|
Doghri, O.
|
|
|
26 |
12S |
p. S346
|
artikel
|
| 1500 |
HTA282 Evolution of Timeframes Within the Overall Time-to-Market Since Marketing Authorisation for New Innovative-Presumed Products in France Since the First Published Economic Opinion
|
Tardu, J.
|
|
|
26 |
12S |
p. S374-S375
|
artikel
|
| 1501 |
HTA307 Evolving Principles for Defining and Assessing the Economic and Societal Value of Cancer Therapies
|
Lee, M.
|
|
|
26 |
12S |
p. S380
|
artikel
|
| 1502 |
HTA219 Examining the Awareness and Perceptions of EU HTA Amongst Irish Pharmaceutical Industry Professionals
|
McCarthy, M.
|
|
|
26 |
12S |
p. S361-S362
|
artikel
|
| 1503 |
HTA78 Examining the Influence of Study Design, Incremental Medical Benefit, and Price-Setting Pathway on Pricing of Digital Health Applications in Germany
|
Haney, E.
|
|
|
26 |
12S |
p. S333
|
artikel
|
| 1504 |
HTA14 Expanding the HTA Cost-Effectiveness Analyses for CheckMate 9LA: Nivolumab Plus Ipilimumab Plus Chemotherapy As First-Line Strategy for Non-Small Cell Lung Cancer
|
Orsini, I.
|
|
|
26 |
12S |
p. S322
|
artikel
|
| 1505 |
HTA99 Expert Validation on Proposed Framework for Differentiated HTA Criteria for Rare Disease Drugs in Brazil
|
Biglia, L.V.
|
|
|
26 |
12S |
p. S337
|
artikel
|
| 1506 |
HTA347 Exploration of the Factors Driving Decisions of the Transparency Commission Based on an Analysis of HAS Meeting Transcripts Using Natural Language Processing
|
Aballea, S.
|
|
|
26 |
12S |
p. S387
|
artikel
|
| 1507 |
HTA259 Exploring Collaboration on HTA Methodology for Medical Technologies in the Dutch ZonMw HTA Methodology 2021-2024 Subsidy Program
|
Michels, R.
|
|
|
26 |
12S |
p. S370
|
artikel
|
| 1508 |
HTA158 Exploring Efficiency of Living Systematic Literature Review (SLR) Tool for Submissions of Clinical Evidence to National Institute for Health and Care Excellence (NICE) by Combining Interventional and Real-World Evidence (RWE)
|
Liu, R.
|
|
|
26 |
12S |
p. S349
|
artikel
|
| 1509 |
HTA102 Exploring Potential Inequity in Access to Medicines for Ultra-Rare Disease in England and Scotland: SMC Ultra-Orphan Pathway Versus NICE HST
|
Bhatt, N.
|
|
|
26 |
12S |
p. S338
|
artikel
|
| 1510 |
HTA81 Exploring the Gap Between Regulatory Labels and Reimbursed Indications of Oncology Drugs in the Netherlands
|
Misrielal, A.
|
|
|
26 |
12S |
p. S334
|
artikel
|
| 1511 |
HTA10 Exploring the Impact of End-of-Life Designation on Access to Oncology Therapies in the United Kingdom
|
Azariadi, A.
|
|
|
26 |
12S |
p. S321-S322
|
artikel
|
| 1512 |
HTA43 Exploring the Link Between Institutional Country-Level Differences and Consideration of Additional Value Elements in HTAs: Results From a Pragmatic Review
|
Radhakrishnan, A.
|
|
|
26 |
12S |
p. S328
|
artikel
|
| 1513 |
HTA7 Exploring the Predictive Accuracy of Treatment Waning Methods: An Analysis of Pembrolizumab across Six Oncology Indications
|
Harrington, H.
|
|
|
26 |
12S |
p. S321
|
artikel
|
| 1514 |
HTA141 Exploring the Role of Patient Experience Data and Patient Involvement in Health Technology Assessment Decision Making
|
C.P., S.
|
|
|
26 |
12S |
p. S346
|
artikel
|
| 1515 |
HTA97 Exploring the Value of RWD Collected From Early Access Programs to Support HTA Decision-Making
|
Proenca, C.
|
|
|
26 |
12S |
p. S337
|
artikel
|
| 1516 |
HTA86 Factors Affecting Time to Reimbursement of Novel Anticancer Drugs in Ireland
|
Henderson, R.
|
|
|
26 |
12S |
p. S335
|
artikel
|
| 1517 |
HTA321 Factors Influencing the Shi Costs of Orphan Drugs After Their Renewed Regular Benefit Assessment Due to Exceeding the Sales Threshold in Germany
|
Brückel, S.
|
|
|
26 |
12S |
p. S382
|
artikel
|
| 1518 |
HTA176 Feasibility of Cervical Cancer Screening Policy Using Self-Collected Samples for HPV DNA Testing in Thailand
|
Kositamongkol, C.
|
|
|
26 |
12S |
p. S353
|
artikel
|
| 1519 |
HTA255 First-in-Class Drugs in HTA: Blunder or Bliss?
|
Politopoulou, K.
|
|
|
26 |
12S |
p. S369
|
artikel
|
| 1520 |
HTA350 Fixed Effect Versus Random Effects Bayesian Network Meta-Analyses in Practice: What Is Used to Inform National Institute for Health and Care Excellence (NICE) Technology Appraisals?
|
Cheah, Z.
|
|
|
26 |
12S |
p. S387
|
artikel
|
| 1521 |
HTA247 Focus on Two Years of Economic Opinions on Orphan Drug: What Are the Specific Features?
|
Sambuc, C.
|
|
|
26 |
12S |
p. S367-S368
|
artikel
|
| 1522 |
HTA12 Focus on Two Years of Economic Opinions on Solid Cancers: What Are the Specific Features?
|
Sambuc, C.
|
|
|
26 |
12S |
p. S322
|
artikel
|
| 1523 |
HTA35 G-BA Vs. InEK: Navigating Divergent Requirements Between the Two Key Bodies Behind Inpatient Drug Reimbursement in Germany
|
Macaulay, R.
|
|
|
26 |
12S |
p. S327
|
artikel
|
| 1524 |
HTA202 Guideline for Costing in Italian Economic Evaluations: A Proposal of the ISPOR Italy Rome Chapter
|
Berto, P.
|
|
|
26 |
12S |
p. S358
|
artikel
|
| 1525 |
HTA243 Guidelines for Incorporating the Societal Perspective and Wider Societal Benefits in Health Technology Assessment
|
Baloghova, K.
|
|
|
26 |
12S |
p. S367
|
artikel
|
| 1526 |
HTA149 Handling Uncertainty in Health-Economic Assessments: Experience From COVID-19 in France
|
Autin, E.
|
|
|
26 |
12S |
p. S347
|
artikel
|
| 1527 |
HTA1 Health Economic Evaluation of a Combined Early Detection Strategy to Prevent Acute Myocardial Infarction
|
Oude Wolcherink, M.
|
|
|
26 |
12S |
p. S320
|
artikel
|
| 1528 |
HTA241 Health Equity and the Health Technology Assessment Process: Are Children and Young People Being Overlooked? A Review of Pediatric National Institute of Health and Care Excellence Technology Appraisals
|
Freigofaite, D.
|
|
|
26 |
12S |
p. S366
|
artikel
|
| 1529 |
HTA69 Health-Related Quality of Life in the German Early Benefit Assessment—An Update
|
Kramer, L.
|
|
|
26 |
12S |
p. S332
|
artikel
|
| 1530 |
HTA8 Health Technology Assessment (HTA) Case Studies: Comparing Acceptability of Real-World Evidence (RWE) in Appraisals for Oncology Medicines
|
Zong, J.
|
|
|
26 |
12S |
p. S321
|
artikel
|
| 1531 |
HTA31 Health Technology Assessment (HTA) of Clinical Care Pathways: Peritoneal Dialysis Versus Hemodialysis
|
Antonini, D.
|
|
|
26 |
12S |
p. S326
|
artikel
|
| 1532 |
HTA73 Health Technology Assessment (HTA) Timelines Analysis in the Post-COVID Era: Comparison of HTA Process Duration in the First Half (H1) of 2023 to H1 2022
|
Zlateva, J.
|
|
|
26 |
12S |
p. S332-S333
|
artikel
|
| 1533 |
HTA150 Health Technology Assessment of Domiciliary Invasive Ventilation for Adults With Spinal Cord Injuries
|
Walsh, K.
|
|
|
26 |
12S |
p. S347
|
artikel
|
| 1534 |
HTA156 Health Technology Assessment of Multiple Myeloma Therapies: Value Demonstration and Value Recognition Challenges
|
Henderson, N.
|
|
|
26 |
12S |
p. S348-S349
|
artikel
|
| 1535 |
HTA331 Health Technology Assessment of Point-of-Care Diagnostics for Antimicrobial Resistance; Perspectives and Recommendations from an Expert Advisory Panel
|
Salih, F.
|
|
|
26 |
12S |
p. S384
|
artikel
|
| 1536 |
HTA100 Health Technology Assessment Paradigm in Rare Diseases: Critical Determinants and Recommendations
|
Jain, P.
|
|
|
26 |
12S |
p. S337-S338
|
artikel
|
| 1537 |
HTA3 Health Technology Assessment Requirements: Sensitive to Bacteriophage Products or Too Resistant to Change?
|
Strydom, M.
|
|
|
26 |
12S |
p. S320
|
artikel
|
| 1538 |
HTA169 Highly Sensible Tactics: Strategic Insights for Navigating Highly Specialised Technology (HST) Topic Selection
|
Soboil, J.
|
|
|
26 |
12S |
p. S351
|
artikel
|
| 1539 |
HTA114 How Are Companion Diagnostics Evaluated and Reimbursed in Europe? Comparative Analysis of the EU-4 and UK
|
Mitchell, C.
|
|
|
26 |
12S |
p. S340
|
artikel
|
| 1540 |
HTA291 How Are Patients Involved in Health Technology Assessment? A Comparative Analysis of European Markets for Advanced Therapies and Implications for Joint Clinical Assessment
|
Świder, A.
|
|
|
26 |
12S |
p. S376
|
artikel
|
| 1541 |
HTA181 How Can Health Technology Assessment Help in Addressing Drug Repurposing Challenges? A Conceptual Framework
|
Abu-Zahra, T.
|
|
|
26 |
12S |
p. S354
|
artikel
|
| 1542 |
HTA126 How Did French Health Technology Assessment Body (Transparency Committee, TC, of the HAS) Assess Drugs with Clinical Development Based on Single Arm Trials in the Last Three Years?
|
Ravinet, P.
|
|
|
26 |
12S |
p. S343
|
artikel
|
| 1543 |
HTA206 How Do the Stricter Pricing Regulations of the Statutory Health Insurance Financial Stabilization Act (GKV-FINSTG) Affect Reimbursement Prices of New Drugs in Germany?
|
Bot, D.
|
|
|
26 |
12S |
p. S359
|
artikel
|
| 1544 |
HTA301 How End of Life Translates to Severity Weighting Under the New National Institute for Health and Care Excellence (NICE) Methodology. A Review of Past Oncology Appraisals
|
Batteson, R.
|
|
|
26 |
12S |
p. S378
|
artikel
|
| 1545 |
HTA300 How Fast Will the EU HTA Child Grow? Estimation of the Number of Procedures in the First Years of Implementation
|
Buchholz, I.
|
|
|
26 |
12S |
p. S378
|
artikel
|
| 1546 |
HTA122 How Has NICE's Severity Modifier Been Implemented?
|
Chunara, F.
|
|
|
26 |
12S |
p. S342
|
artikel
|
| 1547 |
HTA113 How Have Manufacturers Maximised Their Digital Health Technologies’ Chances of Successful Reimbursement in Germany?
|
Patel, M.
|
|
|
26 |
12S |
p. S340
|
artikel
|
| 1548 |
HTA72 How Is Real-World Evidence (RWE) Being Used in Health Technology Assessment (HTA) Decisions? Qualitative Insights from Comparisons of Three RWE Study Types Across Multiple Jurisdictions
|
Hanisch, M.
|
|
|
26 |
12S |
p. S332
|
artikel
|
| 1549 |
HTA234 How Long Is the Weight? A Framework for Linear Interpolation of the National Institute for Health and Care Excellence (NICE) Severity Weighting in the Context of Probabilistic Sensitivity Analysis (PSA): A Case Study
|
Critchlow, S.
|
|
|
26 |
12S |
p. S365
|
artikel
|
| 1550 |
HTA348 How to Align EU HTA with National Market Access?
|
Ecker, T.
|
|
|
26 |
12S |
p. S387
|
artikel
|
| 1551 |
HTA288 How Wide Ranging Is the Implementation of HTA and Cost-Effectiveness Assessment (CEA) in Major Healthcare Markets
|
Ricci, M.
|
|
|
26 |
12S |
p. S376
|
artikel
|
| 1552 |
HTA196 HTA Guidance Updates and Usage of Real-World Evidence (RWE) in Reimbursement Decisions—A 2023 Perspective
|
Takyar, J.
|
|
|
26 |
12S |
p. S357
|
artikel
|
| 1553 |
HTA203 Identification and Comparison of HTA Tools Suitable for Low- and Middle-Income Countries
|
Twardowski, P.
|
|
|
26 |
12S |
p. S358-S359
|
artikel
|
| 1554 |
HTA256 Identifying Current ATMP Market Access Challenges and Strategies in France, Germany, Italy, and Spain
|
Lucion, D.
|
|
|
26 |
12S |
p. S369-S370
|
artikel
|
| 1555 |
HTA363 Impact of ASMR Changes on List Prices: An Analysis of HAS Re-Evaluations
|
Dumoulin, O.
|
|
|
26 |
12S |
p. S390
|
artikel
|
| 1556 |
HTA138 Impact of Publication of the French Commission for Economic and Public Health Evaluation (CEESP) Doctrine on French Medico-Economic Evaluation – a Quantitatve Analysis
|
Hidra, R.
|
|
|
26 |
12S |
p. S345
|
artikel
|
| 1557 |
HTA349 Impact of Technical Exchanges on CEESP Reservations: Analysis of the 2022 CEESP Opinions
|
Attoumani, N.
|
|
|
26 |
12S |
p. S387
|
artikel
|
| 1558 |
HTA287 Impact of the 2020 Update of the French Guidelines for Economic Evaluation on the Economic Opinions Issued By the Economic Evaluation and Public Health Committee (CEESP)
|
Sivignon, M.
|
|
|
26 |
12S |
p. S375-S376
|
artikel
|
| 1559 |
HTA164 Implementing Combination Treatment Cost-Effectiveness Solutions Beyond the Legal Challenges – What Else Needs to be in Place?
|
Taylor, H.
|
|
|
26 |
12S |
p. S350
|
artikel
|
| 1560 |
HTA315 Implications for Rare Diseases: NICE Guidance and Outcomes on Implementing Bayesian Borrowing Approaches for External Control Data
|
Cockerham, A.
|
|
|
26 |
12S |
p. S381
|
artikel
|
| 1561 |
HTA292 Implications of EU HTA on Future Relevance of Surrogate Outcomes in National Assessment
|
Ecker, T.
|
|
|
26 |
12S |
p. S377
|
artikel
|
| 1562 |
HTA224 Improving Access to Behavioral and Mental Health Therapies in the EU: An Analogue Assessment Deep Dive
|
Snow, A.C.
|
|
|
26 |
12S |
p. S362-S363
|
artikel
|
| 1563 |
HTA221 Improving the Reimbursement Application Process: A Predictive Model for Identifying Key Subgroup Specification Parameters for Anti-Obesity Medication
|
Rudolfsen, J.H.
|
|
|
26 |
12S |
p. S362
|
artikel
|
| 1564 |
HTA220 Incorporating Environmental Sustainability Considerations into National HTA Assessments: A Landscape Review
|
Tsantila, S.
|
|
|
26 |
12S |
p. S362
|
artikel
|
| 1565 |
HTA242 Incorporating Health Inequalities (HIs) Considerations into United Kingdom (UK) HTA Decision Making and the Impact on Rare Disease Medicines
|
Patel, A.
|
|
|
26 |
12S |
p. S366
|
artikel
|
| 1566 |
HTA248 Incorporating Patient Perspectives in HTA Assessments for Rare Diseases: Insights From Multiple HTA Assessments
|
Ricci Conesa, H.
|
|
|
26 |
12S |
p. S368
|
artikel
|
| 1567 |
HTA197 Increasing Patient Access in Scandinavia Through Outcome Based Agreements: Can the Spanish Model be Replicated?
|
Sosa, J.
|
|
|
26 |
12S |
p. S357
|
artikel
|
| 1568 |
HTA326 Indication-Based Pricing of the Pharmaceuticals in Croatia: Case-Study Modelling Excercise
|
Bobinac, A.
|
|
|
26 |
12S |
p. S383
|
artikel
|
| 1569 |
HTA295 Insights From Economic Evaluations in Emerging Infection Diseases in France: Focus on COVID-19
|
Vacherot, L.
|
|
|
26 |
12S |
p. S377
|
artikel
|
| 1570 |
HTA19 Insights Into NICE Technology Appraisal Outcomes in Oncology
|
Champsi, S.
|
|
|
26 |
12S |
p. S323
|
artikel
|
| 1571 |
HTA270 Integrating Environmental Sustainability into HTA: The State of the Art and Possible Trajectories
|
Cicchetti, A.
|
|
|
26 |
12S |
p. S372
|
artikel
|
| 1572 |
HTA84 Is Our Evidence Enough? A Review of G-BA's Ongoing Evidentiary Requirements in the Oncology Space
|
Perez-Kempner, L.
|
|
|
26 |
12S |
p. S334-S335
|
artikel
|
| 1573 |
HTA77 Is Stedi Steady? an Exploration of the Uncertainties Underlying the Quantification of the Broader Value of Antibiotics
|
Brassel, S.
|
|
|
26 |
12S |
p. S333
|
artikel
|
| 1574 |
HTA267 Is the BBC Truly Impartial When Reporting on NICE’s Activities?
|
Wang, G.
|
|
|
26 |
12S |
p. S371-S372
|
artikel
|
| 1575 |
HTA340 Is There Equity of Access to Highly Specialized Treatments Between England and Northern Ireland?
|
Hall, A.
|
|
|
26 |
12S |
p. S385-S386
|
artikel
|
| 1576 |
HTA257 Key HTA Learnings from Approved Gene Therapies Across the EU4, England, and the US
|
Kiritharan, P.
|
|
|
26 |
12S |
p. S370
|
artikel
|
| 1577 |
HTA268 Key Issues in the Methods and Process of Health Technology Assessment in China: A National Expert Survey
|
Liu, G.
|
|
|
26 |
12S |
p. S372
|
artikel
|
| 1578 |
HTA201 Knowledge Transfer and Capability Building Program on Institutionalization and Governance of HTA Ukraine: Results and Future Perspectives
|
Piniazhko, O.
|
|
|
26 |
12S |
p. S358
|
artikel
|
| 1579 |
HTA129 Learnings from TC Opinions of Drugs Evaluated for EAP Under New Process
|
Estival, A.
|
|
|
26 |
12S |
p. S343
|
artikel
|
| 1580 |
HTA212 Level of ICER of Health Economic Assessment in France in 2022
|
Sambuc, C.
|
|
|
26 |
12S |
p. S360-S361
|
artikel
|
| 1581 |
HTA361 Living Systematic Review (LSR) in Health Technology Assessment (HTA): Current Guidance, Methods, and Challenges
|
Sauca, M.
|
|
|
26 |
12S |
p. S390
|
artikel
|
| 1582 |
HTA343 Machine Learning Prediction of Drug Overdoses Among Young People
|
Dai-Woodys, L.L.
|
|
|
26 |
12S |
p. S386
|
artikel
|
| 1583 |
HTA40 Making MCDA 'Shiny' With an Adaptive Support Tool for Healthcare Decision-Making: An Application in Broad Molecular Testing With R Shiny
|
Fernandez Coves, A.
|
|
|
26 |
12S |
p. S327-S328
|
artikel
|
| 1584 |
HTA273 Managed Access Agreements in the UK: A Detailed Analysis of NICE's Utilization and Impact on Access
|
Hashim, S.
|
|
|
26 |
12S |
p. S373
|
artikel
|
| 1585 |
HTA87 Mapping Accumulating Evidence Across Multiple Indications in Oncology Health Technology Assessment
|
Anwer, S.
|
|
|
26 |
12S |
p. S335
|
artikel
|
| 1586 |
HTA119 Mapping a Path to Standardized Evidence Quality Tools Across EU HTA Agencies and NICE: Is EU Joint Clinical Assessment Guidance Falling Behind?
|
Mayer, B.
|
|
|
26 |
12S |
p. S341
|
artikel
|
| 1587 |
HTA101 Mapping Opportunities in the Access Landscape for a New Rare Disease Treatment Option in Multiple EU Countries
|
Koenders, J.
|
|
|
26 |
12S |
p. S338
|
artikel
|
| 1588 |
HTA250 Mapping the VF-14 Onto the EQ-5D-5L: The Potential to Estimate Quality-Adjusted Life-Years Without Generic Quality-of-Life Data in Ophthalmology
|
Ndwandwe, S.
|
|
|
26 |
12S |
p. S368
|
artikel
|
| 1589 |
HTA308 Market Access for Anti-Cancer Drugs: Is the Demonstration of a Clinical Benefit on Survival Correlated With Price Level?
|
Grangé, L.
|
|
|
26 |
12S |
p. S380
|
artikel
|
| 1590 |
HTA359 Market Access of ATMPs in France: Challenges and Opportunities
|
Le Mao, J.
|
|
|
26 |
12S |
p. S389
|
artikel
|
| 1591 |
HTA322 Modelling Antifibrotic Therapies for Idiopathic Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Disease: Learnings from NICE Submissions from the Past Decade
|
Penaloza, M.C.P.
|
|
|
26 |
12S |
p. S382
|
artikel
|
| 1592 |
HTA36 Monitoring of the Long-Term Impact of the COVID-19 Pandemic on the Decision Process of the Italian Medicine Agency
|
Canali, B.
|
|
|
26 |
12S |
p. S327
|
artikel
|
| 1593 |
HTA305 Multicriteria Decision Analysis (MCDA) to Elicit Criteria for CAR-T Cell Health Technology Assessment (HTA) in Brazilian Private Healthcare System
|
Murta Amaral, L.
|
|
|
26 |
12S |
p. S379
|
artikel
|
| 1594 |
HTA152 Multidimensional Evaluation of Inebilizumab in Patients With Neuromyelitis Optica Spectrum Disorder
|
Fortunato, A.
|
|
|
26 |
12S |
p. S348
|
artikel
|
| 1595 |
HTA239 Network Meta-Analysis on the Efficacy and Safety of Drugs for the Treatment of Acute Myeloid Leukemia in the Elderly
|
Yu, M.M.
|
|
|
26 |
12S |
p. S366
|
artikel
|
| 1596 |
HTA225 New HTA Model for Digitally Supported Managed Care: Lessons From Parkinson's Disease
|
Borga, L.
|
|
|
26 |
12S |
p. S363
|
artikel
|
| 1597 |
HTA263 NICE Listens: Engaging the Public on How Environmental Sustainability Should Be Considered in Health Technology Assessment and Guideline Development
|
Murray, A.
|
|
|
26 |
12S |
p. S371
|
artikel
|
| 1598 |
HTA366 NICE Technology Appraisals Based on Single-Arm Trials in 2022 – What Can We Learn from Them?
|
Guerra Primo, L.
|
|
|
26 |
12S |
p. S391
|
artikel
|
| 1599 |
HTA144 NICE Value Male Lives More Than Female Lives?
|
Heer, S.
|
|
|
26 |
12S |
p. S346
|
artikel
|
| 1600 |
HTA127 No Half Measures: Health Inequalities in Technology Appraisal
|
Malcolm, R.
|
|
|
26 |
12S |
p. S343
|
artikel
|
| 1601 |
HTA238 Oncological Combination Therapies in the Context of the Early Benefit Assessment According to AMNOG: Status Quo and Quo Vadis
|
Fisenkci, N.
|
|
|
26 |
12S |
p. S365-S366
|
artikel
|
| 1602 |
HTA195 Optimized Recommendations in NICE Technology Appraisals: Permissive or Restrictive?
|
Maslyankov, I.
|
|
|
26 |
12S |
p. S357
|
artikel
|
| 1603 |
HTA289 Optimizing Healthcare Outcomes: Identifying the Conditions for Successful Value-Based Contracts
|
Dumoulin, O.
|
|
|
26 |
12S |
p. S376
|
artikel
|
| 1604 |
HTA208 Paradigm Shift or Incremental Change? Real-World Evidence for Health Technology Assessment: A Critical Appraisal
|
Hao, Y.
|
|
|
26 |
12S |
p. S359-S360
|
artikel
|
| 1605 |
HTA280 Pharmacoeconomic Research As an Area for Drugs Comparison
|
Krysanov, I.
|
|
|
26 |
12S |
p. S374
|
artikel
|
| 1606 |
HTA229 PICO Criteria Applied in Joint Action 3 Differ From National HTA Requirements: A Review of Oncology Drug Assessments in Denmark, France, Germany, and Sweden
|
Konstanski, M.
|
|
|
26 |
12S |
p. S363-S364
|
artikel
|
| 1607 |
HTA111 Population, Intervention, Comparator, Outcomes (PICO) of ATMPs and Potential Impact on the Upcoming EU Regulation on HTA
|
Young, K.E.
|
|
|
26 |
12S |
p. S340
|
artikel
|
| 1608 |
HTA26 Portuguese Clinical Practice and Costs in the Treatment of Acid Sphingomyelinase Deficiency Disease
|
Silva Miguel, L.
|
|
|
26 |
12S |
p. S325
|
artikel
|
| 1609 |
HTA254 Potential Discrepancies/Misalignments in Future EU-HTA Appraisals the POLIVY and Stelara JA3 PICO Example
|
Berto, P.
|
|
|
26 |
12S |
p. S369
|
artikel
|
| 1610 |
HTA20 Predicting Post-AMNOG Price for a New Product Launch in Germany
|
Jha, P.
|
|
|
26 |
12S |
p. S323-S324
|
artikel
|
| 1611 |
HTA320 Predicting Value and Price of Orphan Drugs: A Comparison Across Europe and the US
|
Ganesh, S.
|
|
|
26 |
12S |
p. S382
|
artikel
|
| 1612 |
HTA261 Preparing for the EU Regulation on HTA and Joint Clinical Assessments of Vaccines
|
Largeron, N.
|
|
|
26 |
12S |
p. S370
|
artikel
|
| 1613 |
HTA53 Proportionally Quicker or Easier? International Comparison of NICE’s Proportionate Approach to Technology Appraisals (PATT) With Global Peers
|
Kelly, K.R.
|
|
|
26 |
12S |
p. S329-S330
|
artikel
|
| 1614 |
HTA218 Public Engagement and Its Influence on Health Technology Assessment Outcomes in Latin America
|
Tôrres, L.
|
|
|
26 |
12S |
p. S361
|
artikel
|
| 1615 |
HTA63 Qualitative Analysis of Value-Based Contract Experience, Perception, and Future Adoption across Geographies
|
Sathi, C.
|
|
|
26 |
12S |
p. S331
|
artikel
|
| 1616 |
HTA90 Quality of Clinical Evidence Submitted to a National HTA Agency in Ireland: 10 Years of Drugs for Oncology
|
Eames, H.
|
|
|
26 |
12S |
p. S336
|
artikel
|
| 1617 |
HTA342 Real World Evidence in German HTA: The Challenges of Comparative Routine Practice Data Collection (ABD) for Early Benefit Assessment (AMNOG)
|
Bogner, K.
|
|
|
26 |
12S |
p. S386
|
artikel
|
| 1618 |
HTA23 Reasons for a Negative Pharmaceutical Benefits Advisory Committee (PBAC) Review in Rare Diseases in Australia: A Comprehensive Analysis
|
Mumford, A.
|
|
|
26 |
12S |
p. S324
|
artikel
|
| 1619 |
HTA324 Recent Landscape of Drug Re-Assessments by G-BA – What Is the Impact of New Evidence on the Benefit Assessment Outcome?
|
Lach, K.
|
|
|
26 |
12S |
p. S383
|
artikel
|
| 1620 |
HTA157 Reflection on Medicines That Have Recently Come Off Patent and Have Been Rejected by NICE in the Past 20 Years: A Case Study of Abiraterone for Treating Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (MHSPC)
|
Madani, O.
|
|
|
26 |
12S |
p. S349
|
artikel
|
| 1621 |
HTA88 Reimbursement of CAR-T Cell Therapies in Europe: Key Challenges from Precedents and Lessons for Future
|
Kowalska, M.
|
|
|
26 |
12S |
p. S335
|
artikel
|
| 1622 |
HTA46 Relationship Between the Directness of the Evidence and Identification of Added Therapeutic Value: An Analysis of HTA Procedures
|
Ribeiro, C.
|
|
|
26 |
12S |
p. S328-S329
|
artikel
|
| 1623 |
HTA132 Reporting Patient Preference Studies in Health Technology Assessment Submissions: Does It Make a Difference?
|
Parke, E.
|
|
|
26 |
12S |
p. S344
|
artikel
|
| 1624 |
HTA277 Requirements for Clinical Evidence for Health Technology Assessment Submissions Across Different Countries
|
Smela, B.
|
|
|
26 |
12S |
p. S373-S374
|
artikel
|
| 1625 |
HTA211 Requirements for Economic Evaluations for Health Technology Assessment Submissions across Different Countries
|
Smela, B.
|
|
|
26 |
12S |
p. S360
|
artikel
|
| 1626 |
HTA279 Retrospective Analysis of the French Early Access Experience Following the 2021 Reform
|
Comiti, A.
|
|
|
26 |
12S |
p. S374
|
artikel
|
| 1627 |
HTA66 Review and Analysis of Economic Model Characteristics According to Published HTA Conclusions in Ukraine
|
Ioltukhovskyi, I.
|
|
|
26 |
12S |
p. S331
|
artikel
|
| 1628 |
HTA184 Review of HTA Evaluation for Gene Therapies and Their Future Implications in Europe
|
Famulska, A.
|
|
|
26 |
12S |
p. S354-S355
|
artikel
|
| 1629 |
HTA200 Review of Population-Adjusted Indirect Treatment Comparison Methods in NICE Non-Oncology Appraisals
|
Divya, D.
|
|
|
26 |
12S |
p. S358
|
artikel
|
| 1630 |
HTA159 Review of Survival Modeling Approaches Adopted in NICE Technology Appraisals (TAs) in Non-Small Cell Lung Cancer (NSCLC)
|
Pandey, S.
|
|
|
26 |
12S |
p. S349
|
artikel
|
| 1631 |
HTA278 Risky Business: How Does Risk of Study Bias Impact Health Technology Assessment Submissions?
|
Ishaq, Z.
|
|
|
26 |
12S |
p. S374
|
artikel
|
| 1632 |
HTA58 Scoping Mock-Up: What Can We Learn From an EU-4 Experiment for EU HTA?
|
Ecker, T.
|
|
|
26 |
12S |
p. S330
|
artikel
|
| 1633 |
HTA183 Setting the Right Discount Rate for Health Technology Assessment in the Slovak Republic
|
Cubi-Molla, P.
|
|
|
26 |
12S |
p. S354
|
artikel
|
| 1634 |
HTA163 Setting Treatment Selection Criteria for Breast Cancer From a Clinician Perspective: Is It a Matter of Cost?
|
Gourzoulidis, G.
|
|
|
26 |
12S |
p. S350
|
artikel
|
| 1635 |
HTA271 Shifting Landscape of Indirect Comparison Methodologies and Their Role in Informing NICE Decision-Making Processes
|
Bhatnagar, T.
|
|
|
26 |
12S |
p. S372
|
artikel
|
| 1636 |
HTA252 Shorter Time to Market for Pharmaceuticals Assessed in the Nordic HTA-Collaboration FINOSE
|
Gehrman, J.
|
|
|
26 |
12S |
p. S369
|
artikel
|
| 1637 |
HTA147 Similarities and Differences Between the HTA Methods for Indirect Comparisons in the EU Joint Clinical Assessment and National Assessments by Member States
|
Laughlin, W.
|
|
|
26 |
12S |
p. S347
|
artikel
|
| 1638 |
HTA274 Similarities and Differences in Health Technology Assessment (HTA) Bodies Considerations for Decision-Making: Use of Patient Preference Studies
|
Morrison, S.
|
|
|
26 |
12S |
p. S373
|
artikel
|
| 1639 |
HTA145 Similarity of Guidelines for Direct and Indirect Comparisons Under Eunethta and Country-Specific HTA – Implications for Supportive Agents
|
Ecker, T.
|
|
|
26 |
12S |
p. S346-S347
|
artikel
|
| 1640 |
HTA174 Single-Arm Studies in Rare Diseases and Statistical Methods to Mitigate Lack of Comparative Data: What Kind of Assessment Is More Successful for the French HTA Body?
|
Belamri, M.
|
|
|
26 |
12S |
p. S352
|
artikel
|
| 1641 |
HTA45 Study of HTA Timelines and Outcomes for MHRA-Approved NASs in the Post-Brexit UK via Reliance/Work-Sharing Routes
|
Sola-Barrado, B.
|
|
|
26 |
12S |
p. S328
|
artikel
|
| 1642 |
HTA151 Subjective Well-Being and Mental Health During the COVID-19 Pandemic in Hungary
|
Xu, F.
|
|
|
26 |
12S |
p. S347-S348
|
artikel
|
| 1643 |
HTA9 Success Rate of Cancer Drugs Fund Reappraisals
|
Liu, X.
|
|
|
26 |
12S |
p. S321
|
artikel
|
| 1644 |
HTA16 Summary of Economic Evaluations on Onco-Hematology in France By the Has: What Did We Learn?
|
Boussahoua, M.
|
|
|
26 |
12S |
p. S323
|
artikel
|
| 1645 |
HTA64 Surrogate Endpoints Used in NICE Technology Appraisals for Oncology and Non-Oncology Indications, 2022–23
|
Heptinstall, A.
|
|
|
26 |
12S |
p. S331
|
artikel
|
| 1646 |
HTA82 Surrogate Measures and the Health Technology Assessment of Cancer Drugs in Ireland: A Retrospective Analysis of EMA Cancer Drug Indication Approvals Between 2017 and 2022 and Recommendations Made By the NCPE in Ireland
|
Assi, A.
|
|
|
26 |
12S |
p. S334
|
artikel
|
| 1647 |
HTA103 Systematic Literature Reviews to Identify Clinical and Economic Outcomes in Adults With Pompe Disease
|
Raza, S.
|
|
|
26 |
12S |
p. S338
|
artikel
|
| 1648 |
HTA312 The Association of ESMO-Magnitude of Clinical Benefit Scale Scores and Subsidy Decisions of Targeted Therapies for Solid Tumors in Singapore
|
Cheow, S.
|
|
|
26 |
12S |
p. S380
|
artikel
|
| 1649 |
HTA4 The Challenges of Health Economic Modeling for Mental Health, Behavioral, and Neurodevelopmental Conditions
|
Sinha, A.
|
|
|
26 |
12S |
p. S320
|
artikel
|
| 1650 |
HTA306 The Combination Conundrum: Comparing Reimbursement Outcomes for Oncology Combination Products in the UK and France
|
Tzaras, D.
|
|
|
26 |
12S |
p. S379-S380
|
artikel
|
| 1651 |
HTA336 The Danish Health Technology Council – HTA Organisations As the Nexus between Science and Policy
|
Holst-Kristensen, A.
|
|
|
26 |
12S |
p. S385
|
artikel
|
| 1652 |
HTA182 The EU Regulation on HTA: Developing an Adapted Market Access Framework for Pharmaceutical Assets
|
Young, K.E.
|
|
|
26 |
12S |
p. S354
|
artikel
|
| 1653 |
HTA175 The Impact of Accelerated Regulatory Approval on Health Technology Assessment: An Evaluation of Orphan Drugs in Four Markets
|
Gomes, S.
|
|
|
26 |
12S |
p. S352-S353
|
artikel
|
| 1654 |
HTA304 The Impact of Different HTA Frameworks on Time to Patient Access: A Case Study Assessing the First Commercial Launch Indications for Lynparza, Tagrisso, Imfinzi, Calquence and Enhertu
|
Crean, B.
|
|
|
26 |
12S |
p. S379
|
artikel
|
| 1655 |
HTA134 The Impact of Non-Comparative Data for Non-Orphan Drugs on HTA and Pricing Outcomes in Germany: Can an Added Benefit Ever be Proven?
|
Owens-Smith, I.
|
|
|
26 |
12S |
p. S344
|
artikel
|
| 1656 |
HTA155 The Impact of Phase 2 Clinical Trials on Reimbursement Recommendations in Oncology By Canadian Health Technology Assessment Agencies
|
Ham, M.
|
|
|
26 |
12S |
p. S348
|
artikel
|
| 1657 |
HTA285 The Impact of the Disease Severity Modifier on NICE Technology Appraisal Decisions
|
Lee, J.
|
|
|
26 |
12S |
p. S375
|
artikel
|
| 1658 |
HTA297 The Inclusion of Caregiver Burden in the National Institute for Health and Care Excellence (NICE) Health Technology Appraisals (HTAS) of Treatments for Mental Health Disorders
|
Spencer, C.
|
|
|
26 |
12S |
p. S378
|
artikel
|
| 1659 |
HTA140 The in Need of Medicines Fund: Analysis of NICE Technology Appraisals to Explore Barriers to Managed Access Via the IMF
|
Orchard, M.
|
|
|
26 |
12S |
p. S345-S346
|
artikel
|
| 1660 |
HTA70 The Italian Healthcare System Competences in View of the New European HTA Regulation
|
Belfiore, M.
|
|
|
26 |
12S |
p. S332
|
artikel
|
| 1661 |
HTA190 The JCA Is Coming: Will the EU Band Together?
|
Bryan, A.
|
|
|
26 |
12S |
p. S355-S356
|
artikel
|
| 1662 |
HTA112 The NICE Medical Technologies Evaluation Program: An Analysis of Clinical and Economic Evidence Evaluated in Published Medical Technology Guidance
|
Jager, M.H.
|
|
|
26 |
12S |
p. S340
|
artikel
|
| 1663 |
HTA133 The Number of NICE Appraisal Terminations Is Increasing, and Products With Multiple Indications Are Disproportionally Impacted
|
Mitchell, H.
|
|
|
26 |
12S |
p. S344
|
artikel
|
| 1664 |
HTA188 The Potential Value of Health Technologies Postponing Total Knee Replacements While Increasing Patients’ Quality of Life
|
Otten, T.
|
|
|
26 |
12S |
p. S355
|
artikel
|
| 1665 |
HTA329 The Race to Improve Health Technology Assessment of Gene Therapies: Which Countries Are Embracing Recommendations?
|
Besley, S.
|
|
|
26 |
12S |
p. S384
|
artikel
|
| 1666 |
HTA177 The Safety and Effectiveness of Root Membrane Technique (Socket Shield Technique)
|
Kim, S.
|
|
|
26 |
12S |
p. S353
|
artikel
|
| 1667 |
HTA313 The Same but Different: Inconsistencies in Key Cost-Effectiveness Assumptions for Curative Therapies across Clinically Similar NICE Appraisals
|
Buchanan, V.
|
|
|
26 |
12S |
p. S380-S381
|
artikel
|
| 1668 |
HTA352 The Significance of Literature Reviews in the Process of Decision-Making by the Haute Autorité De Santé
|
Smela, B.
|
|
|
26 |
12S |
p. S388
|
artikel
|
| 1669 |
HTA121 The Triple Bottom Line in Healthcare: A Holistic Sustainability Assessment for Decision Support
|
De Smedt, D.
|
|
|
26 |
12S |
p. S341-S342
|
artikel
|
| 1670 |
HTA28 The Use of Expert Opinions, Patient, and Carer Perspectives and Real-World Evidence in Orphan Disease Submissions Differs for Health Technology Assessment Agencies Across the World
|
Ben Taieb, A.
|
|
|
26 |
12S |
p. S325
|
artikel
|
| 1671 |
HTA249 The Use of Preprints in Health Technology Assessment during Sars-Cov-2 Pandemic
|
García Carpintero, E.
|
|
|
26 |
12S |
p. S368
|
artikel
|
| 1672 |
HTA171 The Use of Qualitative Methods in the NICE HST Deliberative Process
|
Gibson, A.
|
|
|
26 |
12S |
p. S352
|
artikel
|
| 1673 |
HTA346 The Use of Real-World Evidence in Health Technology Assessment Decisions in Sweden and the UK: A Natural Language Processing (NLP) Approach
|
Mohammed, S.
|
|
|
26 |
12S |
p. S386-S387
|
artikel
|
| 1674 |
HTA6 The Value of Looking Beyond Overall Survival: The Role of Oncology-Relevant Endpoints in HTA / Payer Decision-Making
|
Fameli, A.
|
|
|
26 |
12S |
p. S321
|
artikel
|
| 1675 |
HTA123 The View from the Sandbox: Implementing a Safe Space to Co-Develop and Test Innovations in HTA
|
Elvidge, J.
|
|
|
26 |
12S |
p. S342
|
artikel
|
| 1676 |
HTA173 Time to Access Orphan Medicines in Greece
|
Chantzaras, A.
|
|
|
26 |
12S |
p. S352
|
artikel
|
| 1677 |
HTA52 Time to HTA Assessment Completion By HTA Agency Archetype: Five-Year Review for 20 European Countries
|
Izmirlieva, M.A.
|
|
|
26 |
12S |
p. S329
|
artikel
|
| 1678 |
HTA93 Time to Reimbursement of Novel Anticancer Drugs in Ireland Compared to Six European Countries and the UK
|
Redmond, S.
|
|
|
26 |
12S |
p. S336-S337
|
artikel
|
| 1679 |
HTA80 To What Extent Do the EUnetHTA 21 D4.4 Guidelines on Endpoints Recognize Non-Os Endpoints and Patient-Reported Outcomes, and What Opportunities Exist in the Joint Clinical Assessment to Reflect Their Value?
|
Fameli, A.
|
|
|
26 |
12S |
p. S334
|
artikel
|
| 1680 |
HTA233 Transportability of Overall Survival Estimates from US to UK Populations Receiving First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
|
Kent, S.
|
|
|
26 |
12S |
p. S364
|
artikel
|
| 1681 |
HTA237 Treatment Effect Waning in Immuno-Oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence
|
Taylor, K.
|
|
|
26 |
12S |
p. S365
|
artikel
|
| 1682 |
HTA120 Trends in Medical Device Reimbursement Decisions in South Korea: A Novel and Comprehensive Analysis
|
Lee, C.
|
|
|
26 |
12S |
p. S341
|
artikel
|
| 1683 |
HTA275 Trends in Medical Services Reimbursement Outcomes in Australia: A Novel and Comprehensive Analysis
|
Kassem, Y.
|
|
|
26 |
12S |
p. S373
|
artikel
|
| 1684 |
HTA68 Trends in Northern Ireland HTA Guidance Adoption: NICE Shows Dominance over SMC and AWMSG
|
Hill, K.
|
|
|
26 |
12S |
p. S331-S332
|
artikel
|
| 1685 |
HTA154 Trends of Indirect Treatment Comparison Methods Use in NICE Technology Appraisals for Haematologic Cancers
|
Divya, D.
|
|
|
26 |
12S |
p. S348
|
artikel
|
| 1686 |
HTA245 UK Mechanisms to Address Rare Disease Challenges: Does the UK Go Far Enough?
|
Rouse, P.
|
|
|
26 |
12S |
p. S367
|
artikel
|
| 1687 |
HTA135 Uncertainty in AMNOG Benefit Assessments: Reflection of G-BA's Underlying Motivation to Cause AbD
|
Dahlke, J.
|
|
|
26 |
12S |
p. S344-S345
|
artikel
|
| 1688 |
HTA316 Understanding the Application of Various Statistical Analysis Methods to Inform Comparative Effectiveness of Ultra Orphan Treatments: A Review of NICE HST Guidance
|
Siroula, M.
|
|
|
26 |
12S |
p. S381
|
artikel
|
| 1689 |
HTA213 Undertaking Studies to Inform Public Policy: Managing Data Collection to Ensure Data Quality in the EQ-5D-5L UK Valuation Through the Use of Independent Quality Control Assessments
|
Rowen, D.
|
|
|
26 |
12S |
p. S361
|
artikel
|
| 1690 |
HTA56 Unequal Access of Innovative Drug Products Across Canada
|
Feener, S.
|
|
|
26 |
12S |
p. S330
|
artikel
|
| 1691 |
HTA165 Unmet Medical Need in Norwegian Clinical Practice and Cost-Effectiveness Analysis of Polatuzumab in Combination With R-CHP Compared to R-CHOP in Patients With Previously Untreated DLBCL With an IPI Score of Three and Above
|
Westermann, L.
|
|
|
26 |
12S |
p. S350
|
artikel
|
| 1692 |
HTA251 Unraveling the Relationship between Expedited Regulatory Approval By the European Medicines Agency (EMA) and Reimbursement Outcomes for Drugs Approved Under Exceptional Circumstances
|
Guyenet, A.
|
|
|
26 |
12S |
p. S368
|
artikel
|
| 1693 |
HTA139 Uptake of Early Heath Technology Assessment in the United Kingdom: A Literature Review of Empirical Studies
|
Koufopoulou, M.
|
|
|
26 |
12S |
p. S345
|
artikel
|
| 1694 |
HTA27 Use of Clinical Outcome Assessments in Health Technology Appraisals for Rare Disease Indications: A Review of UK, US, and Canadian Submissions
|
Jones, E.
|
|
|
26 |
12S |
p. S325
|
artikel
|
| 1695 |
HTA128 Use of Patient Preference Studies in NICE Submissions in the Last 5 Years
|
Morrison, S.
|
|
|
26 |
12S |
p. S343
|
artikel
|
| 1696 |
HTA294 Using Machine Learning to Predict HTA Approval: Importance of Patient Subgroup Specification Within Obesity
|
Ockert, L.
|
|
|
26 |
12S |
p. S377
|
artikel
|
| 1697 |
HTA178 Using Mixed-Methods Development-Focused HTA and Npv Calculations to Guide Further Investment and R&D: A Case Study on Establishing the Value Proposition for Biosensor-Integrated Self-Reporting Arteriovenous Grafts
|
Owusu Achiaw, S.
|
|
|
26 |
12S |
p. S353
|
artikel
|
| 1698 |
HTA215 Utilization of RWE in HTA Appraisals in England, Scotland, Germany, and France
|
Toomey, J.A.
|
|
|
26 |
12S |
p. S361
|
artikel
|
| 1699 |
HTA358 Value-Based Contracts Types Across Global Healthcare Systems: Comparing Perceptions Between Finance-Based and Outcomes-Based Agreements
|
Mestre-Ferrandiz, J.
|
|
|
26 |
12S |
p. S389
|
artikel
|
| 1700 |
HTA172 Value of French Framework for Early Access Programs for the HTA Appraisal in the Rare Disease Space: The Example of Lanadelumab in Patients With Hereditary Angioedema
|
Schmidely, N.
|
|
|
26 |
12S |
p. S352
|
artikel
|
| 1701 |
HTA325 Valuing Life - Decision-Making for Medicines in Australia: A Retrospective Analysis (2020-2022)
|
Ratkovic, M.
|
|
|
26 |
12S |
p. S383
|
artikel
|
| 1702 |
HTA106 What Are the Main Drivers for Decision-Making Regarding the Incorporation of a Healthcare Technology By CONITEC in Brazil? A Study in the Cardiovascular, Oncology, and Respiratory Fields
|
Bernz, I.
|
|
|
26 |
12S |
p. S339
|
artikel
|
| 1703 |
HTA25 What Is a Highly Specialised Technology (HST)? The Revised NICE HST Criteria in Practice
|
Haria, K.
|
|
|
26 |
12S |
p. S324-S325
|
artikel
|
| 1704 |
HTA231 What Is the Psycho-Oncologic (PsyO) Impact of Progression in Patients with Cancer? A Targeted Literature Review (TLR) to Assess the Available Data
|
Shah, M.
|
|
|
26 |
12S |
p. S364
|
artikel
|
| 1705 |
HTA192 What Must Change if Future Evidence Pricing and Access Challenges Are to Be Successfully Overcome?
|
Teale, C.
|
|
|
26 |
12S |
p. S356
|
artikel
|
| 1706 |
HTA32 When Should the Conduct of RWE Studies Be Prioritized for Reimbursement: Insights from Canadian and Global Stakeholders
|
Boss, J.
|
|
|
26 |
12S |
p. S326
|
artikel
|
| 1707 |
HTA60 Where Can International HTA Collaboration Add Value? the Experience of NICE
|
Garrett, Z.
|
|
|
26 |
12S |
p. S330
|
artikel
|
| 1708 |
HTA168 Widening the Value Lens for Child Health Technologies: Development of a Child-Tailored HTA Value Assessment Framework Using Multi-Criteria Decision Analysis Incorporating Patient, Public, and Expert Perspectives
|
Gauvreau, C.
|
|
|
26 |
12S |
p. S351
|
artikel
|
| 1709 |
HTA108 Willingness-to-Pay for Orphan Drugs – ICER Thresholds Approved by TLV in Sweden
|
Gullon Sanz, J.
|
|
|
26 |
12S |
p. S339
|
artikel
|
| 1710 |
HTA85 Will the New Dutch Criteria for Therapeutic Value for Oncology Drugs Create Inequalities in Access between Countries? a Review of Health Technology Assessment Oncology Submissions.
|
Mehra, N.
|
|
|
26 |
12S |
p. S335
|
artikel
|
| 1711 |
HTA319 3-Year Report Card: RWE Collection in Germany
|
Wake, M.
|
|
|
26 |
12S |
p. S382
|
artikel
|
| 1712 |
HTA91 5 Years of CAR-T Cell Therapies—Comparison of German AMNOG Dossiers in Terms of Available Evidence and Price Development
|
Drews, J.
|
|
|
26 |
12S |
p. S336
|
artikel
|
| 1713 |
MSR147 Accounting for Study Heterogeneity When Modelling the Multi-State Natural History of Rare Diseases
|
Broomfield, J.
|
|
|
26 |
12S |
p. S421-S422
|
artikel
|
| 1714 |
MSR5 Accuracy of Automated Data Extraction for Systematic Literature Reviews
|
Hanegraaf, P.
|
|
|
26 |
12S |
p. S393
|
artikel
|
| 1715 |
MSR29 A Comparative Analysis of Missing Value Imputation Techniques: Parametric Imputation with eCDF (PIE) Vs Markov Chain Monte Carlo Imputation (MCMC)
|
Paul Choudhury, S.
|
|
|
26 |
12S |
p. S398-S399
|
artikel
|
| 1716 |
MSR9 Adjusting for Switches to Multiple Treatments in Randomised Controlled Trials: A Comparison of Inverse Probability Weighting and Two-Stage Estimation Methods
|
Bell Gorrod, H.
|
|
|
26 |
12S |
p. S394
|
artikel
|
| 1717 |
MSR102 Advancing Causal Inference With Machine Learning and Real-World Data: An Application of Targeted Machine Learning and Super Learners on Hospital-Acquired Pressure Injuries From MIMIC IV
|
Wilson, A.
|
|
|
26 |
12S |
p. S412
|
artikel
|
| 1718 |
MSR80 AI-Enabled Risk of Bias Assessment of RCTs in Systematic Reviews: A Case Study
|
Langham, J.
|
|
|
26 |
12S |
p. S408
|
artikel
|
| 1719 |
MSR120 A Method for Adjusting US Health State Utilities for Use in the UK
|
Omar Alsaleh, A.J.
|
|
|
26 |
12S |
p. S416
|
artikel
|
| 1720 |
MSR12 Analysis of Long-Term Survivorship (LTS) Rates for Stage 2B/2C Melanoma Using Published Real-World Data (RWD) and Data From Randomized Controlled Trials (RCTS)
|
Alagoz, O.
|
|
|
26 |
12S |
p. S395
|
artikel
|
| 1721 |
MSR159 A Novel Unanchored Simulated Treatment Comparison Approach for Time-to-Event Data
|
Ren, S.
|
|
|
26 |
12S |
p. S424
|
artikel
|
| 1722 |
MSR83 An Overview of “Multinma” Package: Multilevel Network Meta-Regression
|
Sharma, A.
|
|
|
26 |
12S |
p. S408-S409
|
artikel
|
| 1723 |
MSR42 A Parametric Method for Unanchored Matching-Adjusted Indirect Treatment Comparison (MAIC) Based on Survival Outcomes for Health Economic (HE) Models in Absence of Proportional Hazards (PH)
|
Mol, I.
|
|
|
26 |
12S |
p. S401
|
artikel
|
| 1724 |
MSR99 Application of Artificial Intelligence in Literature Reviews
|
Venkata, S.K.
|
|
|
26 |
12S |
p. S412
|
artikel
|
| 1725 |
MSR6 Application of the Atlas Algorithm to Identify the Carboplatin+Gemcitabine Regimen in Patients with Metastatic Triple-Negative Breast Cancer (MTNBC) through the French Nationwide Hospital Discharge Database (PMSI)
|
Grenier, B.
|
|
|
26 |
12S |
p. S393-S394
|
artikel
|
| 1726 |
MSR163 Artificial Intelligence (AI)-Based Screening: Exploration of Differences in Two Health Technology Assessment (HTA)-Compliant Systematic Literature Reviews (SLRS)
|
Cichewicz, A.
|
|
|
26 |
12S |
p. S425
|
artikel
|
| 1727 |
MSR150 Artificial Intelligence (AI) in Performing Landscape Review and Linguistic Analysis for Curative Intent in Prostate Cancer (PC)
|
Krabbe, L.M.
|
|
|
26 |
12S |
p. S422
|
artikel
|
| 1728 |
MSR67 Art or Science? Selecting Utility Evidence for Decision-Analytic Models Containing Multiple Health-States
|
Hainsworth, R.
|
|
|
26 |
12S |
p. S405
|
artikel
|
| 1729 |
MSR31 A Simulation Study to Examine the Influence of Varied Standard Deviation of Covariates across Trials on Population Adjusted Indirect Treatment Comparisons
|
Essink, E.
|
|
|
26 |
12S |
p. S399
|
artikel
|
| 1730 |
MSR112 Assessing the Feasibility of Applying Natural Language Processing for Systematic Literature Reviews: A Case Study in Non-Small-Cell Lung Cancer
|
Rath, N.
|
|
|
26 |
12S |
p. S414
|
artikel
|
| 1731 |
MSR126 AutoCriteria: Advancing Clinical Trial Study With AI-Powered Eligibility Criteria Extraction
|
Data, S.
|
|
|
26 |
12S |
p. S417
|
artikel
|
| 1732 |
MSR35 Beyond HbA1c: A Contemporary Approach to Modelling Type 2 Diabetes Within the Updated Cardiff T2D Model
|
McEwan, P.
|
|
|
26 |
12S |
p. S400
|
artikel
|
| 1733 |
MSR46 Breaking Through Limitations: Enhanced Systematic Literature Reviews With Large Language Models
|
Reason, T.
|
|
|
26 |
12S |
p. S402
|
artikel
|
| 1734 |
MSR92 Can Artificial Intelligence (AI) Large Language Models (LLMS) Such as Generative Pre-Trained Transformer (GPT) Be Used to Automate Literature Reviews?
|
Guerra, I.
|
|
|
26 |
12S |
p. S410-S411
|
artikel
|
| 1735 |
MSR77 Can Bayesian Informative Priors Improve Extrapolation of Immature Overall Survival? A Case Study in Advanced Melanoma
|
Prawitz, T.
|
|
|
26 |
12S |
p. S407
|
artikel
|
| 1736 |
MSR153 Can ChatGPT Generate Synthetic Data to Train Systematic Literature Review Machine Learning Models?
|
Abogunrin, S.
|
|
|
26 |
12S |
p. S423
|
artikel
|
| 1737 |
MSR17 Can Machine Learning Accurately Predict Payer Behavior?
|
Anstee, K.
|
|
|
26 |
12S |
p. S396
|
artikel
|
| 1738 |
MSR111 Causal Inference and Statistical Considerations for Indirectly Comparing Time-to-Event Endpoints for Treatments with Different Starting Points for Outcome Assessment in Resectable NSCLC
|
Belleli, R.
|
|
|
26 |
12S |
p. S414
|
artikel
|
| 1739 |
MSR151 Causal Machine Learning for Assessing Pneumococcal Vaccine Effectiveness: Innovations in Real-World Data Analysis and Confounding Pathway Adjustment
|
Wilson, A.
|
|
|
26 |
12S |
p. S422-S423
|
artikel
|
| 1740 |
MSR82 Combating Sample Scarcity: A Novel Bayesian Approach to Pediatric Basket Trials
|
Mackay, E.
|
|
|
26 |
12S |
p. S408
|
artikel
|
| 1741 |
MSR3 Comparing Statistical Adjustments to Correct Misclassification of Respiratory Syncytial Virus Infections (RSV) in Claims Data
|
Steinmann, M.
|
|
|
26 |
12S |
p. S393
|
artikel
|
| 1742 |
MSR50 Comparing Treatment Options for Fabry Disease: Feasibility Assessment for Network Meta-Analysis (NMA)
|
Lyn, N.
|
|
|
26 |
12S |
p. S402
|
artikel
|
| 1743 |
MSR137 Consideration of Competing Risks in Early Setting in Oncology and Impact on the Survival Estimates: To Explicitly Model Them? An Example of a French Real-World Cohort in Urothelial Carcinoma
|
Chillotti, L.
|
|
|
26 |
12S |
p. S419
|
artikel
|
| 1744 |
MSR105 Construction of External-Control Arms (ECA) in Relapsed and Refractory Multiple Myeloma (RRMM)
|
Perkins, A.
|
|
|
26 |
12S |
p. S413
|
artikel
|
| 1745 |
MSR75 Correlate: Assessing Dose Effect Using Targeted Maximum Likelihood Estimation (TMLE)
|
Grossman, J.
|
|
|
26 |
12S |
p. S407
|
artikel
|
| 1746 |
MSR149 Cost-Effectiveness Model Conceptualisation in Chronic Graft Versus Host Disease
|
Elisheva, L.
|
|
|
26 |
12S |
p. S422
|
artikel
|
| 1747 |
MSR54 COVID-19: Do All Patients Who Meet the EMA High-Risk Definition Receive Prescription?
|
Aiyaz, M.
|
|
|
26 |
12S |
p. S403
|
artikel
|
| 1748 |
MSR89 Criteria and Methods Applied to Decision-Making to Embark on Late-Stage Clinical Trials With a Multi-Stakeholder Perspective
|
Jiang, C.
|
|
|
26 |
12S |
p. S410
|
artikel
|
| 1749 |
MSR130 Current Trends in Quantitative Bias Analysis for Unmeasured Confounders: A Targeted Literature Review
|
Hwang, S.
|
|
|
26 |
12S |
p. S418
|
artikel
|
| 1750 |
MSR140 Current Trends in Survival Extrapolation Methods: A Review of NICE Health Technology Appraisals for Oncology Drugs
|
Fernandes, L.
|
|
|
26 |
12S |
p. S420
|
artikel
|
| 1751 |
MSR52 Defining Severity Category Thresholds to Guide Psoriasis Symptoms and Impacts Measure Score Interpretation Using Pooled Data from Three Phase 3 Trials in Plaque Psoriasis
|
Augustin, M.
|
|
|
26 |
12S |
p. S402-S403
|
artikel
|
| 1752 |
MSR104 Deriving Caregiver Health Utilities from Patient Endpoints: A Predictive Modelling Approach Using Real-World Survey Data
|
Urbich, M.
|
|
|
26 |
12S |
p. S413
|
artikel
|
| 1753 |
MSR128 Developing a Checklist to Increase Efficiency of VBA Code
|
Medland, S.
|
|
|
26 |
12S |
p. S417-S418
|
artikel
|
| 1754 |
MSR2 Development of an Algorithm to Identify the Type of Diabetes in the French Administrative Health Care Database “Système National Des Données De Santé” (SNDS)
|
Bretin, O.
|
|
|
26 |
12S |
p. S393
|
artikel
|
| 1755 |
MSR19 Disease Diagnosis and Severity Prediction: Artificial Intelligence Applications in Hemophilia A
|
Khatib, M.
|
|
|
26 |
12S |
p. S396
|
artikel
|
| 1756 |
MSR59 Does Interval Time-Trade-Off Reduce Satisfying Effects and Inconsistencies in Valuation Studies?
|
Estévez-Carrillo, A.
|
|
|
26 |
12S |
p. S404
|
artikel
|
| 1757 |
MSR135 Do You Really Need to See the Doctor? Developing a Machine Learning Approach for Optimal Assignment Rules of Physician Visits for Patients After Knee Replacement
|
Cordier, J.
|
|
|
26 |
12S |
p. S419
|
artikel
|
| 1758 |
MSR23 EQ-5D-5L Valuation Studies: Do the Effects of Dimensional Health Problems Interact with Each Other?
|
Vasan Thakumar, A.
|
|
|
26 |
12S |
p. S397
|
artikel
|
| 1759 |
MSR1 Estimating Lifetime Benefits of Optimizing Secondary Preventive Treatment for Atherosclerotic Cardiovascular Disease
|
Gill, J.L.
|
|
|
26 |
12S |
p. S393
|
artikel
|
| 1760 |
MSR107 Estimating Optimal Personalized Treatment Sequencing for Patients with Multiple Myeloma Using Reinforcement Learning
|
Tang, F.
|
|
|
26 |
12S |
p. S413
|
artikel
|
| 1761 |
MSR20 Estimating Undetected Medication Errors at Care Transitions: A Framework to Support Decision-Making
|
Gavan, S.
|
|
|
26 |
12S |
p. S396-S397
|
artikel
|
| 1762 |
MSR156 Evaluating Bias Associated With Inadequate Variable Selection When Using Inverse Probability of Censoring Weights to Adjust for Treatment Switches in Clinical Trials
|
Xuan, J.
|
|
|
26 |
12S |
p. S423-S424
|
artikel
|
| 1763 |
MSR45 Evaluation of the Future Impact of Immuno-Oncology Introduction on Cancer Mortality in Italy
|
Fiorentino, F.
|
|
|
26 |
12S |
p. S401-S402
|
artikel
|
| 1764 |
MSR28 Examining Guidance and Key Principles for Conducting Living Systematic Reviews: A Methods Review
|
Diamond, M.
|
|
|
26 |
12S |
p. S398
|
artikel
|
| 1765 |
MSR61 Existing Automated Tools to Assist Evidence Generation and Better Qualification of Registries and Real-World Data: A Systematic Review From the More-EUROPA Project
|
Godbillot, P.
|
|
|
26 |
12S |
p. S404
|
artikel
|
| 1766 |
MSR30 Existing Practices for the Identification, Selection, or Assessment of Registries and Real-Word Data for Regulatory/HTA Purposes: A More-EUROPA Project Systematic Review
|
Zebachi, S.
|
|
|
26 |
12S |
p. S399
|
artikel
|
| 1767 |
MSR100 Exploring Methods to Include Carbon Footprint into an HTA: The Case of Remote Patient Management
|
Kingma, S.
|
|
|
26 |
12S |
p. S412
|
artikel
|
| 1768 |
MSR143 Extending Bayesian Evidence Synthesis to Include Historical Trial Data for Improved Survival Extrapolations from Early Data Cuts in Metastatic Non-Small Cell Lung Cancer (mNSCLC)
|
Sharpe, D.
|
|
|
26 |
12S |
p. S420-S421
|
artikel
|
| 1769 |
MSR34 Feasibility of Using Finnish Real-World Data to Build an External Control Arm for the Factor Xia Inhibitor Asundexian Pacific-AF Trial
|
Potts, J.
|
|
|
26 |
12S |
p. S400
|
artikel
|
| 1770 |
MSR43 Flexible Parametric and Semi-Parametric Non-Markov Multi-State Models: Estimation, Prediction & Simulation
|
Crowther, M.J.
|
|
|
26 |
12S |
p. S401
|
artikel
|
| 1771 |
MSR53 Flexsurv Methods to Estimate Cure: An Exploration of Methods for Modelling Cure
|
Venkada Subramaniyan, S.
|
|
|
26 |
12S |
p. S403
|
artikel
|
| 1772 |
MSR13 Formulating Bayesian Poly-Hazard Models for Informed and Clinically Interpretable Lifetime Survival Extrapolations in Advanced Non-Small Cell Lung Cancer (aNSCLC)
|
Sharpe, D.
|
|
|
26 |
12S |
p. S395
|
artikel
|
| 1773 |
MSR110 Four Alternative Methodologies for Simulated Treatment Comparison: How Could the Use of Simulation be Re-Invigorated
|
Zhang, L.
|
|
|
26 |
12S |
p. S414
|
artikel
|
| 1774 |
MSR98 Generate Synthetic Data in R for a Hypothetical Alzheimer's Disease Trial
|
Handels, R.
|
|
|
26 |
12S |
p. S411
|
artikel
|
| 1775 |
MSR108 Geographic Search Filters for Embase.Com Interface: An Analysis Utilizing Multiple Case Studies
|
Mangat, G.
|
|
|
26 |
12S |
p. S413
|
artikel
|
| 1776 |
MSR94 Harnessing AI in Health Economics: Enhancing Efficiency, Accuracy, and Decision-Making
|
Bentley, A.
|
|
|
26 |
12S |
p. S411
|
artikel
|
| 1777 |
MSR16 Health-Related Quality of Life Multi-Instrument Comparison for the Use in Children Aged 2-4 Years Old
|
van Heusden, A.
|
|
|
26 |
12S |
p. S396
|
artikel
|
| 1778 |
MSR55 How Different Are EQ-5D-Y Values in Asia? a Comparison Study of Four Jurisdictions
|
Vasan Thakumar, A.
|
|
|
26 |
12S |
p. S403
|
artikel
|
| 1779 |
MSR64 How Is Machine Learning Being Used in HEOR? A Systematic Review of Trends and Methods
|
Kirshner, C.
|
|
|
26 |
12S |
p. S405
|
artikel
|
| 1780 |
MSR87 How Many Simulations of a Dynamic Transmission Model Are Enough to Estimate Uncertainty?
|
Ahern, S.
|
|
|
26 |
12S |
p. S409
|
artikel
|
| 1781 |
MSR125 How Prognostic Factors Are Identified for Population Matching Analysis
|
Thompson, J.C.
|
|
|
26 |
12S |
p. S417
|
artikel
|
| 1782 |
MSR68 How to Choose the Right Insulin in Patients with Type 2 Diabetes: A Joint Modeling Method
|
Wen, S.
|
|
|
26 |
12S |
p. S405-S406
|
artikel
|
| 1783 |
MSR127 How to Estimate 95% Confidence Intervals When Combining Bootstrapping and Multiple Imputation in Economic Evaluations: A Simulation Study
|
Hofstede, Z.M.W.
|
|
|
26 |
12S |
p. S417
|
artikel
|
| 1784 |
MSR93 Hype, Not Hope: Using Bayesian Methods in Drug Development
|
Igl, W.
|
|
|
26 |
12S |
p. S411
|
artikel
|
| 1785 |
MSR141 Identifying and Extrapolating Immature OS Data in Survival Analysis: A Review of the Variation in Methods Used in Oncology STAs for NICE
|
Moura, A.
|
|
|
26 |
12S |
p. S420
|
artikel
|
| 1786 |
MSR117 Identifying Economic Insecurity Among Psoriasis Patients Using Natural Language Processing and Unstructured Clinical Notes
|
Kumar, V.
|
|
|
26 |
12S |
p. S415
|
artikel
|
| 1787 |
MSR145 Identifying Effect of a Treatment from Observational Data in Absence of Contemporaneous Control: Example of the French Study Tosca, Comparing Cemiplimab Vs. Historical Systemic Treatment in Cutaneous Squamous Cell Carcinoma
|
Perrier, S.
|
|
|
26 |
12S |
p. S421
|
artikel
|
| 1788 |
MSR118 Identifying Potential Long-COVID Patients Using Machine Learning: A German Claims Data Analysis
|
Pacis, S.
|
|
|
26 |
12S |
p. S415-S416
|
artikel
|
| 1789 |
MSR155 Identifying Relevant Clinical Regulatory and Health Technology Assessment (HTA) Precedents via Artificial Intelligence (AI)
|
Signorovitch, J.
|
|
|
26 |
12S |
p. S423
|
artikel
|
| 1790 |
MSR63 Implementing Simple Active Learning (AL) Boosters Considerably Improves the Early Identification of Relevant Studies in the Systematic Literature Review (SLR) Process
|
Bravo, À
|
|
|
26 |
12S |
p. S404-S405
|
artikel
|
| 1791 |
MSR33 Improving Analysis of Continuous Predictors: Advantages of Fractional Polynomial Transformations (FP) and Interpretation of “Non-Linear” Odds Ratios (OR) or Hazard Ratios (HR)
|
Valveny, N.
|
|
|
26 |
12S |
p. S399
|
artikel
|
| 1792 |
MSR124 Improving the Efficiency of Using the Guyot Algorithm to Construct Pseudo Individual Patient Data From Kaplan-Meier Survival Curves: Standardized Guidance and Data Preparation
|
Aiello, E.
|
|
|
26 |
12S |
p. S417
|
artikel
|
| 1793 |
MSR10 Incidence, Prevalence, and Clinical Characteristics of Patients with Chronic Lymphocytic Leukemia (CLL) in Spain: Natural Language Processing (NLP) Analysis of Electronic Health Records (EHRs)
|
Hernandez, J.A.
|
|
|
26 |
12S |
p. S394
|
artikel
|
| 1794 |
MSR56 Incorporating Background Mortality Into Survival Extrapolations: Determining the Accuracy Using a Simulation Study
|
Hordijk, D.D.
|
|
|
26 |
12S |
p. S403-S404
|
artikel
|
| 1795 |
MSR7 Incorporating External Data to Inform Overall Survival Extrapolation: A Review of NICE Health Technology Appraisals for Oncology Drugs
|
Cheng, C.Y.
|
|
|
26 |
12S |
p. S394
|
artikel
|
| 1796 |
MSR113 Inferring the Proportion of Durable Responders to Targeted Oncology Therapies in Combination Regimens Using Bayesian Parametric Mixture Survival Models
|
Sharpe, D.
|
|
|
26 |
12S |
p. S414-S415
|
artikel
|
| 1797 |
MSR44 Inflation, the Usual Suspect: Are Oncology Drugs Really Victims of the Macroeconomic Context?
|
Genane, C.
|
|
|
26 |
12S |
p. S401
|
artikel
|
| 1798 |
MSR27 Inter-Reviewer Reliability of Literature Screening and Data Extraction for Human and Machine-Assisted Systematic Reviews
|
Hanegraaf, P.
|
|
|
26 |
12S |
p. S398
|
artikel
|
| 1799 |
MSR136 IPECAD Modeling Workshop 2023 Cross Comparison Challenge on Cost-Effectiveness Models in Alzheimer's Disease and Related Dementias
|
Handels, R.
|
|
|
26 |
12S |
p. S419
|
artikel
|
| 1800 |
MSR90 Is the Current Chatgpt Able to Gatherarticles for HEOR Literature Review
|
Winberg, D.
|
|
|
26 |
12S |
p. S410
|
artikel
|
| 1801 |
MSR58 It's Alive! Feasibility and Benefits of Living Cost-Effectiveness Modeling Following a Living SLR
|
Poirrier, J.E.
|
|
|
26 |
12S |
p. S404
|
artikel
|
| 1802 |
MSR41 Machine Learning and Patient-Reported Outcomes (PROs) in Oncology: A Systematic Literature Review on Methodological Quality
|
Krepper, D.
|
|
|
26 |
12S |
p. S401
|
artikel
|
| 1803 |
MSR79 Matching Plus Regression Adjustment for the Estimation of the Average Treatment Effect on Survival Outcomes: A Case Study with Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma
|
Di Maio, D.
|
|
|
26 |
12S |
p. S408
|
artikel
|
| 1804 |
MSR21 Methodological Aspects of a COVID-19 Vaccine Discrete Choice Experiment Survey in Canada, Germany, UK, and US General Populations
|
Sri Bhashyam, S.
|
|
|
26 |
12S |
p. S397
|
artikel
|
| 1805 |
MSR148 Methodological Aspects of Composite Measures: A Comparison of Techniques for Rescaling and Aggregation
|
Schlick, B.
|
|
|
26 |
12S |
p. S422
|
artikel
|
| 1806 |
MSR101 Methodological Insights on Indirect Treatment Comparisons for Ulcerative Colitis Therapies in NICE Submissions
|
Srivastava, T.
|
|
|
26 |
12S |
p. S412
|
artikel
|
| 1807 |
MSR73 Methods for Incorporating External Evidence: A Comparison of Their Impact on Extrapolations and Uncertainty Estimates Using a Melanoma Case-Study
|
Kearns, B.
|
|
|
26 |
12S |
p. S407
|
artikel
|
| 1808 |
MSR36 Model Framework to Derive Prevalence Estimates of Hepatitis Delta Based on Migration Patterns
|
Talbot-Watt, N.
|
|
|
26 |
12S |
p. S400
|
artikel
|
| 1809 |
MSR18 Modelling Challenges in Geographic Atrophy
|
Intorcia, M.
|
|
|
26 |
12S |
p. S396
|
artikel
|
| 1810 |
MSR69 Modelling Social and Economic Burden of Hepatits C in Russia in Different Scenarios of Control Measures up to 2035
|
Avxentyev, N.A.
|
|
|
26 |
12S |
p. S406
|
artikel
|
| 1811 |
MSR109 Multi-Indication Evidence Synthesis in Oncology Health Technology Assessment: Case-Study on Bevacizumab
|
Singh, J.
|
|
|
26 |
12S |
p. S413-S414
|
artikel
|
| 1812 |
MSR142 Multi-State Modelling Incorporating a Combined Additive and Relative Hazards Model
|
Weibull, C.
|
|
|
26 |
12S |
p. S420
|
artikel
|
| 1813 |
MSR66 Natural Language Processing to Support the Abstract Selection During Systematic Literature Review
|
Damentko, M.
|
|
|
26 |
12S |
p. S405
|
artikel
|
| 1814 |
MSR8 Nesting a Decision Tree into a Markov Model Structure: An Alternative Way of Tracking Movement in a Diagnostic Model
|
Afonso, D.
|
|
|
26 |
12S |
p. S394
|
artikel
|
| 1815 |
MSR49 Non-Systematic Literature Reviews: Can AI Enhance Current Methods?
|
Baisley, W.
|
|
|
26 |
12S |
p. S402
|
artikel
|
| 1816 |
MSR138 On When and How to Use External Data to Inform Long-Term Survival Curve Extrapolation
|
Chen, G.
|
|
|
26 |
12S |
p. S419
|
artikel
|
| 1817 |
MSR139 Performance of Different Survival Models for Extrapolation of Immature OS Data for 2L+ NSCLC Therapies
|
Jacob, J.
|
|
|
26 |
12S |
p. S419-S420
|
artikel
|
| 1818 |
MSR97 Performance of Matching Adjusted Indirect Comparisons for Single-Arm Trials: A Simulation Study
|
Sizelove, R.
|
|
|
26 |
12S |
p. S411
|
artikel
|
| 1819 |
MSR11 Performance of Progression-Based and Time-to-Death Utility Analysis Methods and Their Implications on Economic Models: A Targeted Review
|
Hopmans Galofré, G.
|
|
|
26 |
12S |
p. S395
|
artikel
|
| 1820 |
MSR71 Projecting the Potential Impact of Disease Modifying Therapy on the Future Health and Social Costs of Alzheimer’s Disease
|
Trepel, D.
|
|
|
26 |
12S |
p. S406
|
artikel
|
| 1821 |
MSR146 Proportional Hazards in Survival Analysis: A Review of the Variation in Determining and Presenting PH in NICE STAs
|
Cheah, Z.
|
|
|
26 |
12S |
p. S421
|
artikel
|
| 1822 |
MSR131 Prospects for Automation of Systemic Literature Reviews (SLRs) With Artificial Intelligence and Natural Language Processing
|
Royer, J.
|
|
|
26 |
12S |
p. S418
|
artikel
|
| 1823 |
MSR85 Psoriasis Symptoms and Impacts Measure: Identifying Key Items Reflecting Core Symptoms of Patients with Plaque Psoriasis
|
Warren, R.B.
|
|
|
26 |
12S |
p. S409
|
artikel
|
| 1824 |
MSR154 Qualitative Content Analysis for Concept Elicitation (CACE) in Clinical Outcome Assessment Development
|
Carmichael, C.
|
|
|
26 |
12S |
p. S423
|
artikel
|
| 1825 |
MSR161 Quantifying the Impact of Exposure Prevalence and Selection Bias to Optimize Patient Selection Criteria in Post-Authorization Safety Studies
|
Packnett, E.
|
|
|
26 |
12S |
p. S424
|
artikel
|
| 1826 |
MSR114 Reducing Mortality From Malignant Neoplasms: The Promising Role of Modern Antineoplastic Drugs in Lung Cancer Treatment
|
Avxentyev, N.A.
|
|
|
26 |
12S |
p. S415
|
artikel
|
| 1827 |
MSR122 Relationship Between 3-Meter Backward Walk Test and Grip Strength Test in Community-Dwelling Young-Older Adults
|
Mbada, C.
|
|
|
26 |
12S |
p. S416
|
artikel
|
| 1828 |
MSR160 Screening Tools for Streamlining Systematic Literature Review Process: Reviewers' Perspective
|
Bajko, P.
|
|
|
26 |
12S |
p. S424
|
artikel
|
| 1829 |
MSR24 Shaping the Value Equation in Digital Healthcare: A Holistic Perspective on Patient, System, and Provider Interactions
|
Mühlbacher, A.C.
|
|
|
26 |
12S |
p. S397-S398
|
artikel
|
| 1830 |
MSR95 Simulated Treatment Comparison or Matching-Adjusted Indirect Comparison: Which Wins in the Battle for Prominence and Validity in Population-Adjusted Indirect Treatment Comparison?
|
Pilkington, H.
|
|
|
26 |
12S |
p. S411
|
artikel
|
| 1831 |
MSR22 Standardized Contrasts Across Trials in Individual Patient Data Meta-Analysis With Time-to-Event Outcomes
|
Gasparini, A.
|
|
|
26 |
12S |
p. S397
|
artikel
|
| 1832 |
MSR119 Statistical Methods to Examine Racial and Ethnic Disparities in the Surgical Literature: A Review and Recommendations for Improvement
|
Sox-Harris, A.
|
|
|
26 |
12S |
p. S416
|
artikel
|
| 1833 |
MSR158 Successful Use of Propensity Score Methods for HTA in Germany: A Near-Impossible Task?
|
Bierl, M.
|
|
|
26 |
12S |
p. S424
|
artikel
|
| 1834 |
MSR84 Summarizing Adverse Event Data in the Absence of High-Level Evidence: The Case of Hearing Implants
|
Dejaco, T.
|
|
|
26 |
12S |
p. S409
|
artikel
|
| 1835 |
MSR162 The Curse of Data Maturity in Observational Studies: Practical Advice from Protocol Development to Interpretation of Results
|
Murris, J.
|
|
|
26 |
12S |
p. S424-S425
|
artikel
|
| 1836 |
MSR65 The Impact of Censoring Assumptions in the Generation of Individual Patient Data from Kaplan-Meier Estimates
|
Edmondson-Jones, M.
|
|
|
26 |
12S |
p. S405
|
artikel
|
| 1837 |
MSR144 The Impact of Enhanced Access to Modern Antineoplastic Drugs for Breast Cancer Treatment on Mortality and Economic Development
|
Avxentyev, N.A.
|
|
|
26 |
12S |
p. S421
|
artikel
|
| 1838 |
MSR72 The Impact of Life Expectancy Exclusion Criteria on Survival Curve Extrapolation
|
Vickers, A.
|
|
|
26 |
12S |
p. S406
|
artikel
|
| 1839 |
MSR134 The Impact of Loneliness on Health Service Use and Health-Related Quality of Life Among Informal Carers in Australia
|
Majmudar, I.
|
|
|
26 |
12S |
p. S418-S419
|
artikel
|
| 1840 |
MSR15 The Impact of Response Assessment Timing on Indirect Treatment Comparisons (ITCS) – A Simulation Study
|
Kanters, S.
|
|
|
26 |
12S |
p. S395-S396
|
artikel
|
| 1841 |
MSR39 The Performance of Anchored and Unanchored Population Adjustment Methods (MATCHING-ADJUSTED INDIRECT COMPARISON, SIMULATED TREATMENT COMPARISON, AND MULTIPLE IMPUTATION MARGINALIZATION) in Castration Resistant Prostate Cancer
|
Vickers, A.
|
|
|
26 |
12S |
p. S400-S401
|
artikel
|
| 1842 |
MSR26 The Use of Copilot, a Generative Artificial Intelligence Tool, as VBA Programming Assistant in Excel-Based Health Economic Models
|
Poirrier, J.E.
|
|
|
26 |
12S |
p. S398
|
artikel
|
| 1843 |
MSR74 The Use of Matching-Adjusted Indirect Comparison for Oncology Submissions in NICE
|
Kaur, G.
|
|
|
26 |
12S |
p. S407
|
artikel
|
| 1844 |
MSR32 Tips for Excel(lent) Modelling or R There Better Alternatives?
|
Maervoet, J.
|
|
|
26 |
12S |
p. S399
|
artikel
|
| 1845 |
MSR70 Translation, Cross-Cultural Adaptation, and Psychometric Evaluation of the Brief Illness Perception Questionnaire Into Yoruba Language Among Persons With Chronic Low Back Pain
|
Fatoye, F.
|
|
|
26 |
12S |
p. S406
|
artikel
|
| 1846 |
MSR103 Translation, Cultural Adaptation, and Psychometric Testing of the Hip Disability and Osteoarthritis Outcome Score Into Yoruba Language
|
Fatoye, F.
|
|
|
26 |
12S |
p. S412-S413
|
artikel
|
| 1847 |
MSR25 Uncertain About Uncertainty in Matching-Adjusted Indirect Comparisons (MAIC)? A Simulation Study to Compare Methods for Variance Estimation
|
Chandler, C.
|
|
|
26 |
12S |
p. S398
|
artikel
|
| 1848 |
MSR14 Unleashing the Potential of Artificial Intelligence in Genomic Biomarker Testing for Precision Oncology: A Scoping Review
|
Buch, F.
|
|
|
26 |
12S |
p. S395
|
artikel
|
| 1849 |
MSR116 Unsupervised Clustering and Binary Classification Analysis for Predicting Long COVID Among Adults in EU4 and UK
|
Finlayson, K.
|
|
|
26 |
12S |
p. S415
|
artikel
|
| 1850 |
MSR86 Use of Data Linkage for the Evaluation of Medical Devices: A Systematic Literature Review
|
Gougeon, A.
|
|
|
26 |
12S |
p. S409
|
artikel
|
| 1851 |
MSR60 Use of External Control Arms (ECAs) in Marketing Applications Submitted to European Medicines Agency (EMA): A Targeted Review
|
Houghton, K.
|
|
|
26 |
12S |
p. S404
|
artikel
|
| 1852 |
MSR121 Use of External Control Arms in Pharmaceutical Submissions to the National Institute for Health and Care Excellence for Technology Appraisals: A Targeted Review
|
Nangia, A.
|
|
|
26 |
12S |
p. S416
|
artikel
|
| 1853 |
MSR78 Use of External Control Data to Adjust for Treatment Switching in Cost-Effectiveness Analyses: Lisocabtagene Maraleucel (Liso-Cel) Versus Standard of Care (SOC) in Second-Line Relapsed or Refractory Large B-Cell Lymphoma
|
Chandler, C.
|
|
|
26 |
12S |
p. S407-S408
|
artikel
|
| 1854 |
MSR48 Using Bayesian Methodology to Minimize Control Recruitment in Trials of Relapsed and Refractory (RR) Multiple Myeloma (MM) Through Incorporation of Prior Control Response Information Borrowed From Real-World Evidence
|
Soutar, S.
|
|
|
26 |
12S |
p. S402
|
artikel
|
| 1855 |
MSR115 Using Machine Learning to Assess Potential Cases of Transthyretin Cardiac Amyloidosis in Brazil: A Retrospective Database Approach
|
Zuppo Laper, I.
|
|
|
26 |
12S |
p. S415
|
artikel
|
| 1856 |
MSR88 Validation of a Programmed Probability Score Using the Screening Tool, Sympro to Assist Selection of Studies in Systematic Literature Reviews
|
Kishore, A.
|
|
|
26 |
12S |
p. S410
|
artikel
|
| 1857 |
MSR37 Validation of the Ibadan Knee/Hip Osteoarthritis Outcome Measure (IKHOAM) Among Patients With Knee Osteoarthritis
|
Fatoye, F.
|
|
|
26 |
12S |
p. S400
|
artikel
|
| 1858 |
MSR129 Web Tool Development to Ease the Process of Performing the Meta-Analysis of Kaplan-Meier Curves Published in Various Studies
|
Pandey, S.
|
|
|
26 |
12S |
p. S418
|
artikel
|
| 1859 |
MSR91 What Are Unmet Needs for the Use of Registries in Regulatory/HTA Decision-Making in Europe? A Survey-Based Approach From the More-EUROPA Project
|
Moreira, J.
|
|
|
26 |
12S |
p. S410
|
artikel
|
| 1860 |
MSR133 What Factors Influence the Prescription of Oral Antivirals for COVID-19 in Japan? – a State Transitional Agent-Based Model Analysis
|
Itsumura, N.
|
|
|
26 |
12S |
p. S418
|
artikel
|
| 1861 |
MSR81 When Should I Mix? Improving Understanding of the Predictive Behavior of Mixture-Cure Survival Models Informed by Immature Data
|
Young, R.
|
|
|
26 |
12S |
p. S408
|
artikel
|
| 1862 |
MT34 Adaptation and Cost-Effectiveness Analysis of the "My Health Everyday” Medication Adherence Coaching Application for Hypertension Management in Hungary
|
Kárász, D.
|
|
|
26 |
12S |
p. S433
|
artikel
|
| 1863 |
MT75 Analysis of Manufacturer and Negotiated Price Differential of Digital Health Applications (DIGA) in Germany
|
Chalmers, M.
|
|
|
26 |
12S |
p. S440-S441
|
artikel
|
| 1864 |
MT16 A Review of NICE Submissions for Medical Technologies in the UK: Key Trends over the Last 2 Years
|
Ioannou, P.
|
|
|
26 |
12S |
p. S429
|
artikel
|
| 1865 |
MT8 Assessing Feasibility of Socially Assistive Humanoid Robots in Assisting in Nursing Routine
|
Mlakar, I.
|
|
|
26 |
12S |
p. S428
|
artikel
|
| 1866 |
MT20 Assessing the Economic Impact of Standardization of Operating Room Workflows Through a Digital Solution
|
Kocaman, M.
|
|
|
26 |
12S |
p. S430
|
artikel
|
| 1867 |
MT77 Assessing the Environmental Impact Associated With Disruptive Surgical Bleeding
|
Kocaman, M.
|
|
|
26 |
12S |
p. S441
|
artikel
|
| 1868 |
MT7 Barriers and Facilitators for the Use of Point of Care Diagnostics in Patients With Respiratory Tract Infections in Outpatient Care Related to the Peri-Launch Phase
|
Steigenberger, C.
|
|
|
26 |
12S |
p. S428
|
artikel
|
| 1869 |
MT56 Beyond the Hype - Economic Evaluation and Artificial Intelligence Maturity Level in Healthcare
|
Godoy, C.
|
|
|
26 |
12S |
p. S437
|
artikel
|
| 1870 |
MT66 Characteristics of Patients with Symptomatic Severe Aortic Stenosis Who Underwent Transcatheter Aortic Valve Implantation (TAVI): A Real-World Study in Singapore
|
Foo, Y.B.W.
|
|
|
26 |
12S |
p. S439
|
artikel
|
| 1871 |
MT10 Clinical and Economic Impact of Point-of-Care (POC) Molecular Testing in Patients Presenting With Viral Respiratory Symptoms: A Systematic Literature Review (SLR)
|
Hale, B.
|
|
|
26 |
12S |
p. S428
|
artikel
|
| 1872 |
MT21 Clinical Application of Circulating Tumor Cells in Melanoma Patients: Overview of Current Available Data
|
de Snoo, F.
|
|
|
26 |
12S |
p. S430
|
artikel
|
| 1873 |
MT37 Clinical Utility of Circulating Tumor Cell (CTC) Enumeration-Based Liquid Biopsy and HER2 CTC Assessment in Patients with Metastatic Breast Cancer: Overview of Current Available Data and Interventional Trials
|
Cristofanilli, M.
|
|
|
26 |
12S |
p. S433
|
artikel
|
| 1874 |
MT6 Companion Diagnostics’ Launch and Market Access Landscape: Who Are the Trend Setters and Late Adopters?
|
Cesarec, S.
|
|
|
26 |
12S |
p. S427-S428
|
artikel
|
| 1875 |
MT12 Comparison of Hospital Case Characteristics of Popliteal Artery Aneurysm Repair with ePTFE Covered Stent Grafts with a Heparin Bioactive Surface and Open Surgical Bypass: Highlights from the 2021 Hospital Dataset in Germany
|
Iqbal, K.
|
|
|
26 |
12S |
p. S429
|
artikel
|
| 1876 |
MT17 Cost and Resource Use Outcomes for Left Atrial Appendage Occlusion Patients Contraindicated to Transesophageal Echocardiography
|
Mohr, B.
|
|
|
26 |
12S |
p. S429-S430
|
artikel
|
| 1877 |
MT49 Cost-Effectiveness Analysis of Farapulse™ Pulsed Field Ablation (PFA) in Patients with Paroxysmal Atrial Fibrillation
|
Öztürk, F.
|
|
|
26 |
12S |
p. S435-S436
|
artikel
|
| 1878 |
MT33 Cost-Effectiveness Analysis of Watchman FLX Left Atrial Appendage Closure in Patients with Non-Valvular Atrial Fibrillation
|
Kurnaz, M.
|
|
|
26 |
12S |
p. S432-S433
|
artikel
|
| 1879 |
MT30 Coverage and Payment Implications for Breakthrough Medical Devices Following Translational Coverage of Emerging Technologies (TCET) Proposed Rule in the US
|
Chawla, A.
|
|
|
26 |
12S |
p. S432
|
artikel
|
| 1880 |
MT2 Description of Portal Hypertension Treatment by Transjugular Intrahepatic Portosystemic Shunt: A French National Hospital Database Analysis
|
de Léotoing, L.
|
|
|
26 |
12S |
p. S427
|
artikel
|
| 1881 |
MT39 Development of an Early Economic Model to Assess the Cost-Effectiveness of a Novel Technology for the Treatment and/or Prevention of Cataracts
|
Looby, A.
|
|
|
26 |
12S |
p. S434
|
artikel
|
| 1882 |
MT61 Differences and Similarities of Health Economic Evaluation for Medical Technologies By HTA Bodies
|
D'Souza, V.
|
|
|
26 |
12S |
p. S438
|
artikel
|
| 1883 |
MT13 Digging into the Medical Technology HTA Process in Tunisia
|
Mordin, M.
|
|
|
26 |
12S |
p. S429
|
artikel
|
| 1884 |
MT60 Digital Health Applications (DIGA) in Germany—An Observation of Clinical Evidence Submissions
|
Chalmers, M.
|
|
|
26 |
12S |
p. S437-S438
|
artikel
|
| 1885 |
MT45 Digital Health Applications in the General Practitioner Context of Care: An Empirical Analysis of Patient Acceptance
|
Haering, T.A.
|
|
|
26 |
12S |
p. S435
|
artikel
|
| 1886 |
MT48 Digital Health Technologies: Challenges in Evaluating Same ‘Class’ of Technologies
|
Varghese, A.
|
|
|
26 |
12S |
p. S435
|
artikel
|
| 1887 |
MT68 Digital Therapeutics (DTx) for Alzheimer's Disease, Dementia and Mild Cognitive Impairment: A Pragmatic Review of Clinical Evidence
|
Garg, M.
|
|
|
26 |
12S |
p. S439
|
artikel
|
| 1888 |
MT24 Digital Therapeutics (DTX): Market Access Challenges and Stakeholder Perspectives in Germany
|
Heldt, D.
|
|
|
26 |
12S |
p. S431
|
artikel
|
| 1889 |
MT76 DiMe Library of Digital Endpoints: Strengths, Weaknesses, and Pathways for Improvement in Digital Health Research
|
Alves Favaro, M.
|
|
|
26 |
12S |
p. S441
|
artikel
|
| 1890 |
MT51 Does Current Reimbursement Drive the Adoption of Computer-Aided Applications to Increase the Adenoma Detection in Colonoscopies – a Provider-Based Impact Model for Germany, France, and Italy
|
Behncke, J.
|
|
|
26 |
12S |
p. S436
|
artikel
|
| 1891 |
MT27 Does Da Vinci Multiport Experience Help a Surgeon Learn the New Da Vinci Single Port System When Performing a Radical Prostatectomy?
|
Yankovsky, A.
|
|
|
26 |
12S |
p. S431
|
artikel
|
| 1892 |
MT43 Does Real-World Evidence Play a Role in Decision-Making by HTA Bodies for Medical Technologies?
|
Hartley, L.
|
|
|
26 |
12S |
p. S434-S435
|
artikel
|
| 1893 |
MT69 Early Health Economic Modelling to Support the Development of Lifechamps Digital Platform for Older Cancer Survivors
|
Stafylas, P.
|
|
|
26 |
12S |
p. S439-S440
|
artikel
|
| 1894 |
MT52 Economic and Organizational Advantages of Mrgfus for the Treatment of Essential Tremor in Italy
|
Ferrario, L.B.
|
|
|
26 |
12S |
p. S436
|
artikel
|
| 1895 |
MT72 Effectiveness of Drone Technology on Access to Blood and Its Product in the Eastern Region of Ghana: A Cross-Sectional Study
|
Haruna, F.
|
|
|
26 |
12S |
p. S440
|
artikel
|
| 1896 |
MT18 Endovascular Management of Iliac and Aorto-Iliac Aneurysms and Impact on Morbidity/Mortality in France: A French National Insurance Claims Database Analysis (SNDS)
|
Lajoinie, A.
|
|
|
26 |
12S |
p. S430
|
artikel
|
| 1897 |
MT23 Hypoglossal Nerve Stimulation in Obstructive Sleep Apnea: A Systematic Literature Review
|
Sauermann, S.
|
|
|
26 |
12S |
p. S430
|
artikel
|
| 1898 |
MT38 Identifying High Cost and High Mortality Genetic Disease in the NICU
|
Liu, Z.
|
|
|
26 |
12S |
p. S434
|
artikel
|
| 1899 |
MT46 Implementation of Cost-Consequences Analysis As an Economic Evaluation Method for Artificial Intelligent (AI) Medical and Digital Technologies. the Case of Hosmartai (HORIZON 2020 FUNDED)
|
Hatzikou, M.
|
|
|
26 |
12S |
p. S435
|
artikel
|
| 1900 |
MT26 Implications of the Implementation of the Joint Committee Assessment on Launch Planning for Medical Technologies in Europe
|
Acosta Luis, S.
|
|
|
26 |
12S |
p. S431
|
artikel
|
| 1901 |
MT58 Implications of VivaSight-DL: Procedural Impact of a Camera-Integrated Double Lumen Tube
|
Haislip, I.
|
|
|
26 |
12S |
p. S437
|
artikel
|
| 1902 |
MT14 Inequity in Access to Breast Reconstruction Techniques in Belgian Health System: Is it Justified?
|
Marbaix, S.
|
|
|
26 |
12S |
p. S429
|
artikel
|
| 1903 |
MT3 Intracardiac Echocardiography Operational Experience of Chinese Interventional Cardiologists in Conducting Radio-Frequency Catheter Ablation for Cardiac Arrhythmias: A Cross-Sectional Survey Study
|
Pu, X.
|
|
|
26 |
12S |
p. S427
|
artikel
|
| 1904 |
MT5 Mapping Facilities, Equipment and Trained Personnel of Radiotherapy in Greece
|
Vozikis, A.
|
|
|
26 |
12S |
p. S427
|
artikel
|
| 1905 |
MT71 Modelling the Value of Integrating Digital Cellular Pathology in the United Kingdom
|
Kwarciak, A.
|
|
|
26 |
12S |
p. S440
|
artikel
|
| 1906 |
MT57 Optimization of Patient Scheduling Based on AI Algorithm of the Radiotherapy Department of Liège University Hospital: Presentation of Selected Key Performance Indicators (KPIs) (HosmartAI - Horizon 2020 Funded)
|
Hatzikou, M.
|
|
|
26 |
12S |
p. S437
|
artikel
|
| 1907 |
MT59 Overview of Approved Digital Therapeutics in Belgium
|
Chalmers, M.
|
|
|
26 |
12S |
p. S437
|
artikel
|
| 1908 |
MT28 Physician Experiences and Preferences in Peripheral Bronchoscopy for Diagnosing Patients with Solitary Pulmonary Nodules Suspected of Lung Cancer: A Multi-Country, Cross-Sectional Survey
|
Mewes, J.
|
|
|
26 |
12S |
p. S431-S432
|
artikel
|
| 1909 |
MT11 Potential Budget Impact of Negative Pressure Wound Therapy with Instillation and Dwell Time Versus Control Therapies for Wound Management in Mexico
|
Campos, D.
|
|
|
26 |
12S |
p. S428-S429
|
artikel
|
| 1910 |
MT32 Predictive Factors of Communicating Health-Related Information through the Internet Among Adults in South Korea: A Cross-Sectional Study
|
Shin, S.
|
|
|
26 |
12S |
p. S432
|
artikel
|
| 1911 |
MT50 Real-World Utilization and Outcomes of Transcatheter Mitral Valve Leaflet Repair (TMVLR) in Asian Patients with Mitral Regurgitation: A Singapore Experience
|
Tan, S.H.
|
|
|
26 |
12S |
p. S436
|
artikel
|
| 1912 |
MT53 Remote Symptom Monitoring for Lung Cancer Patients: Lessons Learned from the Lung Aid Study
|
Schmalz, O.
|
|
|
26 |
12S |
p. S436-S437
|
artikel
|
| 1913 |
MT36 Roadmap for Evidence Generation on Remote Monitoring Devices for Parkinson’s Disease
|
Kehagia, A.
|
|
|
26 |
12S |
p. S433
|
artikel
|
| 1914 |
MT70 Robotic-Assisted Surgery Versus Open Surgery in Endometrial Cancer: A Systematic Review and Meta-Analysis
|
Kim, Y.L.
|
|
|
26 |
12S |
p. S440
|
artikel
|
| 1915 |
MT41 Single-Use Vs Reusable Endoscope Reprocessing: A Staff Survey on Safety and Effectiveness
|
Haislip, I.
|
|
|
26 |
12S |
p. S434
|
artikel
|
| 1916 |
MT44 Submission Process and Requirements of Nordic Health Technology Assessment Organisations for Medical Technologies: Results of an Online Survey
|
Kinderås, M.
|
|
|
26 |
12S |
p. S435
|
artikel
|
| 1917 |
MT1 Systematic Review of Renal Denervation for Uncontrolled Hypertension: Meta-Analysis Results for Office and 24-Hour Ambulatory Blood Pressure
|
Sanderson, A.
|
|
|
26 |
12S |
p. S427
|
artikel
|
| 1918 |
MT65 Systematic Review of the Health-Economic Impact of Diagnostic Modality Selection for Patients with Coronary Artery Disease
|
Kluge, B.
|
|
|
26 |
12S |
p. S438-S439
|
artikel
|
| 1919 |
MT67 The Effectiveness of Body Composition Analysis Using Dual-Energy X-Ray Absorptiometry (DEXA) for Diagnosing Sarcopenia: Literature Review
|
Park, E.
|
|
|
26 |
12S |
p. S439
|
artikel
|
| 1920 |
MT74 The Impact of Installing a Rfid Cabinet for the Inventory of Intraocular Lenses As Part of the Cataract Surgery Pathway: A Spanish Public Hospital Perspective
|
O'Boyle, D.
|
|
|
26 |
12S |
p. S440
|
artikel
|
| 1921 |
MT35 The Impact of Patient Engagement with a Digital Diabetes Solution on All-Cause Healthcare Resource Utilization Rates and Charges
|
Wilson, L.
|
|
|
26 |
12S |
p. S433
|
artikel
|
| 1922 |
MT31 The Promising Future of Digital Health: A Road to Reimbursement in US & EU5 Markets?
|
Sheppard, H.
|
|
|
26 |
12S |
p. S432
|
artikel
|
| 1923 |
MT64 The Role of Digital Health Technologies in Out-of-Hospital Management of Mental Health Disorders in the UK
|
Ng, E.
|
|
|
26 |
12S |
p. S438
|
artikel
|
| 1924 |
MT9 The Role of HTA Agencies in Relation to Medical Technologies: A Discourse Analysis
|
Michels, R.
|
|
|
26 |
12S |
p. S428
|
artikel
|
| 1925 |
MT79 This Technology Should be Compared With? And Who for? The Digital Health Population Conundrum
|
Malcolm, R.
|
|
|
26 |
12S |
p. S441
|
artikel
|
| 1926 |
MT40 Trends of Use of Knotless Tissue Control Devices and Smooth Sutures in Robotic Ventral Hernia Repair: A Retrospective Database Analysis
|
Johnson, B.
|
|
|
26 |
12S |
p. S434
|
artikel
|
| 1927 |
MT29 Understanding How Health Technology Assessment Bodies Select Medical Technology for Review: Results of an Online Survey
|
Gildea, L.
|
|
|
26 |
12S |
p. S432
|
artikel
|
| 1928 |
MT63 Value Assessment of Combination Digital Health Technologies Under New NICE Evidence Standards Framework: Evidence Submitted and Key Factors for Positive Recommendation
|
Sitavu-Radu, X.
|
|
|
26 |
12S |
p. S438
|
artikel
|
| 1929 |
MT62 Virtual Reality Training on Medical Devices: A Proof of Concept Study
|
Saunders, R.
|
|
|
26 |
12S |
p. S438
|
artikel
|
| 1930 |
MT25 What Evidence Should Medical Technology Companies Expect HTA Bodies to Review?
|
Mordin, M.
|
|
|
26 |
12S |
p. S431
|
artikel
|
| 1931 |
OP29 A Comparative Study of Patient Safety Culture Between 2013 and 2019 at a University Hospital in a Rural Area in Japan
|
Hirose, M.
|
|
|
26 |
12S |
p. S447
|
artikel
|
| 1932 |
OP12 Adherence to Intravenous to Oral Switching Criteria in a Tertiary Governmental Hospital in Riyadh, Saudi Arabia
|
Alshehri, N.
|
|
|
26 |
12S |
p. S443-S444
|
artikel
|
| 1933 |
OP14 Analysis of Interregional Variability in the Market Penetration of Immuno-Oncological Drugs in Italy
|
Mercati, R.
|
|
|
26 |
12S |
p. S444
|
artikel
|
| 1934 |
OP15 Analysis of the Multidisciplinary Approach for the Management of Patients Affected by Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia in Italy
|
Di Brino, E.
|
|
|
26 |
12S |
p. S444
|
artikel
|
| 1935 |
OP8 A New Complement Inhibitor: Impact of Ravulizumab on Eculizumab and Future Biosimilars Use, and Role of Paris Public Hospitals (AP-HP)
|
Romero, C.
|
|
|
26 |
12S |
p. S443
|
artikel
|
| 1936 |
OP28 Are Best Practice Methods for Expert Elicitation Being Applied in NICE Highly Specialized Technology (HST) Submissions? A Review and Evaluation
|
Ta, A.
|
|
|
26 |
12S |
p. S447
|
artikel
|
| 1937 |
OP18 Are We Ready for a Digital Transformation in HEOR and Market Access?
|
O'Leary, S.
|
|
|
26 |
12S |
p. S445
|
artikel
|
| 1938 |
OP21 A Validated Dutch Translation of the CHEERS II Statement
|
Werbrouck, A.
|
|
|
26 |
12S |
p. S445
|
artikel
|
| 1939 |
OP23 Best Practice for Publication of Health Economics and Outcomes Research/Real-World Evidence (RWE) - a Pilot Study on Guidance Needs and Scope for Development
|
Saal, G.
|
|
|
26 |
12S |
p. S446
|
artikel
|
| 1940 |
OP20 Carer Health-Related Quality of Life in Health Technology Assessments: Process Recommendations for Determining Relevance, Data Collection, and Inclusion in Health-Economic Models
|
Ulvenes, L.
|
|
|
26 |
12S |
p. S445
|
artikel
|
| 1941 |
OP24 Collaborating for Better Outcomes: How Can Value-Based Partnerships Unlock Value Across Stakeholder Groups and Elevate Pharma's Role Within Healthcare Ecosystems?
|
Chong, Y.
|
|
|
26 |
12S |
p. S446
|
artikel
|
| 1942 |
OP22 Content Analysis of Drug Recall Announcements in Saudi Arabia: Between 2016 and 2022
|
Almutairi, M.
|
|
|
26 |
12S |
p. S445-S446
|
artikel
|
| 1943 |
OP7 Coverage and Equity of a Patient Support Program for Diabetes During the Pandemic Period in a Middle-Income Country
|
Rico, I.
|
|
|
26 |
12S |
p. S443
|
artikel
|
| 1944 |
OP25 Developments in Anticancer Drugs Preparation Activity in Hospitals Pharmacies Units (HPU) and Their Impact on the Activity of Paris University Hospitals (AP-HP)
|
Moracchini, M.
|
|
|
26 |
12S |
p. S446
|
artikel
|
| 1945 |
OP16 Environmental Sustainability Success Stories From the Pharmaceutical and Medtech Industries in Europe: A Targeted Literature Review
|
Hamilton, L.
|
|
|
26 |
12S |
p. S444
|
artikel
|
| 1946 |
OP13 Impact of Pay-for-Performance Programs on Diabetes Management: A Critical Analysis
|
Vutova, Y.
|
|
|
26 |
12S |
p. S444
|
artikel
|
| 1947 |
OP17 Mapping Pharma Market Access Executives in Greece
|
Vozikis, A.
|
|
|
26 |
12S |
p. S444-S445
|
artikel
|
| 1948 |
OP19 Monoclonal Antibodies in Oncology: A Comparative Analysis of Subcutaneous Form Use Between Paris University Hospitals (AP-HP) Versus French Hospitals
|
Moracchini, M.
|
|
|
26 |
12S |
p. S445
|
artikel
|
| 1949 |
OP5 Multistakeholder Healthcare Cooperative: A New Paradigm for Healthcare Delivery
|
Javadekar, N.
|
|
|
26 |
12S |
p. S442
|
artikel
|
| 1950 |
OP27 Observations of Patient Preference in the Creation of Treatment Support Materials
|
Malone, J.
|
|
|
26 |
12S |
p. S446-S447
|
artikel
|
| 1951 |
OP6 Overcrowding and Boarding Time: Emergency Department Performance and Impacting Factors
|
Foglia, E.
|
|
|
26 |
12S |
p. S442
|
artikel
|
| 1952 |
OP4 Scientific Communication Plans in Health Economics and Real-World Evidence
|
Belli, K.
|
|
|
26 |
12S |
p. S442
|
artikel
|
| 1953 |
OP3 Single-Use Vs Reusable Endoscopy Reprocessing: An Efficiency Survey of Nurses and Technicians
|
Hoffman, D.
|
|
|
26 |
12S |
p. S442
|
artikel
|
| 1954 |
OP1 Stroke Treatment Units: Requirements and Recommendations
|
Slavchev, G.
|
|
|
26 |
12S |
p. S442
|
artikel
|
| 1955 |
OP10 The Ripple Effects of Healthcare Reforms in Germany: A Reduced Free Pricing Period
|
Focsa, S.
|
|
|
26 |
12S |
p. S443
|
artikel
|
| 1956 |
OP11 What Are the Critical Success Factors for a Biotech’s First Commercialization in Europe to Ensure the Right Decisions Are Made for Their Company, Customers, and Future Patients?
|
Johnstone, E.
|
|
|
26 |
12S |
p. S443
|
artikel
|
| 1957 |
P21 A Comparative Analysis of Large Language Models (LLM) Utilised in Systematic Literature Review
|
Rathi, H.
|
|
|
26 |
12S |
p. S6
|
artikel
|
| 1958 |
P18 Adjusted Comparison of Teclistamab Versus Real-World Physician’s Choice (RWPC) of Therapy in Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
|
Mateos, M.V.
|
|
|
26 |
12S |
p. S5
|
artikel
|
| 1959 |
P5 An Update on Calcitonin Gene-Related Peptide Monoclonal Antibodies Reimbursed Under a Managed Access Protocol in Ireland
|
Finnigan, K.
|
|
|
26 |
12S |
p. S2
|
artikel
|
| 1960 |
P45 Are There Any Differences in the Recommendations for Ultra Orphan Medications: An Assessment of NICE, GBA, and HAS
|
Bhatnagar, T.
|
|
|
26 |
12S |
p. S11
|
artikel
|
| 1961 |
P17 A Retrospective Analysis of Medicare Current Beneficiary Survey Data to Evaluate the Alzheimer's Disease and Related Dementia Risk-Reducing Benefits Offered By HMGCR Inhibitors or Statins
|
Chanpura, M.
|
|
|
26 |
12S |
p. S5
|
artikel
|
| 1962 |
P41 Assessing the Role of Patient Feedback in the National Institute for Health and Care Excellence (NICE) Decision Making in the UK: Are Patient Voices Truly Heard?
|
Pandit, U.
|
|
|
26 |
12S |
p. S10-S11
|
artikel
|
| 1963 |
P25 Association between Adherence to Lenalidomide and Patient-Reported Outcomes in Patients with Multiple Myeloma: A Systematic Literature Search
|
Ramasamy, K.
|
|
|
26 |
12S |
p. S6-S7
|
artikel
|
| 1964 |
P1 Automating Economic Modelling: A Case Study of AI's Potential With Large Language Models
|
Reason, T.
|
|
|
26 |
12S |
p. S1
|
artikel
|
| 1965 |
P37 Can Artificial Intelligence Methods Improve Mapping of Preference Based Measures? an Application of Symbolic Regression
|
Crott, R.
|
|
|
26 |
12S |
p. S10
|
artikel
|
| 1966 |
P13 Carer Preferences and Willingness-to-Pay for Home Care Services for Older People With Dementia: A Discrete Choice Experiment in the Milan Metropolitan Area
|
Meregaglia, M.
|
|
|
26 |
12S |
p. S3
|
artikel
|
| 1967 |
P49 Comparability of Overall Survival in Real-World and Clinical Trial Data for BRAF+ Advanced Melanoma
|
Sajeev, G.
|
|
|
26 |
12S |
p. S12
|
artikel
|
| 1968 |
P29 Conditional Marketing Authorization – Becoming Increasingly More Common But Increasingly Less Relevant
|
Macaulay, R.
|
|
|
26 |
12S |
p. S7-S8
|
artikel
|
| 1969 |
PCR165 Accessibility Vs Standardization: A Study of Electronic Implementation of Patient-Reported Outcomes Measures with Vision-Impaired Participants
|
McDowell, B.
|
|
|
26 |
12S |
p. S480
|
artikel
|
| 1970 |
PCR229 Achieving Increasingly Stringent Disease Control Criteria Was Associated with Greater Quality of Life Improvements in Patients with Active Psoriatic Arthritis: Results from BE OPTIMAL and BE COMPLETE/BE VITAL up to 1 Year
|
Kristensen, L.E.
|
|
|
26 |
12S |
p. S493
|
artikel
|
| 1971 |
PCR10 A Comparative Study of Health-Related Quality-of-Life Outcomes in Patients Undergoing Total Hip Arthroplasty in the Hungarian Public and Private Healthcare
|
Kajos, L.
|
|
|
26 |
12S |
p. S450
|
artikel
|
| 1972 |
PCR265 A Core Outcome Set for the Evaluation of New Healthcare Programs in Sweden
|
Harvey, B.
|
|
|
26 |
12S |
p. S501
|
artikel
|
| 1973 |
PCR93 Actinic Keratosis: Patient Perceptions and Expectations for Treatment (REAKT Study)
|
Amici, J.M.
|
|
|
26 |
12S |
p. S467
|
artikel
|
| 1974 |
PCR255 Adherence to Single and Multiple Inhaled Triple Therapies in Patients with Chronic Obstructive Pulmonary Disease (COPD) in Germany, Considering Different Definitions
|
Requena, G.
|
|
|
26 |
12S |
p. S499
|
artikel
|
| 1975 |
PCR194 A Global Perspective on Self-Reported Productivity Losses Associated With Osteogenesis Imperfecta
|
Westerheim, I.
|
|
|
26 |
12S |
p. S486
|
artikel
|
| 1976 |
PCR228 Among European Individuals with Major Depressive Disorder, Higher Severity of Insomnia Symptoms Is Independently Associated with Poorer Health-Related Outcomes
|
Riise, J.
|
|
|
26 |
12S |
p. S493
|
artikel
|
| 1977 |
PCR160 An Integrated Software Platform to Capture Patient Preference Data Throughout the Medical Product Lifecycle
|
Schneider, P.
|
|
|
26 |
12S |
p. S479
|
artikel
|
| 1978 |
PCR138 An International Study of Patient and Caregiver-Reported Burden and Quality of Life in Wiskott-Aldrich Syndrome
|
Iyengar, S.
|
|
|
26 |
12S |
p. S475-S476
|
artikel
|
| 1979 |
PCR275 An Interpretive Phenomenological Analysis of Financial Toxicity in Indonesian Cancer Patients
|
Pangestu, S.
|
|
|
26 |
12S |
p. S503
|
artikel
|
| 1980 |
PCR212 A Novel Approach to Capturing Real-World Reasons Behind Use and Satisfaction of NVX-CoV2373 Booster Use Among German Adults: Direct-to-Patient Enrollment
|
Calhoun, S.
|
|
|
26 |
12S |
p. S490
|
artikel
|
| 1981 |
PCR49 A Preliminary Comparison between Analytical Hierarchy Process and Discrete Choice Experiment in Health State Preferences in Hong Kong SAR, China
|
Ng, C.C.W.
|
|
|
26 |
12S |
p. S458
|
artikel
|
| 1982 |
PCR120 A Psychometric Evaluation of the RAND 36 Scale Among Japanese Adults With Insomnia in 2023
|
Gordon, A.
|
|
|
26 |
12S |
p. S472
|
artikel
|
| 1983 |
PCR117 A Qualitative Interview Study into the Experiences of Fatigue and Depression in Chronic Hepatitis B
|
Edge, H.
|
|
|
26 |
12S |
p. S471
|
artikel
|
| 1984 |
PCR57 A Qualitative Interview Study to Evaluate Single-Tablet Combination Therapy (STCT) Within a Phase 3 Pulmonary Arterial Hypertension (PAH) Clinical Trial – Interim Analysis
|
Davis, S.
|
|
|
26 |
12S |
p. S459-S460
|
artikel
|
| 1985 |
PCR203 A Qualitative Study of the Health-Related Quality of Life Impact of Geographic Atrophy on Patients
|
Hill, S.
|
|
|
26 |
12S |
p. S488
|
artikel
|
| 1986 |
PCR43 A Review of Migraine-Related Pros in FDA Labelling Claims (2018-2023)
|
Zupan, Z.
|
|
|
26 |
12S |
p. S456-S457
|
artikel
|
| 1987 |
PCR191 Assessing Quality of Care in Haemophilia Using a Value-Based Healthcare Approach
|
Fornari, C.
|
|
|
26 |
12S |
p. S485-S486
|
artikel
|
| 1988 |
PCR123 Assessing the Impact of Relapses on Burden to the Patient and Caregiver in NMOSD
|
Kleman, M.
|
|
|
26 |
12S |
p. S472
|
artikel
|
| 1989 |
PCR177 Assessing the Impact of Relapses on Patient Outcomes in NMOSD
|
Kleman, M.
|
|
|
26 |
12S |
p. S483
|
artikel
|
| 1990 |
PCR157 Assessment of Health State Utilities for Invasive Pneumococcal Disease, Pneumonia, and Acute Otitis Media in Young Children
|
Matza, L.S.
|
|
|
26 |
12S |
p. S478-S479
|
artikel
|
| 1991 |
PCR65 Assessment of the EQ-5D and DMD-QoL for Duchenne Muscular Dystrophy: A Patient and Caregiver Study
|
Morgan, G.
|
|
|
26 |
12S |
p. S461
|
artikel
|
| 1992 |
PCR27 Association between Health-Related Quality of Life and Requirement for Non-Professional Care in Adults with Rare Diseases: A Real-World Study
|
Johnson, B.
|
|
|
26 |
12S |
p. S453
|
artikel
|
| 1993 |
PCR128 A Systematic Literature Review of Patient-Reported Outcomes With Nivolumab Across Gastric and Oesophageal Cancers
|
Kaur, G.
|
|
|
26 |
12S |
p. S473
|
artikel
|
| 1994 |
PCR184 A Systematic Literature Review of Patient-Reported Outcomes With Nivolumab Across Lung Cancers
|
Kaur, G.
|
|
|
26 |
12S |
p. S484-S485
|
artikel
|
| 1995 |
PCR38 A Systematic Literature Review of the Humanistic Burden Associated with Geographic Atrophy
|
Aggarwal, P.
|
|
|
26 |
12S |
p. S456
|
artikel
|
| 1996 |
PCR202 Atoderma: Clinical and Economic Burden of Moderate to Severe Atopic Dermatitis in the Czech Republic
|
Chadimova, K.
|
|
|
26 |
12S |
p. S488
|
artikel
|
| 1997 |
PCR207 A Vignette Study to Derive Health-Related Quality of Life Weights for Patients With Steroid Refractory Chronic Graft-Versus-Host Disease Receiving Third Line Therapy in the United Kingdom
|
Williams, E.
|
|
|
26 |
12S |
p. S489
|
artikel
|
| 1998 |
PCR258 Baseline Demographic and Clinical Characteristics of Patients with Plaque Psoriasis Treated with Brodalumab in the Canadian Real-World Setting: Results from the Care Study
|
Kalia, S.
|
|
|
26 |
12S |
p. S499
|
artikel
|
| 1999 |
PCR30 Benefits and Challenges of Different Qualitative Approaches in Rare Disease: A Case Study in Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Using a Narrative Exercise and Qualitative Interviews
|
Skrobanski, H.
|
|
|
26 |
12S |
p. S454
|
artikel
|
| 2000 |
PCR213 Bridging the Practice to Theory Gap: Uncovering and Addressing Barriers and Facilitators to Evaluation of Patient Support Programs by the Pharmaceutical Industry
|
Moloney, C.
|
|
|
26 |
12S |
p. S490
|
artikel
|
Tijdschrift beschrijving